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1- ABBREVIATIONS  
 
 
 
 
 
 
 
 
Table (1) shows the abbreviation used in this thesis 
 
 
 
 
 
 
 
 
 
 
Phrase  Abbreviation 
Gastrointestinal tract  GIT 
Chemotherapy  CT 
Radiotherapy  RT 
Head and Neck  HN 
Quality of life  QoL 
Health Related Quality of Life  HRQL 
Resting energy expenditure  REE 
Adjuvant pre-operative therapy  APT 
Oxygen consumption per unit time  VO2 
Carbon dioxide output  VCO2 
Stroke volume  SV 
Cardiac output  CO 
Anaerobic threshold  AT 
Peak VO2  PkVO2 
Cardiopulmonary exercise test  CPEX 
Neutral killer  NK 
Bone mineral content  BMC 
Dual energy x-ray absorptiometry  DXA 
Air displacement plethysmography  ADP 
Bioelectrical impedance analysis  BIA 
Body mass index  BMI 
Fat-free mass  FFM 
Colorectal cancer  CRC 
C-reactive protein  CRP 
Lean Body Mass  LBM 
Resting heart rate  RHR 
Systolic blood pressure  SBP 
Diastolic blood pressure  DBP 
High density lipoprotein  HDL-C 
Plasma triglyceride (TG)  TG 
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2-ABSTRACT  
Introduction 
The modern treatment of colorectal cancer consists of surgery, with or without 
adjuvant pre-operative radiotherapy, chemotherapy or chemoradiotherapy (APT) for 
selected cases. In the United Kingdom, therapy may be given prior to surgery in an 
attempt to facilitate surgical excision and improve survival. However, there is some 
evidence that APT in other cancers may adversely affect the patient’s health and 
increase the risk of operative morbidity.  
The association between functional capacity, represented by the maximum oxygen 
consumption per unit time (VO2max) as measured by cardiopulmonary exercise 
testing (CPEX), and the perioperative outcome is well established. A reduction in 
cardiopulmonary reserve may increase the perioperative mortality and morbidity; 
however, sufficient data to demonstrate this are not available yet.  
This study examined the affect of APT on the cardiopulmonary status, body 
composition, cytokines assay, nutritional status and quality of life in patients with 
colorectal cancer. 
Methods 
This is a pilot observational study performed on two groups of patients, no 
intervention was used at this stage. Group one received combined 
ChemoRadiotherapy and Group two received only pelvic radiotherapy. 
Cardiopulmonary function was measured with exercise bicycle to achieve Anaerobic 
Threshold (AT) and Maximum Oxygen consumption (VO2max) using CPEX testing. 
Anthropometric parameters such as mid-arm circumference (MAC), Triceps skin fold 
(TSF), grip strength measurements (GS), Body weight, height and body mass index 
as well as extracellular water (ECW), intracellular water (ICW), total body water 
(TBW) and fat free mass (FFM) were measured using a Bio-electrical impedance 
analyser. 9 cytokines were measured using a Luminex assay in addition to CRP and 
albumin assessment.  Nutritional status and quality of life were evaluated using two 
validated questionnaires (EORTC QLQ-C30 and PG-SGA). These assessments 
were made before and within two weeks after the administration of APT. Wilcoxon 
rank sum test represented in median and interquartile range was used to compare 
results before and after the exposure to APT.  
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Results 
Between January 2010 and January 2011, a total of 36 patients with rectal cancer 
were recruited, 24 patients in group 1 had combined chemoradiotherapy (mean age 
59.4, 18 males and 6 females) and 12 patient in group 2 had radiotherapy only 
(mean age 71.8, 10 males and 2 females). Group 1 had a significant decline in 
VO2max with p=0.005, an increase in the ventilatory equivalent ratio for CO2 
(VE/VCO2) with p= 0.001, a reduction in TSF, MAC, GS and TBW with p- values of 
0.007, 0.006, 0.010 and 0.000 respectively after APT exposure. Group 2 had no 
significant changes in their CPEX data, however, they showed a marked decline in 
TSF, MAC, GS, TBW and FFM with p- values of 0.013, 0.013, 0.002 and 0.034 
respectively after APT exposure. Both groups showed a highly significant overall 
reduction in the health related quality of life data with no significant changes in their 
plasma cytokines, CRP and albumin post APT. 
 
Conclusions 
These data suggest that APT has a significant effect upon the cardiopulmonary 
capacity with reduced VO2max as well as an increased VE/VCO2. There were also 
signs of fluid depletion and reduced muscle bulk represented by a significant 
reduction in TBW, FFM, MAC and TSF. Therefore, these important physiological 
changes could be deleterious and affect the peri and post-operative recovery and 
increase the morbidity of surgery in colorectal cancer patients. In view of this, a 
period of optimisation following APT and prior to surgery may serve to minimise the 
risk of such complications.  
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3.0 INTRODUCTION 
3.1 Colorectal Cancer (CRC) 
3.1.1 Background 
Colorectal Cancer (CRC) is the second commonest cancer causing death from 
malignant disease in the United Kingdom (UK). Approximately 35,000 new cases and 
over 16,000 deaths each year related to CRC with an overall 5 year survival of 
approximately 55% [1].  
Nearly 20% of colorectal tumours are rectal with an additional 10% in the 
rectosigmoid junction. Approximately 25% of CRC develop in the sigmoid colon and 
20% arise in the caecum [2, 3]. Around 3% of patients with CRC present with more 
than one tumour (synchronous tumours) and a previous colonic neoplasm increases 
the risk of a second tumour (metachronous tumour). 98% of CRC are 
adenocarcinomas, however, rectal cancers can also present as lymphoma (1.3%), 
carcinoid (0.4%) and sarcoma (0.3%) [2, 3]. 
Colorectal cancer is about equal for both males and females with a peak age of 65 
years old. Furthermore, the incidence, pathogenesis, aetiology, epidemiology and 
screening methods are the same for both colonic cancer and rectal cancer.  
Over the last 30 years, there has been a considerable advance in the management 
of CRC, although very little overall reduction in patients’ mortality and morbidity.  
The time of diagnosis remains the gold standard prognostic factor for many cases [4, 
5]. Early detection through various screening programmes plays an important role in 
improving the outcome of patients with colorectal cancer in developed countries. For 
example, in the United States, the mortality rate of colorectal cancer patients was 
reduced by 50% when appropriate screening methods were applied [6]. The UK CRC 
screening programme will be discussed in more details in the screening section of 
this chapter. 
In order to direct research programmes towards improving patients management and 
outcome, it is important to fully understand the CRC biological and genetic behaviour. 
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3.1.2 Pathogenesis  
The large bowel mucosa usually regenerates every 6 days. Crypt cells migrate from 
its base to the surface, where differentiation and maturation start to occur. Cancers 
are believed to arise within pre-existing adenomas [7, 8]. These develop, through a 
series of molecular and genetic mutations, which occur over 10-20 years, from 
normality, through dysplasia to invasion [9].  
The majority of cases of CRC (75%) are sporadic and develop in people with no 
specific risk factors [10]. 
A further 25% of cases are known to have a positive family history, definite 
environmental factors and/or a history of previous colonic polyps. 
Factors that have been recognised to increase the incidence of CRC include dietary 
red meat, animal fat and low-fibre [13], increased consumption of tobacco [11], 
increased alcohol intake (more than 30g daily) [12], lack of exercise and obesity [13, 
14]. Meta-analysis of case-controlled studies showed that high-fibre diet has a 
protective mechanism against colorectal cancer as it forms a bulky and soft stool that 
dilutes carcinogens as well as decreases the colonic transit time and allowing less 
time for harmful substances to be in contact with the colonic mucosa [8]. 
High dietary calcium has been identified to reduce the risk of colorectal neoplasia. 
This is achieved by the binding of calcium to the bile and fatty acids to form calcium 
salts which may have anti-proliferative effects to reduce the crypt cell production at 
the mucosal level. Other dietary vitamins and minerals, such as selenium, 
carotenoids, and vitamins A, C, and E, may have protective effects by scavenging 
free-oxygen radicals in the colon [15].  
Patients having undergone a cholecystectomy may theoretically have a higher risk of 
developing CRC as there is a continuous exposure of the intestinal mucosa to the 
free flow of bile acids by-products which have a carcinogenic effect [16]. A meta-
analysis by Giovannucci et al revealed that the resultant bile acid metabolism 
increases the risk of cancer of the proximal colon [17]. However, the increased 
incidence is not sufficient to warrant screening of this cohort of patients [2]. 
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Additionally, about 10% of the CRC cases have a genetic pathogenesis which can 
happen via three recognised genetic pathways [18]. These are: 
a) The adenomatous polyposis coli gene (APC) adenoma-carcinoma pathway 
(responsible for 1% of all CRC cases). 
This process of mutation usually starts with an event at the adenomatous polyposis 
coli (APC) gene. This is located on the long (q) arm of chromosome 5 between 
positions 21 and 22 and considered to be a tumour suppressor gene that prevents 
the uncontrolled cellular growth that might result in cancerous transformation. APC 
mutation normally activates oncogene c-Myc and Cyclin D1 via its encoded protein. 
These oncogenes drive the mutation process to a malignant phenotype [19]. APC 
was initially discovered in patients with familial adenomatous polyposis (FAP), which 
is rare autosomal dominant inherited syndrome characterised by the development of 
more than 100 colonic adenomas. It accounts for 1% of cases of colorectal cancer. 
However, APC mutations are very frequently involved in sporadic colorectal cancers 
[20, 21]. FAP can be associated with, desmoid tumours, bone osteoma, and rarely 
brain neoplasia. Independently, these polyps do not possess a higher risk of 
neoplastic change compared with polyps found in other normal individuals [22]. 
Nevertheless, the presence of a large number of these polyps in FAP patients gives 
them a 100% risk of developing CRC if the colon is not surgically removed before the 
age of 40 years [23].  
b) The hereditary nonpolyposis colorectal cancer (HNPCC) pathway 
(responsible for 4-7% of all CRC cases).  
HNPCC is an autosomal dominant inherited syndrome that is characterised by the 
lack of DNA mismatch repair. This is caused by mutations of MSH2, 
MLH1, and PMS2 genes. This will lead to high frequency microsatellite instability (H-
MSI), which is found in approximately 4-7% of CRC cases [24, 25]. These patients 
have the same risk of developing colonic polyps as other people; however, these 
HNPCC polyps are more likely to have neoplastic transformation [26, 27]. 
Additionally, they have a higher incidence of endometrial, gastric, thyroid and brain 
cancers [28]. 
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The revised Amsterdam criteria [29] are used to determine patients who are at high 
risk of HNPCC. All criteria (below) must apply for a diagnosis to be made [30]: 
1. Three or more relatives who are diagnosed with an HNPCC-associated 
cancer (colorectal, endometrium, small bowel, ureter, or renal pelvis). 
2. One affected individual is a first-degree relative of the other two. 
3. One or more cases of cancer are diagnosed before the age of 50 years. 
4. At least two generations are affected. 
5. FAP should be excluded. 
6. Tumours have undergone a pathological review. 
 
c) The ulcerative colitis dysplasia pathways (responsible for 1% of all cases). 
Patients with Inflammatory Bowel Disease (IBD) have a relatively higher risk of 
developing CRC through a different pathway (non adenoma-carcinoma sequence). 
The incidence of colorectal cancer in patients with ulcerative colitis (UC) increases 
1% per year after having the disease for more than 10 years [31, 32]. Patients should 
have an annual colonoscopy screening to rule out dysplastic changes as the latter 
has a 30% risk of CRC [33, 34].  
KRAS oncogene may also be involved in CRC pathogenesis. Loss of heterozygosity 
(LOH) in chromosome 18 region q21 will lead to the inactivation of SMAD4 (DPC4), 
and deleted in colon cancer (DCC) tumour suppression genes [35, 36]. This will 
ultimately increase the chance of developing CRC. In addition, deletion of 
chromosome arm 17p and mutations affecting p53 tumour suppressor gene allow 
resistance to apoptosis and play role in colonic carcinogenesis [37, 38]. 
Apart from the previously described genetic mutations, epigenetic events such as 
abnormal DNA methylation can also play an important role in the colorectal 
carcinogenesis via silencing of tumour suppressor genes or activation of oncogenes, 
which will eventually lead to neoplastic transformation [39-41]. 
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3.1.3 Incidence  
The incidence and mortality rates of CRC have been declining in the last 20 years 
due to the implementation of modern screening procedures that allow the detection 
and removal of colorectal polyps before any malignant transformation. In 1985, the 
incidence rate in the UK was 66.3/100,000 population which has declined to 
45.5/100,000 in 2006 [3]. 
The incidence rate of CRC varies significantly across the world with an approximate 
944,717 new cases identified in 2000. The majority of those CRC patients were 
found in US, Australia, New Zealand, Israel, Japan, Canada and Eastern Europe. 
However, lower incidence rates were identified in Algeria and India [2]. Hence, 
incidence is higher in westernised countries compared to the developing nations. It 
has also been found that five-year survival rates are lower among blacks (55%) 
compared to whites (66%) [3]. 
Males carry higher risk of developing CRC with worse prognosis than women. 
Roughly, the male-female ratio is about 1.37-1 with a mortality rate of 25.4/100,000 in 
males and 18/100,000 in females in 1999 [3]. 
Around 90% of CRC occur after the age of 50 years [2]. However, it can still occur in 
younger adults and children. Usually, the incidence of CRC increases after age of 35 
years with a rapid rise after age of 50 years, peaking at the seventh decade of life 
[42].  
 
3.1.4 Screening  
The aim of colorectal cancer screening is to decrease mortality through diagnosis 
and treatment of precancerous lesions (adenomatous colorectal polyps) before 
malignant transformation [43] as well as detection of early curable cancerous lesions.  
Four randomised controlled trials (RCTs) of mass screening using the faecal occult 
blood (FOB) test have been carried out: one in the UK [44],  one in Denmark [45], 
one in the USA [46] and one in Sweden [47]. These trials demonstrated a reduction 
in bowel cancer specific mortality in the screened groups, using biennial screening, 
annual screening or a combination of the two with follow up periods ranging from 11 
to 18 years.  
 14 
A meta-analysis of these four trials [48] reported a 16% reduction in bowel cancer 
specific mortality with screening [odds ratio (OR) 0.84; confidence interval (CI) 0.78–
0.89], and a 15% reduction in those trials using only biennial screening (OR 0.85; CI 
0.78–0.93). 
In 2009, published figures from the National Cancer Intelligence Network showed 
that screened patients who were picked up with Dukes’ stage A colorectal cancer 
had more than 90% chance of surviving the disease compared to only about 15% 
survival before the introduction of the FOB screening [49].  
The proportions of cancers detected by screening for each Dukes’ stage during the 
first phase of the screening pilot in England is as fellow: 16.8% of un-staged polyp 
cancers, 25.2% of Dukes’ stage A, 26.0% Dukes’ stage B, 25.2% Dukes’ stage C 
and 1.5% of Dukes’ stage D [50]. 
Following these demonstrations of mortality reduction, the Department of Health 
commissioned a pilot screening programme to assess the feasibility of using biennial 
FOB test screening as a population screening tool for bowel cancer in the UK. Three 
pilot screening rounds for men and women aged 50–69 years were successfully 
implemented in Coventry and Warwickshire in England and in Tayside, Grampian 
and Fife in Scotland. The first round of screening demonstrated that screening for 
bowel cancer using the FOB test is feasible within the context of the NHS [51]. 
Therefore, the National Health Service (NHS) has officially started the Bowel Cancer 
Screening Programme. The specifics of the programme vary according to the 
location of the population: 
• In England, people aged 60 to 75 will be offered screening every two years. 
• In Scotland, people aged 50 to 74 will be offered screening every two years. 
• In Wales, people aged 60 to 71 will be offered screening every two years.  
• In Northern Ireland, people aged 60 to 69 will be offered screening every two 
years [52].  
FOB testing can detect around 26% of CRC cases. It is easy, cheap, non-invasive, 
widely acceptable by the population and can pick up large number of patients with 
less advanced, symptoms free, disease [53-56].  
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The sensitivity of FOB test (proportion of individuals who have bowel cancer that test 
positive) has been reported to be 55.0–92.2% in RCTs [48, 57]. It has a false-positive 
result mostly caused by red meat or vegetables with high peroxidase content. FOB is 
the main screening method used by the NHS Bowel Cancer Screening Programme 
followed by a lower gastrointestinal endoscopy, if FOB was positive, to investigate 
these patients further [52]. FOB is a newly screening method introduced to the NHS, 
hence, its long term results are not known yet. However, a recent study showed that 
around 2,500 patients could potentially be saved every year in the UK by 2025 FOB 
screening test [58, 59].  
Higher risk patients will be offered an early regular CRC screening method 
regardless to their age, as per the guidelines for colorectal cancer screening and 
surveillance in moderate and high risk groups. These groups are [60, 61]:  
A. Individuals with inherited conditions such as familial adenomatous polyposis 
(FAP), hereditary non-polyposis colorectal cancer (HNPCC), Peutz-Jeghers 
syndrome and juvenile polyposis syndrome. This group also include 
screening of  their close relatives.  
B. Patients with previously treated CRC.  
C. Acromegaly patients. 
D. Patients with ulcerative colitis or Crohn's disease. 
E. Patients with previous benign colonic polypectomy. 
F. First-degree relatives of patients who had colorectal cancer, especially if they 
were below 45 years of age. 
CRC screening can also be done through other methods such as:  
1. Colonoscopy or flexible sigmoidoscopy: Colonoscopy is usually performed for 
right colonic lesions while flexible sigmoidoscopy is done for left colonic 
tumours. The later method can not be used in assessing rectal cancers as 
these lesions are too low and could be easily missed [62]. Both are expensive 
and invasive procedures which carry some risks of perforation and bleeding. 
It is not widely acceptable by patients, although, it allows direct visualisation 
of the colonic mucosa, estimation of the size of the lesion and degree of 
obstruction plus the capability of obtaining a diagnostic biopsy assess 
ulceration and determine the degree of fixation [55, 63]. Sometimes, this 
method is used to place a colonic stent as a palliative procedure for 
obstructing bowel cancer.  
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2. Rigid proctosigmoidoscopy: Again, this method allows direct visualisation of 
the colonic mucosa, estimation of the size of the lesion and degree of 
obstruction plus the capability of obtaining a diagnostic biopsy, ulceration 
assessment and determines the degree of fixation. It is easy to perform, 
inexpensive and more acceptable compared to the previous method as it can 
be done in the outpatient clinics with no sedation. Moreover, proctoscopy 
gives an accurate measurement of the distance/level of the lesion from the 
anal verge as this is important to decide the type of the subsequent surgical 
resection needed for such patients [62, 64]. However, only the rectum and the 
lower part of the sigmoid colon could be visualised with this method.  
3. Stool DNA screening: Sloughed mucosal cells in the patient stool is tested by 
using polymerase chain reaction (PCR). It is useful to assess genetic 
changes in CRC cases plus it is cost effective and has high sensitivity for 
invasive cancer [65, 66]. 
4. Faecal immunochemical test: This is a monoclonal antibody assay to spot 
human haemoglobin in the patient stool. The presence of the globin molecule 
is suggestive of colorectal bleeding as this molecule usually broken down in 
the upper GI tract. Hence, this could be used as a screening tool as it is easy 
and non invasive, however, this procedure is slightly expensive and not 
available in many health centres [67, 68]. 
5. Double-contrast barium enema: This is a traditional diagnostic method for 
detecting colonic lesions with low sensitivity compared to the newer 
techniques used for CRC screening, thus, not widely used recently [69, 70]. 
However, recent studies from the UK proven around 90% sensitivity of barium 
enema in detecting CRC cases. This method is easy, cheap, non invasive 
and acceptable by most patients [71, 72].  
 
 
 
 
 
Figure (1) shows the double-contrast barium enema 
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6. CT colonography (Virtual colonoscopy): This method was introduced in 1994 
with a diagnostic performance likely exceeding barium enema and optical 
colonoscopy [73, 74]. By employing state-of-the-art multislice technology, CT 
colonography allows a complete examination of the colon and surrounding 
organs in less than 30 seconds. Then, these images are reconstituted into a 
3-dimensional replica of the entire colon and rectum. This provides a good 
visualization of the entire colon, including the antegrade and retrograde views 
of the flexures and haustrations [75]. However, this is a diagnostic test only, 
thus, patients with positive finding will require a subsequent colonoscopy to 
obtain a tissue diagnosis. It is also expensive, not widely available and need 
expert radiologist to interpret the results.  
 
 
 
 
 
 
Figure (2) shows CT colonography (Virtual colonoscopy) 
Each of the above screening tests has some advantages and limitations. Eventually, 
tests availability and patient preference guide the selection of the screening method. 
People with positive FOB test are normally offered a colonoscopy. If bowel cancer is 
detected at colonoscopy (or via other further investigations), the care of the patient 
will be handed over from the screening centre to the relevant multidisciplinary team 
(MDT). Following consultation by the MDT and discussion with the patient, an 
individual programme of treatment and care will be agreed. Around 8 in 10 people 
who have bowel cancer detected will have surgery to remove the cancer. After 
surgery, over 50% of people will live for more than five years. Pre- or postoperative 
chemotherapy or radiotherapy may be offered to patients. CRC screening is very 
important as shown in the previous figures to diagnose the condition early and give 
the best chance of a cure. 
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3.1.5 Presentation  
Detailed patient and family history should be obtained in any suspected case with a 
thorough assessment of risk factors for the development of CRC. Despite the modern 
screening programmes, patients with CRC can present with rectal bleeding which 
occurs in 60% of rectal neoplasm [76, 77]. This is usually not profuse and can 
sometimes be associated with mucous discharge. Change in bowel habit (43% of 
cases) is another symptom. It can be either constipation or diarrhoea, which is due to 
the presence of large rectal villous component [78]. Additional symptoms are iron-
deficiency anaemia, abdominal pain (20% of the cases), intestinal obstruction, 
intestinal perforation, incomplete evacuation and tenesmus. At later stages when the 
CRC is started to invade the spinal nerves and bladder/prostate, patients will suffer 
from back pain as well as urinary urgency, frequency and dysuria. Furthermore, 
patients can have generalised non-specific constitutional symptoms such as malaise, 
appetite and weight loss, fatigue, pelvic pain plus possible symptoms and signs e.g. 
hepatic and pulmonary. Lesions in the right colon are more likely to cause 
microscopic per rectal bleeding and diarrhoea, while tumours in the left hemicolon 
could present with bowel obstruction, perforation or rectal bleeding. Clinical findings 
are usually non specific and vary between localised abdominal mass and/or 
tenderness, ascitis, lymphadenopathy and hepatomegally. Digital per rectal 
examination (DPR) can pick up low rectal tumours and also can show any per rectal 
bleeding. DPR can assess tumour size, mobility and ulceration as well as local 
lymphadenopathy and anal sphincteric function. If the rectal tumour is more than 8cm 
from the anal verge, rigid sigmoidoscopy is performed to take a biopsy. However 
physical findings could be absent in such patients [79].  
The National Institute for Health and Clinical Excellence (NICE) recommends urgent 
referral for the following patients [80]: 
• Aged ≥ 40 years who report rectal bleeding with a change of bowel habit towards 
looser stools and/or increased stool frequency persisting for six weeks or more. 
• Aged ≥ 60 years who report rectal bleeding persisting for six weeks or more without 
a change in bowel habit and without anal symptoms.  
• Aged ≥ 60 years who report a change in bowel habit to looser stools and/or more 
frequent stools persisting for six weeks or more without rectal bleeding. 
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• Of any age with a right lower abdominal mass consistent with involvement of the 
large bowel. 
• Of any age with a palpable rectal mass (intraluminal and not pelvic; a pelvic mass 
outside the bowel would warrant an urgent referral to a urologist or gynaecologist). 
• Who are men of any age with unexplained iron deficiency anaemia and a 
haemoglobin level of ≤ 11 g/100 ml. 
• Who are non-menstruating women with unexplained iron deficiency anaemia and a 
haemoglobin level of ≤ 10 g/100 ml. 
 
3.1.6 Investigation  
Haematological investigations are usually performed on patients with CRC to assess 
their end organ function as well as evaluation of the body tumour load. These include 
full blood count which can sometimes show a hypochromic, microcytic anaemia, 
suggesting iron deficiency due to a microscope or macroscopic blood loss. Hence, all 
middle-aged male patients and postmenopausal females with iron deficiency 
anaemia should have their gastrointestinal tract investigated [81, 82]. 
Further investigations include liver and renal function tests plus serum electrolytes 
and carcinoembryonic antigen (CEA) level. CEA has a sensitivity of 76% and 
specificity of 90% [83].  
The later should be obtained pre and postoperatively from CRC patients as elevated 
CEA might indicate a disseminated disease with advanced stage and/or recurrence 
[84].  
A raised serum CEA level more than 100 ng/mL generally indicates metastatic 
disease and warrants further work up [85]. Hence, it is a bad prognostic indicator to 
have an elevated serum CEA in patients with CRC, although, it has not yet been 
included in the colorectal cancer conventional TNM staging guidelines by the 
American Joint Committee on Cancer AJCC [86]. CEA is mainly used in the follow up 
post CRC resection.  
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Preoperative imaging of the chest and abdomen should be obtained for staging 
purposes. This is usually done by chest radiograph, chest and abdominal 
computerized tomography (CT scan) [87], ultrasound of the abdomen and liver plus 
abdominal and pelvic magnetic resonance imaging (MRI) for rectal cancers [88-90].  
 
 
Figure (3) shows CT scan of the abdomen showing Caecal Cancer 
 
Figure (4) shows rectal cancer in a Pelvic MRI scan  
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If the CT scan results are not very clear or there is a doubt in the pre-operative 
disease staging, then Positron emission tomography (PET) is used to properly 
evaluate the thoracic and abdominal disease [91]. The newest addition, a fusion 
PET-CT scan, allows for detection of metastatic deposits and has added tissue-
based resolution of CT scan. A combination of positron emission tomography and 
computed tomography (PET/CT) can increase the detection rate of colorectal 
metastases [92, 93]. 
Colonoscopy and CT pneumocolon are used to identify the primary site of disease in 
patients with of colorectal cancer [94], also colonoscopy and sigmoidoscopy are 
useful in obtaining an endoscopic guided biopsy to confirm the diagnosis [95, 96]. 
The sensitivity and specificity of CT pneumocolon is 95.2%, 40.9% in detection of 
local invasion, and 75.0%, 90.9% in detection of lymph node metastasis [97]. 
Hence, detecting transmural extension, perienteric spread of tumours and distant 
lymph node involvement is still an area of conflict to most radiologist and oncologists 
[98]. 
 
3.1.7 Histopathology  
A recent study is the United States showed that about 96% of CRCs were 
adenocarcinomas, approximately 2% were other specified carcinomas (including 
carcinoid tumors), about 0.4% were epidermoid carcinomas, and about 0.08% were 
sarcomas [99]. Adenocarcinoma may be well-differentiated or poorly differentiated.  
 
3.1.8 Staging, classification and prognosis 
Colorectal cancer is staged pre and postoperatively. Preoperative staging is made by 
radiological imaging, such as CT and MRI scan, to find out the presence of cancer 
and/or metastasis; depth of the tumour as well as obtaining the final staging of the 
colorectal cancer [100]. On the basis of these imaging, a decision will be made at the 
MDT to proceed to surgery or Adjuvant Pre-operative Therapy (APT) first.  
Colorectal cancer in the UK was originally divided into 3 pathological stages, as 
determined by Cuthbert Dukes, a pathologist at St. Mark Hospital in London, in 1932. 
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These are Dukes A (confined to the bowel muscle), Dukes B (invasion through the 
outer layer of the bowel wall), Dukes C (spread to lymph nodes). Dukes D was added 
later, denoting spread to distant organs (liver and lung most commonly). Stage B was 
subdivided into B1 (no penetration into muscularis propria) and B2 (penetration 
through muscularis propria). Stage C was also subdivided into C1 (tumour limited to 
the rectal wall with nodal involvement) and C2 (tumour penetrating through the rectal 
wall with nodal involvement).  
The TNM staging system for all solid tumours was devised by Pierre Denoix between 
1943 and 1952, using the size and extension of the primary tumour, its lymphatic 
involvement and the presence of metastases to classify the progression of cancer 
[101]. This has superseded Dukes’ classification. 
TNM is developed and maintained by the International Union Against Cancer (UICC) 
to achieve consensus on one globally recognised standard for classifying the extent 
of spread of cancer. The TNM staging system, developed by the American Joint 
Committee on Cancer (AJCC) and the International Union against Cancer (UICC) in 
2002, is used to stage the primary tumour after excision by pathological assessment. 
 
Tumour categories (T) 
Tx: No description of tumour’s extent or incomplete information. 
Tis: In situ carcinoma; the tumour involves only the muscularis mucosa. 
T1: Cancer has grown through muscularis mucosa and extends into the submucosa. 
T2: Cancer has grown through  submucosa and extends into the muscularis propria. 
T3: The cancer has grown through the muscularis propria and into the outermost 
layers of the colon but not through them; it has not reached any nearby organs or 
tissues. 
T4a: The cancer has grown through the serosa (visceral peritoneum) 
T4b: The cancer has grown through the wall of the colon and is attached to or 
invades nearby tissues or organs. 
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Node categories (N) 
Nx: No description of lymph node involvement or incomplete information. 
N0: No cancer in nearby lymph nodes. 
N1a: Cancer cells found in 1 nearby lymph node. 
N1b: Cancer cells found in 2 to 3 nearby lymph nodes. 
N1c: Small deposits of cancer cells found in areas of fat near lymph nodes, but not in 
the lymph nodes themselves. 
N2a: Cancer cells found in 4 to 6 nearby lymph nodes 
N2b: Cancer cells found in 7 or more nearby lymph nodes 
 
Metastasis categories (M) 
M0: No distant spread seen 
M1a: The cancer has spread to 1 distant organ or set of distant lymph nodes 
M1b: The cancer has spread to more than 1 distant organ or set of distant lymph 
nodes, or has spread to distant parts of the peritoneum [102]. 
Staging of colorectal cancer is based on the TNM classification as below: 
Stage 0: Tis, N0, M0: The cancer is in the earliest stage. It has not grown beyond the 
inner layer (mucosa) of the colon or rectum. This stage is also known as carcinoma 
in situ or intramucosal carcinoma. 
Stage I: T1-T2, N0, M0: The cancer has grown through the muscularis mucosa into 
the submucosa (T1) or it may also have grown into the muscularis propria (T2). It has 
not spread to nearby lymph nodes or distant sites. 
Stage IIA: T3, N0, M0: The cancer has grown into the outermost layers of the colon 
or rectum but has not gone through them (T3). It has not reached nearby organs. It 
has not yet spread to the nearby lymph nodes or distant sites. 
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Stage IIB: T4a, N0, M0: The cancer has grown through the wall of the colon or 
rectum but has not grown into other nearby tissues or organs (T4a). It has not yet 
spread to the nearby lymph nodes or distant sites. 
Stage IIC: T4b, N0, M0: The cancer has grown through the wall of the colon or 
rectum and is attached to or has grown into other nearby tissues or organs (T4b). It 
has not yet spread to the nearby lymph nodes or distant sites. 
Stage IIIA: One of the following applies. 
T1-T2, N1, M0: The cancer has grown through the mucosa into the submucosa (T1) 
and it may also have grown into the muscularis propria (T2). It has spread to 1 to 3 
nearby lymph nodes (N1a/N1b) or into areas of fat near the lymph nodes but not the 
nodes themselves (N1c). It has not spread to distant sites. 
T1, N2a, M0: The cancer has grown through the mucosa into the submucosa (T1). It 
has spread to 4 to 6 nearby lymph nodes (N2a). It has not spread to distant sites. 
Stage IIIB: One of the following applies. 
T3-T4a, N1, M0: The cancer has grown into the outermost layers of the colon or 
rectum (T3) or through the visceral peritoneum (T4a) but has not reached nearby 
organs. It has spread to 1 to 3 nearby lymph nodes (N1a/N1b) or into areas of fat 
near the lymph nodes but not the nodes themselves (N1c). It has not spread to 
distant sites. 
T2-T3, N2a, M0: The cancer has grown into the muscularis propria (T2) or into the 
outermost layers of the colon or rectum (T3). It has spread to 4 to 6 nearby lymph 
nodes (N2a). It has not spread to distant sites. 
T1-T2, N2b, M0: The cancer has grown through the mucosa into the submucosa (T1) 
or it may also have grown into the muscularis propria (T2). It has spread to 7 or more 
nearby lymph nodes (N2b). It has not spread to distant sites. 
Stage IIIC: One of the following applies. 
T4a, N2a, M0: The cancer has grown through the wall of the colon or rectum 
(including the visceral peritoneum) but has not reached nearby organs (T4a). It has 
spread to 4 to 6 nearby lymph nodes (N2a). It has not spread to distant sites. 
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T3-T4a, N2b, M0: The cancer has grown into the outermost layers of the colon or 
rectum (T3) or through the visceral peritoneum (T4a) but has not reached nearby 
organs. It has spread to 7 or more nearby lymph nodes (N2b). It has not spread to 
distant sites. 
T4b, N1-N2, M0: The cancer has grown through the wall of the colon or rectum and 
is attached to or has grown into other nearby tissues or organs (T4b). It has spread 
to at least one nearby lymph node or into areas of fat near the lymph nodes (N1 or 
N2). It has not spread to distant sites. 
Stage IVA: Any T, Any N, M1a: The cancer may or may not have grown through the 
wall of the colon or rectum, and it may or may not have spread to nearby lymph 
nodes. It has spread to 1 distant organ (such as the liver or lung) or set of lymph 
nodes (M1a). 
Stage IVB: Any T, Any N, M1b: The cancer may or may not have grown through the 
wall of the colon or rectum, and it may or may not have spread to nearby lymph 
nodes.  
It has spread to more than 1 distant organ (such as the liver or lung) or set of lymph 
nodes, or it has spread to distant parts of the peritoneum (the lining of the abdominal 
cavity) (M1b). 
In England and Wales, about 90% of patients diagnosed at stage I and 78% 
diagnosed with stage II will survive the disease beyond 5 years. However, only 48% 
of patients with stage III and 7% with stage IV will survive the disease beyond five 
years [103]. 
Colorectal cancer survival rates were compared across Europe by Gatta et al which 
showed significant inter-country differences [104]. Late presentation and/or delay in 
treatment initiation has contributed to the poorer survival in the UK compared with the 
rest of Western Europe [105]. Therefore, cancer governance groups, multidisciplinary 
meetings, urgent 2-weeks referrals and 30-days diagnosis to treatment policies were 
adopted in the UK to improve patients care and survival.  
The prognosis of patients with CRC is a function of clinical and histopathological 
stage [102]. Emergency presentation with large bowel obstruction or bowel 
perforation has been shown to be associated with worse prognosis [106]. 
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Molecular prognostic indicators such as mutations of deleted in colon cancer gene 
(DCC), p53, EGFR amplification, loss of heterozygosity for 18q and KRAS mutations 
have all been investigated but have not been shown to be of clinical value [107]. 
However, a retrospective metanalysis showed that deficient mismatch repair (dMMR) 
is associated with better clinical outcome for patients with resectable colorectal 
cancer [108, 109]. Moreover, fluorouracil-based adjuvant chemotherapy benefited 
patients with stage II or stage III colonic cancer with microsatellite-stable tumours or 
tumours exhibiting low-frequency microsatellite instability, but not those with tumours 
exhibiting high-frequency microsatellite instability [110]. 
Local recurrence in rectal cancer is more common than colon cancer [111, 112]. This 
is due to the anatomy and the lymphatic drainage of rectum. Local recurrence is 
multifactorial and widely dependent on the surgeon experience, location of the 
primary tumour, grade and stage of the primary tumour as well as the specimen 
resection margins [113, 114].  
Therefore, pelvic exenteration and/or abdominal perineal resection of rectum might 
be the surgical treatment of choice for local recurrence. Otherwise, palliative 
radiotherapy is a potential treatment for locally unresectable disease [115-118]. 
 
3.1.9 Follow up of CRC 
Follow up patients with CRC is important to detect any postoperative complications 
such as wound infection/dehiscence, stoma problems, or urinary and sexual 
difficulties after rectal surgery. It is also essential to detect early signs of recurrent 
disease and metachronous tumours with initiation of specific management plans. 
Moreover, follow up is important to provide a psychological support to patients and 
finally it is a way of performing audit to improve the clinical service.  
Previous reported trials show that around 85% of CRC recurrence occurs within the 
first 3 years of the surgical resection of the primary tumour [119-121]. Hence, CRC 
patients should undergo a rigid and systematic follow up protocol for at least 5 years 
following the primary tumour resection.  
Any CRC follow up programme usually include outpatient visits as well as clinical, 
haematological, radiological and colonoscopic evaluation.  
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There are many possible protocols in clinical practice combining the type and the 
frequency of these tools [122]. Therefore, follow up programmes are widely 
dependent on the availability of tools and local resources.  
In the United States, the American Society of Clinical Oncology guidelines on 
colorectal cancer surveillance panel recommends an annual computed tomography 
(CT) of the chest and abdomen for 3 years after primary therapy and patients who 
could be candidates for curative-intent surgery. In addition, pelvic CT scan for rectal 
cancer surveillance, especially for patients with several poor prognostic factors, 
including those who have not been treated with radiation. Moreover, colonoscopy at 
3 years after operative treatment, and, if results are normal, every 5 years thereafter; 
flexible proctosigmoidoscopy every 6 months for 5 years for rectal cancer patients 
who have not been treated with pelvic radiation. They also recommended taking a full 
history and physical examination every 3 to 6 months for the first 3 years, every 6 
months during years 4 and 5, and subsequently at the discretion of the physician. 
Carcinoembryonic antigen (CEA) is recommended to be done every 3 months 
postoperatively for at least 3 years after diagnosis, if the patient is a candidate for 
surgery or systemic therapy. Chest x-rays, full blood counts, and liver function tests 
are not recommended and molecular or cellular markers should not influence the 
surveillance strategy based on available evidence [6, 123]. 
In the UK, there are no rigid rules and guidelines for CRC follow up protocols. It is 
widely dependent on the hospital resources, local experience and regional 
guidelines. This could be any of the above combination with any frequency aiming 
mainly to balance risks and benefits with cost-effective considerations. Although, 
most of these protocols include an intense follow up programme during the first 3 
years after primary resection due to the high probability of tumour recurrence. 
 
3.1.10 Surgical Treatment 
The definition of the rectum is different according to Surgeons and Anatomists. 
Surgical definition of the rectum starts at the level of the sacral promontory, while 
anatomists define the rectum as starting at the level of the 3rd sacral vertebra. Hence, 
the length of rectum varies from 12 cm to 15 cm. The rectum is different from the rest 
of the colon, in that the outer layer is made of longitudinal muscle.  
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The rectum contains 3 folds, namely valves of Houston. The superior (10 cm to 12 
cm) and inferior (4 cm to 7 cm) folds are located on the left side and middle fold (8 
cm to 10 cm) is located at the right side [124]. 
The Dutch Colorectal Cancer Group study defined rectal cancer as tumour located 
within 12 cm of the anal verge by rigid proctoscopy. They also found that the risk of 
recurrence of rectal cancer depends on the location of the cancer [125]. 
Planning for surgical management of rectal cancer is a complicated matter, as 
special attention should be directed towards long-term benefits, lifestyle as well as 
genitourinary and anal function preservation. Of course, the main aim of any surgery 
for rectal cancer is to achieve a complete tumour resection in order to reduce the 
chance of pelvic local recurrence, which carries a subsequent poor prognosis. Then 
careful consideration should be directed towards patient functional capacity, anal and 
rectal reservoir function as well as quality of life [126, 127].  
Surgical resection of primary rectal neoplasia is often difficult because the edges of 
the tumour may lie adjacent to or invade vital structures such as; iliac vessels, 
sacrum and prostate urinary bladder, uterus, adenxa and vagina.  
Radical surgical therapy for rectal cancer comprises of 2 main techniques; anterior 
resection (AR) and abdominal perineal resection (APR). Selection method is 
dependent upon surgeon experience as well as disease and patient-related factors. 
Preservation of the anal sphincter is more difficult in obese males, patients with 
preoperative incontinence, direct involvement of anal sphincter muscles with 
carcinoma and bulky tumours within 5 cm from the anal verge [128].  
Transanal Excision  
Patients with early stages of rectal cancer might undergo this procedure when the 
tumour has the following characteristic; a low rectal lesions (within 8-10 cm) or 
occupying less than one third of the rectal circumference, mobile exophitic or 
polypoid lesions which are less than 3 cm in size [129], T1 well or moderately 
differentiated tumours and finally clinical and radiographical negative nodal status  
[130]. In this method, full-thickness rectal wall containing the lesion is excised leaving 
a 1 cm margin of normal tissue with or without primary closure of the defect.  
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This method has possible downsides such as perineural invasions, lymph node 
metastasis, positive resection margins, lymphovascular invasion and recurrent lesion 
[131]. Failure of transanal excision of rectal cancer might need a subsequent radical 
surgery such as AR or APR with or without with en bloc resection the pelvic side wall 
with autonomic nerves, coccyx, prostate, seminal vesicle, bladder, vagina, ureter, 
ovary and uterus [132, 133]. A recent study in 2011 showed that local excision in 
early-stage rectal cancer may result in high local recurrence rate; hence, it is only 
recommended in highly selective groups of patients with a tumour size of 2.5 cm or 
less [134]. Transanal local excision has advantages such as sphincter preservation, 
rapid recovery low perioperative morbidity [135]. The 5-year survival rate after 
transanal excision ranges from 65-100% with a risk of local recurrence of up to 40% 
[136]. Therefore, rigid selection criteria should be applied for this method and 
patients should be informed about the possible risks.  
Endocavitary Radiation  
With the same selection methods applied for transanal excision, stage I rectal cancer 
can also be treated with Endocavitary Radiation. This is different from external beam 
radiotherapy as a larger dose of radiation is delivered to a smaller area over a shorter 
period of time via a special proctoscope in theatre, with sedation, as a day case 
[137]. Weekly radiotherapy is performed for a total of 6 weeks with high-dose (20Gy 
to 30 Gy) and low-voltage radiation (50kV). This can cause a quick shrinkage of the 
rectal cancer with an overall survival rate of 83% and a local recurrence rate as high 
as 30% [138]. 
Transanal Endoscopic Microsurgery (TEM) 
This is another method of local excision for rectal cancer performed by the use of a 
special rigid proctoscope with CO2 insufflation. TEM has not come into wide use yet 
because of it requires a significant learning curve and there is a lack of availability 
[139]. A recent study showed that TEM had a lower rate of positive margins and 
longer disease-free survival when compared with transanal excision. TEM was 
superior to standard resection concerning morbidity, whilst less effective in obtaining 
negative surgical margins, and was associated with higher local and overall 
recurrence. No survival advantage was observed in favour of either procedure. 
Unfavourable tumour preoperative histology did not seem to influence the selection 
between TEM and SR [140, 141]. 
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Anterior resection of rectum (AR) 
The main sphincter-preservation surgery performed for rectal neoplasia is anterior 
resection of the rectum (AR). This should be performed for fit patients with no 
extensive pelvic disease and good pre-operative sphincter function. In this type of 
surgery, primary colorectal or coloanal anastomosis is performed with or without a 
temporary defunctioning loop ileostomy to protect the anastomosis. Possible 
complications of AR include urinary dysfunction, secondary detrusor muscle 
weakness (3-15%) as well as sexual dysfunction such as retrograde ejaculation and 
impotence (5-70% of men patients) [142, 143]. The local recurrence rate after TME 
(total mesorectal excision) is around 4%, which is lower than after transanal excision 
(20%) [144, 145].  
The rate of anastamotic leak in AR ranges from 3-11% for upper and middle third 
colorectal anastomosis while it is higher for the lower third, up to 20% [144, 145]. 
Therefore, many surgeons elect to protect lower anastomosis with a temporary 
defunctioning loop ileostomy, especially if patients had neo-adjuvant treatment [146].  
During AR, full mobilization of the rectum, sigmoid colon, and usually the splenic 
flexure is performed. Mobilization of the rectum is done by sharp dissection in the 
avascular plane that separates the entire mesorectum from the surrounding 
structures; this is called total mesorectal excision (TME). Dissection involves the 
anterior peritoneal reflection and Denonvilliers fascia anteriorly and preserves the 
inferior hypogastric plexus posteriorly and laterally with direct visualisation. 
Mesorectal spread can occur by direct invasion, lymphatic spread, or perineural 
invasion of tumour [62, 143, 147]. Maurer et al has showed an impressive reduction 
of the local recurrence rate after the introduction of TME in rectal cancer with a 
marked survival improvement in patients without systemic disease [148]. 
Resection and colo-anal anastomosis (CAA)  
Ultra low rectal cancer, which is located close to the anal sphincter, can be treated 
via this method with an immediate protective temporary loop ileostomy [149]. TME is 
carried out in the pelvis down to the levator ani muscles followed by a straight tube 
CAA via the double-stapled technique. This procedure does not require permanent 
colostomy and is considered as a good alternative to abdomino-perineal excision 
[150]. 
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However, it is associated with morbidity such as increased frequency and urgency of 
bowel plus incontinence of stool and flatus [147, 151]. To avoid these adverse 
events, a colonic J-pouch may be created, which acts as a reservoir, and 
immediately stapled to the anal canal to form a new colo-anal anastomosis. This 
creation of a neorectum makes the functional result of a coloanal anastomosis more 
predicable [152, 153]. 
Abdominal perineal resection (APER)  
This is used for low rectal tumours where successful achievement of a negative 
resection margin will result in loss of anal sphincter function.  
APER is mainly offered to patients with low rectal cancer as well as those with 
significant co-morbidities or based on patients’ preference as well as involvement of 
sphincter or dysfunction and pelvic fixation of the tumour [154, 155]. 
APER has certain disadvantages such as the need for permanent colostomy, slightly 
higher short-term and long-term morbidity and mortality [156] plus higher rate of 
sexual and urinary dysfunction [126]. 
The mainstay of treatment of colonic cancer is surgical excision. This comprises 
excision of both the primary tumour and the regional lymph nodes. The aim of 
surgery is to remove the whole tumour and achieve a clear margin of tissue around 
the tumour.  
Right hemicolectomy  
This is usually indicated for caecal and right hemicolonic neoplasia. During this 
method, the caecum as well as the ascending colon are mobilised up to the middle 
third of the transverse colon. The ileocolic, right colic and right branch of the middle 
colic pedicles are ligated, divided and excised. Some patients might have omental 
deposits of neoplasia, this should have en bloc with the primary tumour [157, 158].  
Neoplastic lesions located at the proximal or middle third of the transverse colon are 
treated with extended right hemicolectomy where the ileocolic, right colic, and middle 
colic pedicles are divided and the specimen is removed together with its mesentery 
[157, 158]. 
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Left hemicolectomy 
Lesions at the splenic flexure and the left hemicolon usually require this type of 
resection. The inferior mesenteric vein, the left branch of the middle colic vessels and 
the left colic vessels along with their mesenteries are ligated/divided and included 
with the specimen [157, 158].  
Sigmoid colectomy  
is performed for sigmoid colonic cancer where the inferior mesenteric artery is 
divided at its origin with pelvic dissection towards the rectum until reaching adequate 
resection margins. Careful mobilisation should be performed to avoid injury of the left 
ureter and the left ovarian or testicular vessels [157-159]. 
Subtotal colectomy with ileorectal anastomosis  
Patients with HNPC, FAP or metachronous lesions in a separate colonic segment are 
required to have this surgery [157-159].  
These days, colorectal resections of cancerous lesions are often performed with a 
minimally invasive, laparoscopic approach. The same oncological principles with 
appropriate resection margins rules are applied here. Prospective randomized trials 
have shown no significant differences in the peri and postoperative complications, 
peri-operative mortality rates, re-admission or re-operation rates or the rate of 
surgical wound recurrence. At a median follow-up of 7 years, no significant difference 
was found in the 5-year disease-free survival rate (69% versus 68% in the 
laparoscopy-assisted colectomy and open colectomy groups, respectively) or overall 
survival (76% versus 75%). Overall laparoscopic colectomy provides comparable 
oncologic outcomes (cause-specific survival, disease recurrence, number of lymph 
nodes harvested) to those achieved with an open approach [160-166]. 
Over the last 10 years, improvements have been made for those patients with 
advanced colonic cancer and distant metastasis who present with intestinal 
obstruction. with the intraluminal colonic stent may be used as a palliative method. 
However, a recent multi-centre randomised controlled trial has showed that colonic 
stent has no decisive clinical advantages to emergency surgery. It could be used as 
an alternative treatment in as yet undefined subsets of patients, although with caution 
because of concerns about tumour spread caused by perforation [167],[48] 
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Major surgery remains a high risk undertaking for many patients. The UK MRC-
CLASICC study, a multicentre project comparing open and laparoscopic surgery for 
colorectal cancer reported significant 30% complications in both arms of the study. 
The perioperative mortality rate was 5% whilst 12% of patients suffered from surgical 
complications such as wound dehiscence or infection, anastomotic leak or bleeding. 
More patients had non-surgical complications such myocardial infarction, chest 
infection or thromboembolic event [168]. Risk factors such as advanced age and 
limited functional capacity are linked to the development of such complications, 
however, the biological mechanisms behind this are not fully understood yet. 
 
3.1.11 Adjuvant pre-operative therapy (APT)  
Although radical surgical resection of colorectal cancer is the mainstay of treatment, 
surgery alone has a high local recurrence rate of up to 30-50% in patients with 
advanced stages of rectal cancer [169, 170]. Rectal adenocarcinomas are sensitive 
to ionizing radiation. Radiation therapy can be delivered preoperatively, 
intraoperatively, or postoperatively with or without chemotherapy. 
Over the last 15 years, noticeable advances have been made in systemic therapy for 
colorectal cancer, which has considerably improved outcome. Before this, the only 
approved cytotoxic agent for colorectal cancer was 5-fluorouracil (5FU). This blocks 
the methylation of deoxyuridylic acid to thymidylic acid, thereby interfering with DNA 
synthesis. Over the last 15 years, new regimes have been introduced into the 
oncology practice such as oxaliplatin and irinotecan [171], oral fluoropyrimidines 
(capecitabine and tegafur) as well as biologic agents such as bevacizumab, 
cetuximab, and panitumumab. Most of these are used post operatively as adjuvant 
treatment. These new agents have improved the cure rate for stage 2 and 3 as well 
as improved the survival rate for stage 4 CRC.  
Treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and 
leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 
4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 
percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; 
P=0.04).  
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Results for irinotecan alone were similar to those for fluorouracil and leucovorin. 
Severe diarrhoea was more common during treatment with irinotecan, fluorouracil, 
and leucovorin than during treatment with fluorouracil and leucovorin, but the 
incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 
percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were 
less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding 
irinotecan to the regimen of fluorouracil and leucovorin did not compromise the 
quality of life [172].  
It is established that combination regimens provide improved efficacy and prolonged 
progression-free survival in patients with colorectal cancer [173].  
Over the past two decades it has become clear that large rectal tumours can be 
downstaged with preoperative radiotherapy or chemoradiotherapy.  
Similarly, evidence is being gathered that suggests large colonic tumours can be 
downstaged by chemotherapy with or without an immuno-modulator. Both 
preoperative treatments (collectively known as adjuvant preoperative therapy - APT) 
increase the chances of complete removal of the tumour with surgery. 
APT is widely used in the UK where patients are generally managed from the outset 
by multidisciplinary teams including surgeons, oncologists, pathologists and 
radiologists. It is widely used in the treatment of breast cancer [174] and gastro-
oesophageal cancer as demonstrated by the UK MRC oesophageal cancer (OEO2) 
and MAGIC trials [175, 176]. 
Adjuvant Preoperative Therapy (APT) offers advantages in comparison with adjuvant 
post-operative treatment. It is important to reduce the size of the tumour and viability, 
make it operable, improve the survival rate, preserve anal sphincters, reduce the 
chance of local recurrence and eradicate micrometastasis [177-183]. Treatment of 
micrometastasis is important prior to an operation as surgery promotes growth factor 
activity in early postoperative period which may lead to tumour progression [184].  
Both short course radiotherapy and combined chemoradiotherapy have a place in the 
preoperative treatment of rectal cancer [185]. In rectal cancer, the response rate after 
treatment with preoperative chemotherapy and radiotherapy is approximately double 
that after radiotherapy alone (20% vs. 10%) [178].  
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Pre-operative Radiotherapy (Rectal cancer) 
Preoperative high-dose short-course radiotherapy for five days has been shown to 
reduce the risk of local recurrence and to improve survival, after curative surgery to 
rectal cancer [186, 187]. Pre-operative radiotherapy is thought to work better on well-
oxygenated tissues that is present before the surgical resection.  Postoperatively, 
tissues are relatively hypoxic and may be more resistant to radiotherapy. 
Furthermore, preoperative radiotherapy carries less risk of radiation enteritis as the 
small bowel loops are matted together in the pelvis after the major surgical resection 
of rectum [147, 188]. It does not reduce the risk of distant metastasis and has no 
effect on sphincter function in rectal cancer surgery [189]; however, radiotherapy 
decreases the risk of tumour recurrence and the overall mortality in patients with 
stage II or III rectal disease [190, 191]. In rectal cancer, pre-operative radiotherapy 
might delay the surgical resection due to its complication [192, 193]. It can also 
change the accuracy of the pathological staging due to the radiation damage of the 
cellular protein [194, 195]. 
Pre-operative ChemoRadiotherapy (Rectal cancer) 
In locally advanced and initially unresectable rectal cancers (T3 or greater, node 
positive), combined chemoradiotherapy may downstage the tumour and allow 
potentially curative surgery [196]. Pre-operative 5-fluorouracil (5-FU) administration 
increases the bowel sensitivity to radiotherapy, hence, reducing its side effects such 
as diarrhoea. This combined therapy improves local control, distant spread and 
survival [197]. Until recently, APT has not been widely used in the treatment of 
colonic cancer because of the poor response to chemotherapy and limited accuracy 
of radiological staging. Radiotherapy is not used for colonic tumours as the resulting 
damage to the adjacent small bowel would be too severe.  
Pre-operative Chemotherapy and Immuno-modulators (Colonic cancer) 
Recently, however, The National Cancer Research Institute (NCRI) has designed a 
trial to evaluate the efficacy of neoadjuvant treatment by using preoperative 
chemotherapy with or without an anti-Epidermal Growth Factor Receptor (EGFR) 
monoclonal antibody to improve outcome in high-risk operable (T3 or greater, node 
positive) colonic cancer. This is called the FOxTROT trial (Fluoropyrimidine, 
Oxaliplatin and Targeted Receptor pre-Operative Therapy) [198].  
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The systemic effect of chemotherapy alone, radiotherapy alone or combined 
chemoradiotherapy may place the patient at a stage to be less able to cope with the 
physiological demands of anaesthesia and surgery.  
It is generally well known that chemotherapy can cause nausea, vomiting, diarrhoea, 
weight and appetite loss, generalised weaknes and hair loss. The effects of the 
chemical agents are multiple, such as fatigue [199], impaired exercise tolerance 
[199], malnutrition [200, 201], an induction of an inflammatory response [202] and a 
reduced quality of life [203]. These are due to the hypoxia induced at cellular level 
affecting normal and tumour cells. 
Radiotherapy can also cause radiation enteritis. This progressive disease causes 
intestinal fibrosis and obliterative endarteritis, results in significant morbidity and 
mortality [204]. Clinical or subclinical radiotherapy-induced diarrhoea, enteritis, and 
colitis occur in around 60% of patients with colorectal cancer [205, 206]. The severity 
of enteritis is mainly dependent on the primary tumour, radiation dose, and type and 
combination of radiation injuries. Radiation can also cause a stimulation of an 
inflammatory response [202] and a reduced quality of life via the direct effect on the 
gastrointestinal tract [203]. 
There is enough evidence that combination chemoradiotherapy increases the rate of 
complications compared to one therapy alone [207]. This synergetic effect might lead 
to potential problems related to adjuvant preoperative therapy such as perianal 
sepsis, delayed surgical wound healing and a higher rate of anastomotic dehiscence 
[177-179, 208, 209]. Therefore, it is not known yet what might be the possible 
adverse effects of the APT on the real body physiology, functional capacity, 
inflammatory status and quality of life.  
Below are the available preoperative regimes in the United Kingdom: 
A- Short course Radiotherapy (Rectal tumours) 
Short-course preoperative radiotherapy usually involves 5 Gray (Gy) administered 
daily over 5 days without chemotherapy, followed by surgery [210]. External 
radiotherapy regime is delivered according to the guidelines provided in Report 50 of 
the International Commission on Radiation Units and Measurements. This includes 
radiation applied to the primary tumour as well as the regional, mesorectal, presacral, 
and internal iliac lymph nodes.  
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The radiotherapy dose is 25Gy in 5 fractions. This will involve all sites of gross 
tumour including diseased lymph nodes and extramural vascular invasion including 
the intervening normal rectal wall. Then a 1cm margin is applied in all directions 
(superior, inferior, laterally anteriorly and posteriorly). The superior limit is usually the 
S2/3 interspace for mid and lower third rectal cancers and is determined on the 
sagittal or scout view on the planning system. This will extend above the S2/3 
interspace in some patients. The inferior limit is at the superior limit of puborectalis.  
The lateral border in the true pelvis is the medial aspect of obturator internus (in the 
absence of pelvic lymph node involvement and the lateral aspect – bony side wall – 
in the presence of pelvic lymph node involvement). The posterior border is the 
anterior aspect of the bony sacrum. Normal critical tissues such as small bowel, 
femoral heads, and bladder can be contoured at the discretion of the clinician and 
doses to these organs kept to a minimum [185, 211, 212].  
The immediate associated side effects with this type of therapy are perianal skin 
erythema, lethargy, increased bowel frequency as well as urinary urgency, frequency 
and dysuria. Other late effects involves bowel (urgency, frequency, faecal 
incontinence); sexual (dypareunia, vaginal stenosis in females; erectile and 
ejaculatory failure males); sterility (men and women); delay in healing of perineal 
wound and secondary malignancy [213, 214]. 
B- Long course intravenous Chemoradiotherapy (Rectal tumours) 
This is a 5-weeks course (25 days with weekends off) of combined treatment. It 
usually entails 25 fractions of 45Gy pelvic radiotherapy together with Leucovorin 
20mg/m2 flat dose followed by 5-Fluorouracil 350mg/m2 administered on days 1-5 
and 29-33.. Patients need to have Weekly full blood count, renal function tests and 
liver profile to monitor any possible regime adverse events [179, 215, 216]. 
C- Long course oral Chemoradiotherapy (Rectal tumours) 
This is a 5-weeks course (25 days with weekends off) of combined treatment. It 
usually entails 25 fractions of 45Gy pelvic radiotherapy and Oral Capecitabine (5-
Fluorouracil based chemotherapy) 900mg/m2 twice/day, taken on the days of 
radiotherapy only.. Patients need to have Weekly full blood count, renal function tests 
and liver profile to monitor any possible regime adverse events [179, 215-217].  
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D- Chemotherapy only (colonic tumours) 
It is now established that adjuvant combination chemotherapy produces a moderate 
but persistent improvement in survival for patients with stage III (node-positive) CRC. 
There is now also good evidence, from the QUASAR1 study [109] and metanalysis, 
that chemotherapy in stage II (node-negative) disease reduces the risk of recurrence 
and death from CRC. 
Nevertheless, for many patients the current treatment strategy of surgical excision 
followed by adjuvant chemotherapy fails either to clear locoregional spread or to 
eradicate distant micrometastases [218]. Around 10% of recurrence of colonic cancer 
is confined to the resection site. However, the proportion of metastases that 
subsequently occur due to incomplete local clearance is much higher with a more 
aggressive phenotype [219]. 
APT has been studied in many solid tumour types and has been shown to be of great 
benefit in oesophageal, gastric and rectal cancers. There is no enough strong 
evidence that pre-operative anti-cancer therapy is effective in colonic cancers. This is 
due to two reasons: 
• Drug therapy used to give a low response rates, leaving a significant risk of 
tumour growth during the neoadjuvant treatment phase. 
• Radiological staging was inaccurate, and the value of chemotherapy in node-
negative disease was unproven. 
However, recent advances in radiology and in chemotherapy allowed the possibility 
to investigate neoadjuvant chemotherapy for patients with locally advanced colon 
cancer. 
FOxTROT (Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative 
Therapy) is a large national multi-centre randomised trial run by the University of 
Birmingham to assess the efficacy of using preoperative chemotherapy with or 
without an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody to 
improve outcome in high-risk operable (T3 or greater, node positive) colonic cancer. 
FOxTROT is aiming to establish whether giving chemotherapy regimen pre-
operatively improves disease-free survival and/or whether the addition of an EGFR 
targeted monoclonal antibody (panitumumab) increases tumour shrinkage for 
patients with normal KRAS tumours.  
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Arm A of the trial entails giving six weeks of pre-operative oxaliplatin/fluoropyrimidine 
(OxFP) chemotherapy followed by surgery then 18 (or 6) weeks of post-operative 
OxFP chemotherapy while arm B of the randomisation includes the same 
chemotherapy regimen with concomitant panitumumab for the first 6 weeks [198].  
Patients in Arms A and B receive neoadjuvant treatment for six weeks starting as 
soon as possible after randomisation.  
This comprises three 2-week cycles of OxMdG or, optionally for patients not 
randomised for panitumumab, two 3-week cycles of OxCap. Patients in Arm B (who 
will have been established to have KRAS-wild type tumours) also receive 
panitumumab, by IV infusion over 60 minutes on day 1 of each cycle of neoadjuvant 
OxMdG chemotherapy: i.e. panitumumab (2-weekly) for 3 cycles at 6 mg/kg.  
In our study, we have only recruited patients with rectal cancer as its adjuvant pre-
operative therapy is different from the FOxTROT trial used for colonic cancers, 
hence, the pathophysiologial changes will be different too. Patients with rectal 
cancers were divided into two groups according to their APT regiment: 
Group 1: Patients who received combined preoperative ChemoRadiotherapy.  
Group 2: Patients who received preoperative pelvic radiotherapy only. 
 
3.1.12 Area of concern 
The timing of surgical resection after APT administration is widely dependent on the 
size, location, extent and grade of the rectal carcinoma. It might also be surgeon 
dependent. 
From previous published literatures, there are some evidences that APT has a 
significant effect on the postoperative mortality and morbidity as it can be associated 
with an increased risk of intestinal obstruction, intestinal failure and faecal 
incontinence. A comparative analysis of the available studies is difficult because of 
the different inclusion criteria and chemoradiotherapy modalities used and because 
of variations in the standardization of surgical procedures [220-227].  
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There is concern that APT is a two-edged sword. It is debilitating for an individual, 
and so affects the individual’s fitness for subsequent major surgery.  
Although enabling better treatment of the cancer, it might increase the risks of the 
subsequent operation. APT may reduce the functional capacity of the patient. It can 
change the preoperative body physiology, which is a risk factor for both postoperative 
complications and early disease recurrence [228]. 
If APT has a demonstrably detrimental effect, health professionals should devise 
methods to then improve patients physiological fitness before major excisional 
surgery is performed to reduce the morbidity of the surgery. 
The current practice in the UK is to wait for a maximum of 6-8 weeks after finishing 
the APT course before undergoing any surgical resection. This is considered as the 
optimal period for pathological response [229, 230]. A recent study showed that delay 
in surgical resection after APT administration has a significantly better physiological 
outcome for patients with rectal cancer [231]. 
Therefore, the aim of this research programme is to employ specific tests to assess 
the effect of APT on functional capacity and subsequently fitness for surgery on 
patients awaiting colorectal cancer resection. Also, we aim to explore the mechanism 
by which APT might affect body composition, physical and nutritional status, 
inflammatory cascade and health related quality of life (HRQL). 
3.2 Surgical physiology and Cardiopulmonary exercise testing (CPEX) 
3.2.1 Metabolic response to surgery 
Major surgery makes considerable physiological demands on patients. Previous data 
from both cardiac and non-cardiac surgery indicate that patients who suffer 
postoperative complications have evidence of increased oxygen extraction and 
increased arterio-venous oxygen difference in the postoperative period [232, 233]. 
The reasons behind this are increased oxygen demand after surgery with insufficient 
oxygen delivery in the postoperative period.  
The metabolic response to surgery may increase oxygen demand in that period and 
other factors such as shivering may increase this further. It has previously been 
suggested that patients with inadequate oxygen delivery are unable to meet the 
demands of surgery [234].  
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3.2.2 Preoperative assessment 
Different tests have been used in practice to investigate patients undergoing major 
non-cardiac surgery to assess their perioperative risk. These include: treadmill 
testing, nuclear cardiology studies and dobutamine stress echocardiography. The 
main limitation of these methods is that they give information only on response of the 
cardiovascular system to stress. Cardiopulmonary exercise (CPEX) testing provides 
a global assessment of the integrated response to increasing aerobic work involving 
the cardiovascular, respiratory, neuro-pyschological and skeletal muscle systems, all 
of which are activated during the neurohumoral stress response to surgery [235]. 
There is a strong association between limited exercise capacity and postoperative 
complications. Limited functional capacity is identified as an important component of 
preoperative risk stratification in the American college of Cardiology guidelines on 
preoperative risk assessment in non-cardiac surgery [236]. Hence, cardiopulmonary 
exercise (CPEX) testing is of value to asses the functional capacity of an individual. 
It is well established that there is an association between the patient’s response to 
cardiovascular stress such as exercise or inotropic drugs and the risk of 
complications following non-cardiac surgery [237]. Patients with limited cardiac 
reserve or those who demonstrate inducible myocardial ischemia are more likely to 
suffer major perioperative complications [236].  
3.2.3 CPEX testing  
CPEX testing has been used in physiological research and in the assessment of 
patients with cardiopulmonary disease [238]. In recent years, it has been widely used 
for measuring functional reserve prior to surgery. A number of studies have 
demonstrated an association between functional capacity expressed in terms of 
oxygen uptake at anaerobic threshold (AT) or peak exercise (VO2 peak) and the 
incidence of postoperative complications [239, 240]. 
Patients with reduced functional capacity have changes in oxygen delivery and 
handling at cellular level which might contribute to a delayed and impaired recovery 
after surgery [241]. This might be due to increased vasoconstriction, mitochondrial 
dysfunction and/or autonomic imbalance [242].  
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During cellular metabolism, skeletal muscle fatigue reflects the failure to maintain 
peak cytosolic (Ca2+) during contraction.  
In healthy muscle, fatigue-dependent changes in sarcoplasmic reticulum (SR) 
function appear to be the main cause of a loss in force production. However, a 
decrease in store operated Ca2+ entry has been linked to age related exercise 
intolerance [243]. In addition, the ability to sustain skeletal muscle force production is 
related to the rapid attainment of high rates of oxidative phosphorylation [244]. 
The CPEX test is an incremental exercise test using a bicycle or a treadmill during 
which the patient's gas exchange and ECG changes are monitored. It allows the 
objective measurement of a patient’s functional capacity by measuring the ability of 
an individual to perform aerobic work. The test produces a number of measures of 
cardiopulmonary performance, of which the two most commonly used in the 
perioperative setting are anaerobic threshold (AT) and peak oxygen uptake (VO2 
peak). 
3.2.4 Evidence to support CPEX 
In a study in 1993, the CPEX test identified patients at greatest risk of postoperative 
death [245]. Important additional information to that provided by the standard 
exercise test included: a precise determination of aerobic capacity, the causes of 
dyspnea with exertion, respiratory gas exchange and prognosis in patients with heart 
failure.  
Under steady-state conditions, oxygen consumption per unit time (VO2) and carbon 
dioxide output (VCO2) measured at the mouth are equivalent to oxygen utilization 
and carbon dioxide production occurring in the cell; thus, external respiration equals 
internal respiration [246]. 
In healthy people, predictable physiologic changes occur during exercise. These 
changes include a reduction in systemic vascular resistance, increases in oxygen 
extraction, and augmentation of stroke volume (SV) and heart rate, resulting in an 
increase in cardiac output (CO). When the metabolic demands of exercise begin to 
exceed oxygen delivery to working muscles, anaerobic metabolism ensues [247, 
248]. 
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However, even with low-intensity exercise, anaerobic energy production may make a 
small contribution that markedly increases at exercise intensities greater than the 
anaerobic threshold (AT). This is evidenced by rising blood lactate levels and lactate-
pyruvate ratios. Lactic acid is then buffered by bicarbonate, producing excess non-
metabolic carbon dioxide via the carbonic anhydrase reaction. 
The peak VO2 (PkVO2) is the highest VO2 achieved during the cardiopulmonary 
exercise test and generally occurs at or near peak exercise. Moreover, if the VO2 
curve demonstrates a plateau, such that VO2 no longer increases despite 
progressive increments in workload, then the PkVO2 can be labelled the VO2max.  
The VO2max is the best and most reproducible index of cardiopulmonary fitness or 
disability. The PkVO2, VO2max, and AT are reported as a weight-adjusted value in 
millilitres of VO2 per kilogram of body weight per minute to facilitate inter-subject 
comparisons [249, 250]. 
Cardiopulmonary exercise testing is a relevant modality in the clinician’s diagnostic 
armamentarium for evaluation and treatment of many commonly encountered clinical 
problems. Measurement of exercise gas exchange provides objective and 
reproducible indices of functional capacity, generates information in determining the 
origin of dyspnoea on exertion, and provides prognostic capabilities in the 
assessment of patients with heart failure [177-179, 251]. CPEX testing mimics the 
postoperative situation, as it requires an increased cardiac output to satisfy the 
increased oxygen demand. Patients identified as having poor oxygen delivery on the 
bicycle ergometer are expected to have a poor ability to increase cardiac output 
following surgery [177-179, 252]. Compromised results of CPEX testing might be 
associated with an increased risk of cardiopulmonary mortality and morbidity in the 
postoperative period [253, 254].  
A recent consensus statement of assessment of functional capacity identified both 
VO2peak and AT as acceptable measures of functional capacity [255]. Older and 
colleagues reported that patients with an AT of <11ml/kg/min and myocardial 
ischemia had a significantly increased risk of peri-operative death [252]. Swart and 
Carlisle reported a significantly higher incidence of postoperative cardiac events in 
patients with an AT <11ml/kg/min who were randomly allocated to receive ward care 
instead of HDU care (absolute difference 15%, 95% CI 5%-30%, p=0.005) (Swart, 
2007). They also found that hospital length of stay was lowest in those with an AT > 
10.9 ml/kg/min. 
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It is even more reliable at detecting those not at risk, in that there were no deaths 
related to cardiopulmonary complications in any patient identified through CPEX 
testing as fit for major surgery with ward management [252]. 
 
3.3 Body composition and Nutrition  
3.3.1 Body composition and Malnutrition in relation to APT 
Body composition is a general term which refers to hydration, nutrition/wasting, bone 
mineral content and total body fat [256]. There are some data to suggest that APT 
can affect the body fluid and fat distribution. This will subsequently alter the body 
physiology at cellular level during and after surgery by changing the fluid distribution 
and the lean body mass [257].  
The incidence of malnutrition in patients with cancer ranges from 40 to 80% [258] 
and most frequently occurs in patients with cancer of the gastrointestinal tract [259].  
Malnutrition has a detrimental effect on patients with gastrointestinal tract cancers as 
it increases the risk of infections related to treatment whilst reducing the response to 
treatment, HRQL and life expectancy [260-262]. 
Chemotherapy can affect the intracellular protein synthesis, which in turn deteriorates 
the overall nutritional status [263]. It also has indirect general effects such as nausea, 
vomiting, anorexia, and mucositis. 
Patients submitted to radiotherapy, particularly of the gastrointestinal tract, are also 
at higher risk of malnutrition [264], as it can cause mucositis, nausea, vomiting, 
diarrhoea and anorexia [200, 201]. Although these effects are transient, the effect on 
nutritional status can affect patients’ well-being and clinical outcome. There is some 
evidence that APT may be associated with a degree of subclinical Inflammation 
which in turns lead to an increased risk of protein energy malnutrition [265].  
While symptomatic manifestations of radiation injury and their nutritional 
consequences have long been recognized, the potential for therapy has rarely been 
explored. It is recommended that all patients identified as being malnourished or at 
risk of malnutrition receive early and ongoing nutrition intervention by a dietician to 
help maintain energy and protein intakes during radiotherapy treatment [266].  
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Traditionally, body weight and BMI have been used as outcome measures in dietetic 
practice, but these measures do not reflect the body composition changes that may 
occur during chronic disease such as cancer. It is the loss of fat-free mass (FFM) that 
is responsible for the reduced functional status, increased mortality and other 
negative outcomes associated with malnutrition. Body fat is easier to gain than FFM, 
so studies that show improved body weight may not translate into reductions in 
morbidity or improvements in functional status [267]. 
3.3.2 Overview on body compartment  
In order to adequately understand the figures from body composition studies and 
interpret the results towards patients management, it is crucial to be familiarised with 
the basic theory of body composition analysis and the different compartments that 
may be measured [256, 268]. 
The basic two-compartment model divides the body into a homogenous fat mass 
(FM) and a heterogeneous fat-free mass (FFM).  FFM which is also called lean body 
mass (LBM) includes bone mineral and “lean” tissue. The major component of lean 
tissue is water. Typically, TBW accounts for 73% of FFM. However, this percentage 
may vary among normal individuals [269]. ECW can be further split into extravascular 
fluid (reflecting tissue hydration and oedema) and intravascular volume (impacting on 
blood pressure and cardiac function). 
 
 
 
 
 
 
 
 
Figure (5) Diagram illustrating two-compartment model of body composition and division of 
fat-free mass (FFM) into its constituents. Fat-free mass is divided into extracellular water 
(ECW), extracellular solids (ECS), including bone mineral, intracellular water (ICW), and 
intracellular solids (ICS). ICW + ICS comprises body cell mass (BCM) [270] 
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Changes in FFM correspond to changes in nutrition and/or hydration. In some 
patients however, such as renal failure patients, FFM is stable due to concurrent 
wasting with fluid retention, while changes in BCM specifically reflect body nutrition 
and wasting status. Extracellular water is the compartment that predominantly 
changes with hydration [271]. 
3.3.3 Available methods of measuring body compartments in clinical practice  
Direct estimation of the body fat mass (FM) has never been easy and it is still a major 
challenge for many clinicians. A number of body composition techniques are 
available to assess body composition and FM directly such as hydrodensitometry, 
air-displacement plethysmography, computed tomography (CT) scan, dilution 
method, magnetic resonance imaging (MRI), densitometry, in vivo neutron activation, 
measurement of total body potassium and dual-energy x-ray absorptiometry (DXA).  
Although, they have been crucial in the development of the field of body composition 
analysis and act as standards for evaluation of newer techniques, these are 
complicated techniques [272]. They are not applicable to be used in the routine 
clinical practice due to relatively high cost, radiation exposure, and 
portability/availability [256].  
Hydrodensitometry or underwater weighing (UWW) is the earliest and most common 
method of directly assessing FM. This technique was initially formulated at an 
academic level based on Archimedes' principle with a special focus on body fitness, 
exercise and sports performance. Different equipments are available to do 
underwater weighing ranging from easy to sophisticated machines. The patient will 
be initially weighed outside a water tank, then inside after complete body immersion. 
The volume of water displaced and/or the subject’s weight underwater, combined 
with the subject’s outside weight are used to calculate the density of the whole body. 
Bones and muscles density is more and fat is less dense than water [273].  
Therefore, a person with more bone and muscle will weigh more in water than a 
person with less bone and muscle, meaning they have a higher body density and 
lower percentage of body fat [273]. This is based on the 2-compartment body 
composition model and assuming that the water or potassium content of the FFM is 
constant for all ages, 0.732 l/kg for body water [274] and 68.1 meq/kg for body 
potassium [275].  
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There is still a considerable uncertainty regarding the individual’s percentage of fat 
due to normal variations in body hydration, protein, and mineral content.  
Thus, it has been estimated that the total cumulative error for body fatness (% fat) is 
around 3–4% of body weight for the individual [276, 277]. However, this method is 
not ideal for everyone as muscular individuals tend to have denser bones and 
muscles than thin people, which means an underestimation of their body fat 
percentage [278]. While the body fat of elderly patients suffering from osteoporosis 
may be overestimated [279]. There are also a number of individual variations related 
to gender, ethnicity, growth, sexual maturation, aging, physical activity and different 
diseases [280]. Also, a direct measurement of the residual lung air volume is 
required, and a completely still water tank with no wind or movement is necessary 
[281, 282]. For the residual lung volume correction, the most commonly used method 
is oxygen dilution with a closed-circuit spirometer system [283].  
Hence, many people find it difficult, invasive and uncomfortable as it involvs total 
submersion and complete air expulsion  from the lungs [284]. 
Another method of directly estimating body composition is the air-displacement 
plethysmography (ADP), where the individual is immersed not in water but in a 
closed air-filled chamber [285]. This method uses two chambers, one for the patient 
and the other serves as a reference volume. After getting the individual inside the 
ADP, the door is closed and sealed, with a slight increase in the pressure as well as 
oscillating the diaphragm separating the two chambers to alter the volumes. The 
relationship of pressure versus volume at a given temperature is used to solve for the 
volume of the subject chamber. ADP can give multiple readings over a short period 
of time, which can reflect a true change in body composition of the individual. This 
technique is better and more acceptable for patients than the UWW, as it doesn’t 
include an immersion in water. However, all of the other technical limitations are the 
same as for UWW. Data from previous literatures showed nearly similar results could 
be obtained in healthy individuals from both UWW and ADP methods [286, 287]. 
Dilution method is another technique of measuring body composition where the 
compartment volume is estimated by the ratio of the dose of a tracer, administered 
orally or intravenously, to its concentration in that body compartment within a short 
time after the dose administration. Two fluid samples are collected from the individual 
(urine and/or saliva and/or blood) during this method.  
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The first sample is obtained just before the tracer administration, to measure the 
background levels, and the second sample is collected after waiting a sufficient 
amount of time for penetration of the tracer within the compartment of interest (ICW, 
ECW and TBW) [288].  
Sometimes a significant amount of the tracer is excreted before reaching a 
satisfactory saturation; hence, a cumulative urine sample and/or multiple blood 
samples must be collected to adjust the dose estimation [289]. This method of 
assessing body composition is based on four assumptions; the tracer is distributed 
only in the exchangeable pool, it is equally distributed within this pool, it is not 
metabolized during the equilibration time and finally the tracer equilibration is 
achieved relatively rapidly. If any of these requirements is violated, then the ratio of 
administered dose to fluid concentration must be adjusted [290-292]. 
Total Body Electrical Conductivity (TOBEC) is another method based on lean tissue 
being a better conductor of electricity than fat.  
The patient lies in a cylinder, which generates a very weak electromagnetic field. The 
strength of the field depends on the electrolytes found in the person's body water. In 
about 10 seconds, TOBEC makes 10 conductivity measurements that estimate the 
FFM. Although very accurate, its use is limited due to the high cost of the equipment, 
the lack of portability and the need for trained personnel to perform the test [293].  
Magnetic Resonance Imaging (MRI) scan is another method to measure exact body 
composition volumes in which a magnetic field stimulate water and fat molecules in 
the body to produce a measurable indicator. The individual lies within a strong 
magnetic device with a field magnitude greater than the earth’s field. Some nuclei will 
attempt to align with or against the magnetic field [294] while a computer scans the 
body. This method is repeated at each position along the length of the individual until 
the whole body is mapped and cross-sectional MRI images at each slice can be 
generated. High-quality images will eventually show the amount of fat and its 
distribution. MRI takes about 30 minutes and is very safe as it uses no ionizing 
radiation, but use is limited due to the high cost of equipment and analysis. It is not 
portable, needs a special isolated area and trained personnel to perform the test 
[293]. Also, the patient needs to hold their breath during scanning of the abdomen, to 
reduce artifacts introduced by movement.  
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Computed Tomography (CT) scan produces cross-sectional images of the body to 
measure compartment volume. A collimated x-ray tube provides a fan-shaped beam 
that is passed through the body, while an array of detectors is positioned on the 
opposite side of the subject to detect the transmitted radiation. As the beam rotates 
around a person, data are collected, stored and applied to complex algorithms to 
build images that determine body composition [256].  
This anatomical image is like MRI views, except it contains additional information for 
the tissue’s true density at each pixel. Variable algorithms are available in clinical 
practice to reconstruct these images to obtain useful clinical data. CT scan is 
particularly useful in giving a ratio of intra-abdominal fat to extra-abdominal fat. It is 
non-invasive, accurate and highly sensitive; but potentially limited by the exposure to 
high dose of radiation needed per pixel of image, high equipment cost and the need 
for trained personnel to perform the test [293].  
Dual energy X-ray absorptiometry (DEXA) is another way of measuring body 
compartment volumes. It is a relatively new technology, very accurate and precise.  
DEXA is based on a three-compartment model that divides the body into total body 
mineral, FM and FFM. This technique is based on the assumption that bone mineral 
content is directly proportional to the amount of photon energy absorbed by the bone 
being studied. When an X-ray or photon source is placed on one side of the body, 
the intensity of the beam on the opposite side is related to the thickness, density and 
chemical composition of the intervening tissues [295, 296]. The attenuation through 
bone, lean tissue and fat is different, reflecting their differences in densities and 
chemical composition [295]. With increasing photon energy, the differences in the 
attenuation properties for these tissues decrease. 
DEXA uses a whole body scanner that has two low-dose x-rays at different sources 
that read bone and soft tissue mass simultaneously. The sources are mounted 
beneath a table with a detector overhead. The scanner passes across a person's 
reclining body with data collected at 0.5 cm intervals. A scan takes between 10-20 
minutes. DEXA is becoming the new "gold standard" because it is very reliable, 
provides a higher degree of precision in only one reading and has the ability to show 
exactly where fat is distributed throughout the body. Its disadvantages are that it is 
not accurate in measuring extremely obese patients, the cost of equipment is quite 
high and the individual will be exposed to radiation [293]. Also, it is not portable, 
needs a special isolated area and trained personnel to perform the test.  
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Another method available in clinical practice to accurately measure, not estimate, 
changes, in body composition is Bioelectrical Impedance Analysis (BIA). This is one 
of the most practical, easy and non-invasive methods, which uses a Bioelectrical 
Body Composition Analyzer to measure intracellular, extracellular and total body 
water using Weight Manager Software.  
The basic concept of this method depends on a dilution analysis of the body weight, 
assuming that TBW represents 73% of FFM [257]. 
The ability of tissues, and therefore the whole body, to conduct an electric current 
has been recognized for a long time. This forms the basis for the technique of BIA. 
The aqueous tissues of the body, due to their dissolved electrolytes, are the major 
conductors of an electrical current, whereas body fat and bone have relatively poor 
conductance properties [297, 298]. It is also possible to indirectly obtain FM data 
from the BIA machine by deducting FFM from the total body weight (TBW). 
Furthermore, BIA machine can supply other data such as the body resistance to the 
two fluid compartments. 
A 50 kHz alternating electrical current is passed between skin electrodes placed at 
the hands and feet and subsequent the measured impedance is inversely 
proportional to body water content [299]. This technique is probably the most 
frequently used nowadays, due mainly to the relatively inexpensive cost of the basic 
instrument, its ease of operation, and its portability.  
In our programme, longitudinal measurements are compared on the same patient 
before and after APT administration, thus, reducing the chance of errors as each 
patient is controlling him or herself. In recent years, BIA has emerged as a simple, 
reproducible method used for the evaluation of FFM and body composition [300].  
BIA is a validated bed-side technique for the estimate of total body (TBW) and 
extracellular (ECW) water with reproducible measurements of water spaces and can 
be used to monitor hydration changes [301, 302].  
For these reasons, BIA technique was the chosen method to measure changes in 
body composition for our study. Changes in body composition in women with breast 
cancer have previously been demonstrated with this technique in which there was an 
increase in body fat and a decrease in percentage of lean soft tissue and skeletal 
mass after chemotherapy [270].  
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3.3.4 Anthropometric measurements to assess malnutrition 
Nutritional status can also be assessed indirectly through changes in body weight, 
height and body mass index (BMI) [303]. In addition, measuring the subcutaneous 
skin folds (biceps, triceps, subscapular, suprailiac, and medial calf) using a Holtain 
caliper, is another method of nutritional screening [304] which uses a special 
equation is used to derive a body fat percentage. This is based upon the assumption 
that the subcutaneous fat is a proportional reflection of the total body fat and that the 
sites selected for measurement represent the average fat thickness all over the body. 
Furthermore, handgrip calculation is another indicator of muscle strength and fitness, 
which could be also used in practice [305, 306]. The above anthropometric 
measurements are easy to do, inexpensive and portable.  
However, the obtained results could be very subjective as precision is totally 
dependent on the clinician skills and the site measured. [293]. 
 
3.3.5 Nutritional support during APT 
Adequate nutritional support during radiotherapy can decrease the impact of side 
effects, minimise weight loss, improve Quality of Life (HRQL) and help patients to 
recover from the radiotherapy more quickly [307].  
However, a more pro-active approach may be even better. Ravasco et al. found that 
concurrent individualized dietary counselling is the most effective means of improving 
patients’ nutritional intake, status, and HRQL, thereby lessening radiotherapy 
induced morbidity in patients with colorectal cancer [203, 308, 309]. Early 
intervention and sensible partnership with patients are the keys to success [310]. 
Therefore, early and intensive nutritional intervention provides beneficial outcomes 
which in turn yield many benefits such as minimising weight loss, preventing the 
deterioration in nutritional status, maintaining a reasonable global HRQL and physical 
function in colorectal cancer patients receiving APT.  
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3.4 Cytokines and markers of inflammation  
3.4.1 Inflammatory markers in relation to CRC and APT 
There is high variability in recurrence and survival rates within each TNM stage of 
CRC, and prognosis is most strongly correlated with the histopathological staging of 
the tumour [311]. It is increasingly recognised however, that variations in outcome in 
cancer patients are not solely determined by tumour characteristics but also by host-
response factors, such as the release of C- Reactive Protein (CRP) and pro-
inflammatory cytokines [311-313]. Cytokine and CRP levels have thus been 
scrutinised to determine whether they can be utilised as individualised non-invasive 
prognostic indicators or treatment targets, which could help clinicians optimise cancer 
care. 
In 2001, McDonnell showed that patients with oesophageal cancer who underwent 
neoadjuvant treatment did not have significant changes in their plasma cytokines 
[314].  
However and in 2003, Wichmann et al showed that preoperative chemoradiotherapy 
for advanced rectal cancer results in a significant preoperative and postoperative 
immune dysfunction as indicated by depression of lymphocyte subpopulations, 
monocytes, granulocytes, and proinflammatory cytokine release [315].  
These findings are of importance because increased perioperative morbidity and 
mortality rates have been observed after preoperative chemoradiotherapy [316]. 
3.4.2 Overview on Cytokines  
The systemic inflammatory response is propagated, and the severity modulated, by a 
number of humeral mediators such as lipid metabolites, reactive nitrogen and oxygen 
metabolites, nucleotides and cytokines. These mediators interact with each other as 
a molecular network to regulate the inflammatory response. 
Cytokines are a group of soluble, low molecular weight glycoproteins, which act to 
regulate both the amplitude and duration of the systemic inflammatory response. 
Cytokines are highly active at very low concentrations and may act on cells in a 
paracrine and autocrine manner. Activated CD4 cells are programmed to secrete 
cytokines with one of two distinct antagonistic profiles. Type 1 helper cells (Th1) 
secrete cytokines with inflammatory properties (TNF-α, IL-1ß, IL-6, IL-8 and IL-12).  
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Type 2 helper T cells (Th2) produce anti-inflammatory cytokines (soluble TNF-α 
receptors (sTNF-α R), IL-1Ra, IL-4, IL-10, TGF-β). Tumours can act as an 
inflammatory insult and so levels of cytokines have been shown to alter in patients 
with malignancy. There are considerable data to suggest that cytokine profiles (e.g.  
IL-6) are raised, and associated with a diminished quality of life, in patients with 
advanced malignancy [317]. 
Pro-inflammatory cytokines are necessary for initiation of an effective inflammatory 
process. The early hyper-inflammatory response is followed by a counter regulatory 
mechanism. This mechanism is characterised by the release of anti-inflammatory 
cytokines. 
An inflammatory cytokine network may influence survival, growth, mutation, 
proliferation, differentiation, and movement of both tumour and stromal cells. From 
our literatures search, we have found that IL-6, IL-1 and TNF-α are the most studied 
cytokines in the context of colorectal cancer and neoadjuvant therapy. 
IL-6 
Il-6 plays a central role in mediating a cellular and physiological inflammatory 
response. In this capacity, Il-6 has been found to delay neutrophil apoptosis, thereby 
inhibiting resolution of inflammation, which has been linked to postoperative mortality 
in colorectal cancer. Il-6 also affects immunoregulation, angiogenesis, and osteoclast 
activation. It has been implicated as a promoter of cancer growth by enhancing the 
colony formation of human colon carcinoma cells, increasing carcinoma cell 
invasiveness, and promoting secondary tumour formation [318-321]. Clinically, serum 
IL-6 levels increase in colorectal cancer patients relative to healthy controls, and are 
correlated with tumour size, stage, and survival in advanced malignancy [322-326]. 
However, in one study pre-operative Il-6 was not found to be an independent 
prognostic factor [323], and in another, was not significantly correlated with disease 
free and overall survival [327]. The loss of expression of the soluble IL6 receptor (sIL-
6R) in colorectal cancer is significantly correlated with disease progression, and is 
thought to be due to consumption of the receptor as a result of Il-6 binding [328]. 
In vitro and in vivo studies have shown IL-6 can be induced by ionizing radiation 
[329, 330]. Exposure to radiation initiates a programmed molecular and cellular 
response to promote tissue repair, which includes the up-regulation of pro-
inflammatory cytokines and the induction of nuclear factor κB activity [331].  
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Whilst studies have speculated that Il-6 may be associated with post radiotherapy 
fatigue, there is yet to be any definitive evidence [329, 331, 332]. However, raised Il-6 
before neoadjuvant radiotherapy has been found to be predictive of weight loss and 
food intake reductions. In the same study, weight loss and food intake reduction 
before or after radiotherapy was significantly associated with a raised Il-6 (and TNF 
α) and non-response to radiotherapy [333]. 
In neoadjuvant chemoradiotherapy in advanced rectal cancer, IL6 levels were not 
significantly different from control patients after chemoradiotherapy. However, they 
were significantly higher in patients without preoperative therapy on Days 1 and 2 
after surgery [315]. In an oesophageal cancer study, elevated serum IL-6 levels after 
neoadjuvant 5FU based chemoradiotherapy, but not before, were correlated with a 
poor response to chemoradiotherapy and poor survival. In this study, raised Il-6 
levels were also positively correlated with residual tumour volume and CRP [334].  
Another study investigating a cetuximab enhanced Folfox-4 neoadjuvant 
chemoradiotherapy regimen for the treatment of oesophageal cancer, showed a 
significant increase in IL-6 after chemoradiotherapy. However, no major difference 
between cytokine variation levels among responding and non-responding patients 
was found [335]. 
IL-1 
It has been reported that raised IL-1 has been associated with a poor prognosis in 
colorectal cancer patients and is an important mediator of VEGF expression and Il-6 
production [322, 336]. However, Il-1’s association with survival has not been 
demonstrated universally [323]. Il-1 receptor antagonist (Il-1ra) blocks IL-1 signal 
transduction, the Il-1/Il-6 inflammatory cascade, and is a competitive inhibitor of 
VEGF expression.  IL-1ra is produced in the postoperative period in response to IL-6 
production.  However, in nutritionally depleted patients undergoing surgical stress 
this negative feedback loop was found not to exist. The attenuation of a pro-
inflammatory cytokine network antagonist has potentially negative implications for 
clinical outcomes in malnourished patients, as peri-operative pro-inflammatory states 
can adversely affect the prognosis of cancer patients. The use of synthetic IL-1ra 
(anakinra) to ameliorate these circumstances requires further study, and the effect of 
neoadjuvant therapy is described below [336-339]. 
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The effect of ionizing radiation on IL-1 has been studied in various tumour types, 
producing a range of differing results [329]. There is only a small amount of literature 
concerning the changes to IL-1 during neoadjuvant therapy in colorectal cancer. The 
role of post neoadjuvant IL-1 as a potential indicator of peri-operative and long term 
outcomes does not seem to have been investigated.  
TNF 
Tumour necrosis factor (TNF)-α is a cytokine produced by activated macrophages 
and tumour cells. It was first identified as a host induced substance that is selectively 
toxic to tumour cells at high doses [340]. However, at physiological levels it is tumour 
promoting through its direct effects on cancer cells, its induction of the chemokine 
system, its activation of NF-κB and Il-6, and its stimulation of epithelial-mesenchymal 
transition [341, 342].  
It induces cellular proliferation, inhibits apoptosis, and is associated with the 
symptoms of weight loss, and fever. Elevated levels of TNF are found in the majority 
of colorectal cancer patients, regardless of the stage of disease [343-345]. High TNF-
α expression has also been found to be significantly associated with recurrence of 
colorectal tumours and was found to be an independent prognostic factor in the same 
study[346]. TNF-α is often found to decrease after surgery, though post-operative 
patterns seem to vary [323, 344, 347]. 
TNF-α can also induced by ionizing radiation [329, 330], though significant increases 
have not been found in all studies [329, 332, 348]. In a rectal cancer study 
considering neoadjuvant chemoradiotherapy, post chemotherapy TNF-α levels were 
lower, but not significantly, than controls pre-operatively, but were found to be 
significantly lower than control patients at 1,2, and 5 days after surgery [315].  
In contrast, in the oesophageal cancer study discussed previously [335], TNF-α was 
found to be significantly lower after a cetuximab enhanced Folfox neoadjuvant 
chemoradiation regimen. However, as with both Il-6, and Il-1B, there was no 
significant difference in the increase between responding and non-responding 
patients. It is thus not yet clear as to how neoadjuvant therapy affects TNF-α 
production, and how this impacts on survival. Nevertheless, both anti TNF-α drugs 
(e.g. infliximab & ertanercept) [341] and pro TNF-α drugs (e.g. TNFerade) [349] are 
being investigated in a range of cancers with varying success [341]. 
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VEGF 
Vascular Endothelial Growth Factor (VEGF) is an important cytokine involved in both 
vasculogenesis and angiogenesis, and can be induced by IL-6 [350]. It has been 
found that VEGF levels are higher in metastatic tumours, and that a positive VEGF 
status is associated with a significant reduction in five year survival [327, 343, 351-
353]. Preoperative elevated VEGF levels have also been found to be associated with 
reduced survival, tumour size, and CEA concentrations [327, 354]. One study found 
no association between neoadjuvant long course radiotherapy, VEGF expression, 
and response to treatment [355, 356]. However, another study that evaluated VEGF 
in tumour biopsies before experimental short course neoadjuvant radiotherapy found 
that VEGF negative tumours were more than four times more likely to undergo 
complete tumour regression than their VEGF positive counterparts [355].  
Moreover, it has also been demonstrated that VEGF positivity is an indicator of poor 
disease-free survival following preoperative chemoradiotherapy [357].  
Further research into the development of more effective neoadjuvant regimens for 
VEGF positive patients, together with the continued investigation of anti-VEGF drugs 
or techniques, might yet yield benefits for this subgroup of patients [353, 355, 358-
361]. 
IL-8 
Il-8 is a chemokine involved in the growth, signalling and the up-regulation of 
inflammatory responses as well as the emergence of a vascular supply [362, 363]. In 
one colorectal study, pre-operative Il-8 was not correlated with survival, but was 
found to be significantly higher in CRC patients than in those without cancer [323]. 
It has also been shown that overexpression of Il-8 is associated with liver metastases 
and poor outcomes in colorectal cancer patients, and resistance to oxaliplatin [362, 
364-366]. In a cetuximab enhanced folfox neoadjuvant chemoradiotherapy regimen 
for oesophageal cancer, Il-8 was seen to decline after both radiotherapy and 
chemotherapy, but not significantly so.  
There are few other studies that consider the use of Il-8 as a prognostic factor in the 
context of neoadjuvant therapy [335].  
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IL-23 
Il-23 is a pro-inflammatory cytokine that is structurally similar to Il-12, and induces the 
production of pro-inflammatory cytokine IL-17, which promotes angiogenesis and 
regulates VEGF. IL-23 has been associated with both pro-tumour [367-369] and anti-
tumour activity [368]. One recent study looked at IL-23 before and after adjuvant 
chemotherapy and found no significant change in serum levels, and no association 
with disease stage or the presence of metastases [368]. The importance of Il-23 as a 
prognostic indicator in colorectal cancer patients, with or without neoadjuvant therapy 
is yet to be determined. 
IL-10 
IL-10 is an anti-inflammatory cytokine with immunoregulatory functions. This cytokine 
is produced primarily by monocytes and to a lesser extent by lymphocytes. It down-
regulates the expression of pro-inflammatory cytokines. TGFβ is an anti-proliferative 
factor and so exerts an anti-inflammatory effect. 
IL-10 can have both a tumour promoting and a tumour inhibiting factor [342, 369, 
370]. Whilst its anti-inflammatory function may be anti-tumoural, it might promote 
tumour growth by inhibiting apoptosis and stimulating cell proliferation. A high 
systemic level of Il-10 has been found in advanced colorectal malignancies, and pre 
and post-operative Il-10 levels have been used to predict tumour recurrence after 
surgery [369, 371]. There has been very little research into the effects of neoadjuvant 
therapy on IL-10. In the cetuximab enhanced folfox neoadjuvant study in 
oesophageal cancer previously discussed, IL-10 significantly increased after 
radiotherapy and chemotherapy; however, there was no significant difference in 
cytokine changes between responders and non-responders [335].  
CRP 
C- Reactive Protein (CRP) is a readily available inflammatory marker that has been 
studied as a prognostic biomarker in a number of solid tumours. During acute 
inflammation, the production of CRP in the liver is directly stimulated by IL-6. Once 
stimulated, CRP rapidly reflects circulating Il-6 levels, and in the context of 
malignancy, has been found to correlate with the tumour tissue concentration of IL-6 
[347, 372].  
 58 
CRP has a half-life of approximately 19 days, up-regulates the expression of 
adhesion molecules and stimulates the release of further IL-1, IL-6, IL-18, and TNF-α 
from mononuclear phagocytes [340, 347]. A raised CRP has been linked with the 
prognosis of prostate [373, 374], breast [375, 376], colon [377], ovary [343], bone 
[343], stomach [378], lung [379, 380], pancreatic [381, 382], and skin tumours [343]. 
The mechanism by which CRP is linked to prognostic outcomes is unknown. 
However, a raised CRP may be a surrogate marker for a pro-angiogenic 
environment, a marker of poor T-cell lymphocytic infiltration, and a marker of the 
compromised cytochrome P450 3A system. These potential associations are all 
speculated to be the determinants of the CRP-outcomes relationship. 
 
Raised circulating concentrations of CRP were found to be correlated with tumour 
bulk, and predicted overall and cancer-specific survival, in patients undergoing 
potentially curative surgery for colorectal cancer whether measured before or after 
operation. The prognostic value of preoperative CRP was also found to be 
independent of Duke’s stage [312, 383-385]. Later studies have shown that in TNM 
stage I or II patients, CRP could predict early disease recurrence, even when a CEA 
test could not [372]. However, in one recent colorectal cancer study, pre-operative 
CRP levels showed no correlation with regard to disease free survival and overall 
survival (median follow up duration 18.53 months) [327]. The prognostic value of 
CRP can be combined with hypoalbuminaemia to create the Glasgow Prognostic 
Score (GPS) [379, 386]. The GPS has been reported to be superior to CEA and CA 
19-9 in predicting survival [339]. The modified GPS (mGPS) also reflects cachexia, 
loss of weight, lean tissue and performance status [387]. Indeed, mGPS has been 
found to be independently associated with a risk of post-operative infective 
complications in those undergoing curative resection. Most importantly however, the 
mGPS has been reported to have prognostic value independent of high risk 
pathological tumour features in node negative disease [385, 386, 388, 389] 
Radiotherapy can cause a raised CRP, which has been found to be associated with 
an increased frequency and severity of fatigue symptoms [390, 391].  It is possible 
that preoperative administration of radiation therapy may induce significant 
immunologic dysfunction that could influence postoperative recovery as well as 
metastatic growth of disseminated cancer cells [315]. Unfortunately, potential 
relationships between radiotherapy, CRP, and morbidity and mortality have not been 
investigated extensively in the colorectal cancer context. 
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The majority of studies that consider the relationship between preoperative CRP and 
colorectal cancer survival tend to have either excluded participants who have 
undergone neoadjuvant radiotherapy or do not address the issue [312, 337, 339, 
344, 372, 383-385, 388, 392-394]. 
One study found that Glasgow prognostic score (GPS) measured prior to 
preoperative chemoradiotherapy in non T4 tumours predicted a poor prognosis [395], 
and another found that preoperative CRP levels were an independent prognostic 
marker for survival after neo-adjuvant treatment [396]. A very recent study 
demonstrated that elevated serum CRP levels after preoperative chemoradiotherapy, 
but not before, was correlated with poor response to chemoradiotherapy [334].  
3.4.2 Cytokines, Body physiology and Carcinogenesis  
The mechanisms behind the associations between body physiology and the 
inflammatory markers in colorectal cancer patients are complex. The relationship 
between CRP and cytokines (predominantly Il-1, Il-6, and TNFα) together with short 
and long term outcomes has been studied in a number of solid tumours with varying 
results. Cytokines are small cell signalling proteins which stimulate the release of 
CRP from hepatocytes, modulate immunological control and may influence survival, 
growth, proliferation, and differentiation of tumour cells. Cytokines found in tumours 
are more likely to contribute to tumour growth, immunosuppression and progression 
than they are able to mount an effective host antitumour response [321, 383, 397].  
Inflammation is intimately involved in carcinogenesis and cancer progression in 
colorectal cancer. An appreciation of this process is necessary to enable us to 
understand why host response factors might play a role in predicting prognosis. 
Inflammation, infection and genetic events activate a multiplicity of transcription 
factors (e.g. nuclear factor-κB (NF-κB)) that coordinate the production of 
inflammatory mediators such as cytokines and chemokines [341]. These factors 
activate various leucocytes and further transcription factors in inflammatory, stromal, 
and tumour cells, resulting in further release of inflammatory mediators. IL-1β, IL-6, 
IL-23 and TNF-α are the key cytokines involved in cancer related inflammation, and 
together with chemokines coordinate autocrine and paracrine interactions between 
malignant cells and infiltrating leukocytes. These interactions affect the growth of the 
primary tumour, and increase the migration, invasion and survival of malignant cells.  
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Thus, one might expect all of these cytokines to become more prevalent when the 
tumour burden is high or the patient is not responding to treatment. Whilst for the 
most part this seems true, the reality is more complex [341]. 
Following an inflammatory insult e.g. advanced malignancy; the balance between the 
biological effects of the pro-inflammatory and anti-inflammatory cytokines is thought 
to affect the clinical outcome of the disease. An excessive, inappropriate production 
of pro-cytokines can have a deleterious effect, resulting in: defective tissue 
microcirculation and hypoxia. In contrast, anti-inflammatory cytokines (IL-4, Il-10 and 
IL-13) appear to be important in the control and down-regulation of the inflammatory 
response. 
Few studies have examined the effect of APT on levels of cytokines. A small study 
has shown a rise in inflammatory markers after treatment with chemotherapy, but 
data are sparse [202]. 
It has also been shown that in elderly healthy people, higher levels of pro-
inflammatory cytokines (IL-6 and TNF-α) were associated with lower muscle mass 
and lower muscle strength in both men and women. This is relevant as colorectal 
cancer occurs much more frequently in the elderly [398]. The effect of the various 
cytokines is thought to be at least partly hereditary, and may affect the surgical 
outcome [399].  There are also considerable data to suggest that cytokine profiles 
(e.g.  IL-6) are raised, and associated with a diminished quality of life, in patients with 
advanced malignancy [317].   
The colorectal cancer literature in the adjuvant chemotherapy setting broadly 
supports the notion that inflammation can predict outcomes. An elevated 
preoperative CRP was found to be predictive of a poor outcome in patients receiving 
adjuvant 5-FU chemotherapy [400], and the mGPS was found to be a predictor of 
mortality in the 5FU based ‘Folfiri’ and ‘Folfox’ regimens for advanced or 
unresectable disease [401].   
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3.4.3 Exercise and Cytokines  
Exercise training and an increase in physical activity has a significant effect on CRP. 
It has been found that a 6 months course of supervised exercise programme has 
reduced CRP in adult men and women at risk for developing ischemic heart disease 
[402].  
Nutrition therapy with anti-inflammatory agents and exercise activities will support 
lean tissue anabolism and prevent the adverse physiological and physical outcomes 
as well as promoting successful health, functionality, and quality of life outcomes of 
patients who are being treated with anti-cancer therapy [403].  
Short-term rehabilitation programme with moderate exercise leads to a shift to a 
more pro-inflammatory state (decreased antagonist/cytokine ratio). This might be 
clinically beneficial (decreased rates of infection, relapses and/or second tumours) 
but needs long-term studies [404]. 
At present it is not possible to accurately predict why similarly staged colorectal 
patients undergoing APT can have remarkably different treatment outcomes. The use 
of CRP and cytokines as predictive biomarkers in this context is not well researched 
[210, 327]. In this project, we will discuss what is currently known about the 
relationship between CRP, cytokines, APT, and outcome of surgery within a clinical 
context. 
  
3.5 Health related quality of life (HRQL) and Physical activity 
3.5.1 HRQL 
In recent years, the study of exercise programmes used as an integral part of holistic 
therapy for patients with cancer has become an increasingly popular area of study.  
Many such studies specifically look at the resulting effect on health related quality of 
life (HRQL). These studies are particularly popular in respect to patients with breast 
cancer, however, there is little information specifically relating to colorectal cancer.  
Furthermore, no studies look specifically at the effects of exercise on quality of life 
during a preoperative phase where preoperative adjuvant therapy may be given. 
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Colorectal cancer results in a number of disease and treatment related factors that 
can adversely affect HRQL of patients. The symptom profile of disease includes: 
change in bowel habit, per-rectal bleeding, weight loss, malaise, abdominal pain and 
tenesmus. These symptoms can easily lead to poor nutritional intake and a change in 
normal activity levels resulting in malnutrition and reduced physical fitness. This, in 
turn, will affect HRQL as patients become less able to carry out activities of daily 
living (ADLs) and leisure time activities [405, 406]; furthermore the side effects of 
treatment may contribute to a deterioration in HRQL [407]. 
It is possible that a negative cycle of deterioration is initiated; fitness and inability to 
perform ADLs leads to further reductions in HRQL, resulting in less activity and 
further reductions in fitness [405-408]. 
Health related quality of life is a concept that has developed over recent years. It 
encompasses a number of domains of HRQL such as physical, nutritional and 
psychological, as well as profiles of symptoms and treatment side effects.  
There are many standardised and validated measuring tools that have been used for 
studies investigating HRQL. The tools most commonly used in the existing literature 
are shown in table 2. 
Although, the study of exercise as a mediator of HRQL has become increasingly 
popular it has been skewed to some specific cancer types.  
Much of the evidence available currently comes from cohorts of patients with breast 
cancer.  It might be considered that application of these data to colorectal cancer 
should be done cautiously [409], as the pathology of the diseases, the treatments 
used, and the demographics of the patients differ significantly between these two 
types of cancer. 
However, several studies have addressed the questions using patient cohorts of 
mixed malignancy type. One such study showed no diagnosis related pattern of 
response to the exercise intervention [410] and thus, it seams that those studies of 
exercise during cancer treatment in any malignancy type can provide evidence to 
support this investigation. 
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Tool Measures 
European Organisation for Research and  
Cancer Treatment Quality Of Life  
Questionnaire 
 
EORTC QLQ-C30 
 
 
9 multi-item scales:  
1. functional scales (5): 
•  physical,  
•  role,  
•  cognitive,  
•  emotional,  
•  social 
2. symptom scales (3) 
•  fatigue,  
•  pain,  
•  nausea and vomiting 
3. global health and quality-of-life scale. 
Functional Assessment of Cancer  
Therapy-Colorectal 
 
FACT-C 
 
 
5 multi item scales (36 items in total) 
•  Physical (7 items) 
•  Functional (7 items) 
•  Social/family (7 items) 
•  Emotional well being (6 items) 
•  Colorectal Cancer Subscale (9 items) 
Symptom Check List 
 
SCL-90r 
 
 
12 multi item scales (90 items in total) 
•  Somatization 
•  Obsessive-Compulsive  
•  Interpersonal Sensitivity  
•  Depression  
•  Anxiety 
•  Hostility 
•  Phobic Anxiety  
•  Paranoid Ideation  
•  Psychoticism  
•  Global Severity Index  
•  The Positive Symptom Distress Index,  
•  Positive Symptom Total  
medical outcomes short form 36 
 
SF-36 
 
 
8 multi item scales 
•  physical functioning 
•  role limitations (physical) 
•  bodily pain 
•  general health 
•  vitality (energy/fatigue) 
•  social functioning 
•  role limitations (emotional) 
•  mental health 
Satisfaction with Life Scale 
SWL 
 
5 single item scale 
 
Profile of Mood Status 
 
POMS 
 
 
6 multi item scales 
•  Tension-Anxiety 
•  Anger-Hostility 
•  Fatigue-Inertia 
•  Depression-Dejection 
•  Vigor-Activity 
•  Confusion-Bewilderment 
 
Table (2) shows different Health Related Quality of Life (HRQL) assessment tools 
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3.5.2 Physical activity  
Little evidence is available in the literature about the impact of physical activity on 
patient with colorectal cancer and the post-operative course of the disease. However, 
there are enough data to support the positive role of exercise training in general 
patient well being and cardiopulmonary function [411].  
Recent work has critically examined the effects of exercise in contributing to 
improvements in health. A number of studies in patients with breast cancer have 
shown a beneficial effect of exercise on cardiovascular function, in patients who have 
finished their treatment. These indicate that such an approach is safe and promote 
the concept of an individualised approach [59].  
Most of the studies that examine the relationship between physical activity and 
quality of life in cancer have been performed in women with breast cancer. The 
Health, Eating, Activity, and Lifestyle (HEAL) Study developed a tool to investigate 
changes in physical activity levels after a diagnosis of breast cancer relative to pre-
diagnosis levels and to assess the influence of disease stage, adjuvant treatment, 
age, and body mass index (BMI) on these changes [412].  
This was shown to be a reliable indicator. Such studies may have a bearing to our 
approach to colorectal cancer patients. In patients who have been treated for 
colorectal cancer, performing moderate intensity exercise (Home-based exercise) 3-5 
times per week for 20-30 min each time can increase cardiovascular fitness and is 
associated with improvements in quality of life, as measured by the Functional 
Assessment of Cancer Therapy-Colorectal (FACT-C) scale [413].  
Studies in animals that have received chemotherapy suggest that exercise can 
preserve myosin heavy chain isoforms in cardiac muscle [62], and can enhance 
endothelium-dependent vaso-relaxation, following vasoconstriction induced by 5-FU 
[63] These protect against the effects of chemotherapy. 
In the clinical situation, most studies assess exercise following treatment. However, 
there are a small amount of data of its effects prior to, and during, treatment. In an 
Italian study, 8 patients who had been classed as unfit for surgery for lung cancer 
were allocated to a 4 week supervised exercise programme.  
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Both FEV1 and FVC were significantly increased and all 8 patients subsequently had 
successful surgery. There was no mortality. The authors suggested that physical 
exercise could have induced a recruitment of dormant lung parenchyma [64]. 
Seventy patients who were receiving chemotherapy were allocated to a 9 hour 
weekly training programme over 6 weeks with measurement of VO2max. Exercise 
was well tolerated and there was an improvement in aerobic fitness [65]. 
Exercise appears to be a safe, efficacious strategy to maintain or to improve physical 
and mental well-being; however, it is critical that exercise be individualized to specific 
needs of the cancer survivor, who already has a compromised system, to prevent 
exacerbation of physiological and psychological toxicities that occur as a result of 
cancer treatments [414].  
3.5.3 APT effect on HRQL and their relation to exercise  
The effects of APT on health related quality of life (HRQL) are multiple, but the major 
effects are thought to include: fatigue [199], impaired exercise tolerance [199], 
malnutrition [200, 201] and a reduced quality of life [203]. 
Anti-cancer treatment with chemotherapy (CT) and/or radiotherapy (RT) has an 
impact on the overall HRQL as it is a subjective multidimensional construct reflecting 
functional status, psychosocial well-being, and health and disease treatment-related 
perceptions [203, 309]. 
Exercise training has beneficial effects on cardiopulmonary function and HRQL in 
postmenopausal breast cancer survivors who had completed surgery, radiotherapy, 
and/or chemotherapy with or without current hormone therapy use [415]. 
Different assessment tools are available in the clinical practice to measure HRQL. 
Some of those are generic tools, such as SF36, which is a multi-purpose health 
survey to yield a profile of functional health and well-being scores as well as 
psychometrically-based physical and mental health summary measures.  
In addition, disease-specific assessments tools are also available in the clinical 
setting to measure HRQL, physical and nutritional changes such as the European 
Organisation for Research and Treatment of Cancer (EORTC QLQ-C30) and the 
Patient Generated Subjective Global Assessment (PG-SGA). 
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PG-SGA is a validated questionnaire used to define a specific nutritional intervention 
needed to optimise the overall nutritional status in patients with gastrointestinal 
cancer such as patient and family education, nutritional supplements, enteral and 
parenteral triage.  
While EORTC QLQ-C30 is more a disease-specific tools used to assess HRQL in 
patients with colorectal cancer such as physical, emotional and cognitive and social 
functioning as well as social, symptom and financial scales.  
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4.0 AIMS, OBJECTIVES and RATIONALE  
4.1 Primary Aim: 
To assess the cardiopulmonary reserve (represented by VO2max) before and after 
the administration of adjuvant pre-operative chemotherapy and/or radiotherapy (APT) 
using the CPEX testing.  
4.2 Secondary Aims:  
A- To assess changes in body composition before and after APT exposure. Those 
changes will be assessed using Hand-Grip measurements, anthropometric tools and 
bioelectrical impedance analysis (BIA).  
B- To assess changes in plasma cytokines before and after APT using a venous 
blood sample to measure pro-inflammatory markers (TNFα, IP-10, RANTES, IL-6, IL-
18) and anti-inflammatory markers (IL-1β, IL-1ra, IL-10, MIF) as well as plasma CRP 
and albumin.  
C- To assess changes in the HRQL, physical activity and nutritional status before 
and after APT using 2 validated instruments (EORTC QLQ-C30 and PG-SGA 
questionnaires). 
D- To establish any correlations between the study outcomes using Spearman 
correlation test after APT exposure: 
1- Primary correlations:  
• Inputs: CPEX variables  
• Outputs: Demographics, Body composition, Cytokines and HRQL variables 
2- Secondary correlations: 
• Inputs: HRQL variables  
• Outputs: Body composition variables. 
E- To assess the trend of changes between the two groups of patients post APT 
exposure using mixed Anova test.  
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4.3 Null hypotheses: 
Adjuvant pre-operative therapy (APT) has no effect on the cardiopulmonary function, 
nutritional and physical status, HRQL, inflammatory markers and body composition in 
patients with colorectal cancer. 
4.4 Alternate hypotheses:  
Adjuvant pre-operative therapy (APT) has a significant effect on the cardiopulmonary 
function, nutritional and physical status, HRQL, inflammatory markers and body 
composition in patients with colorectal cancer.  
4.5 Objectives and Rationale: 
This study examined the effect of pre-operative adjuvant therapy (APT) on patients 
with adenocarcinoma of the rectum. Patients were identified from the MDT meeting 
and those with an advanced tumour on the operative staging, needing APT, were 
recruited.  
CPEX testing was used to measure changes in functional capacity (represented 
mainly by VO2max and AT) before and after APT administration. CPEX testing is 
considered to be one of the practical and reliable methods to interpret the physiology 
behind oxygen delivery and consumption at tissue level following surgery. The test is 
capable of identifying high risk patients with an increased risk of cardiopulmonary 
mortality and morbidity in the postoperative period [177-179, 252], [253, 254].  
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5.0 METHODS 
5.1 Recruitment 
Patients were identified from the MDT meeting that comprised oncologists, 
radiologist, colorectal surgeon, pathologists and nurse practitioners. Those patients 
with an advanced rectal tumour on pre-operative staging, who were deemed to 
require adjuvant pre-operative therapy (APT), were recruited.  
Patients were selected from the MDT meeting and approached during their first visit 
to the Oncologist at the outpatient clinic. A brief 10 minutes face to face interview 
was conducted between the main study investigator and the selected patient after 
they finished their oncology appointment. The project aims and methods were 
explained to the participant who was provided with a written covering letter explaining 
the aims and methods of the study, a patient information sheet, a consent form, a GP 
letter and two questionnaires in a prepaid self-addressed envelope.  
The approached patient was given at least 24 hours to decide about participation in 
the project. The principal investigator then contacted each participant by phone to 
enquire about their final decision. After the participant accepted entrance into the 
study, they were advised to sign the provided written consent and return it together 
with the first set of fulfilled questionnaires in the enclosed prepaid envelope. A 
helpline number was provided in the covering letter to allow patients to ask any 
questions about the study or if they had difficulty completing the questionnaire. 
  
Thereafter, each patient was allocated to one of the two groups, as per the MDT 
decision: 
Group 1: Patients who will receive combined ChemoRadiotherapy.  
Group 2: Patients who will receive only pelvic radiotherapy. 
 
Each patient was provided with a single appointment (arranged with the participant 
by telephone) to attend the project-specific outpatient clinic. This clinic was located at 
the cardiology physiology department of Leeds General Infirmary.  
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During this initial visit, the following assessments were made: 
 
• Cardiopulmonary fitness (measured with CPEX test) 
• Body composition analysis (measured with BIA) 
• Anthropometric measurements - body weight, height, body mass index, 
triceps skin folds, mid arm circumference and hand grip measurements.  
• A single venous blood sample of 5ml to check for inflammatory markers, CRP 
and albumin.   
• Patients were asked to bring their first set of filled questionnaires.  
 
After completion of the adjuvant pre-operative therapy, patients were subsequently 
contacted by the principal investigator and invited them for a second visit to repeat 
the same assessments above with filling of the second set of questionnaires.  
The study-specific two clinic visits (pre and post APT) were carried out before and 
within two weeks after the administration of the anticancer treatment. This is to give 
the best reflection of the APT effects on the physiology of colorectal cancer patients. 
Patients were provided with travel expenses as well as drinks and snacks during their 
visits and stay for the tests.  
5.2 CPEX 
Cardiopulmonary fitness was measured with the CPEX testing at the exercise testing 
laboratory of Leeds general Infirmary. Changes in VO2max and anaerobic threshold 
(AT) were measured before the administration of APT and 14 days within the finish of 
treatment. Pre-operative cardiopulmonary exercise testing was performed using a 
standard protocol [416].  
5.2.1 Pre-test baseline Data Collection 
The following baseline data were collected on all patients who were recruited: 
• Age, gender, body weight and height.  
• Blood pressure and any history of hypertension 
• History of ischemic heart disease including details of any angina, myocardial 
infarction, cardiac surgery or coronary angioplasty 
• Any history of heart failure 
• Any history of cerebrovascular disease 
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• Any history of diabetes mellitus 
• Hyperlipidaemia 
• Plasma creatinine and any history of any renal impairment 
• Details of current medication 
5.2.2 Exclusion Criteria for CPEX Testing 
• Acute Myocardial infarct (within 7-10 days of transmural infarct or within 5  
days if minor and uncomplicated) 
• Uncontrolled arrhythmias causing symptoms or haemodynamic compromise; 
• Left main stem stenotic lesions in excess of 50% 
• Malignant hypertension 
• Pulmonary oedema 
• De-saturation at rest to less than 85% while breathing room air 
• Acute inflammatory conditions (pericarditis, myocarditis) 
• Unstable angina (patient should be pain free for 4 days before CPEX) 
• Dissecting aneurysm 
• Acute or recent pyrexial illness 
• Thyrotoxicosis 
• Syncope 
• Thrombosis of lower extremities 
5.2.3 The CPEX Test 
The tests were performed by cardiorespiratory technicians and supervised and 
interpreted by medical staff with training and experience of CPEX testing. The CPEX 
test equipment consists of an electronically braked cycle ergometer, 12 lead ECG 
and a gas analyser/metabolic cart. The patient wears a nose clip and breathes 
through a mouth piece connected to a pneumotachograph and metabolic cart 
allowing breath by breath analysis of oxygen uptake and carbon dioxide excretion. 
The patient is connected a 12-lead ECG during the test which, together with a special 
software, allow ST-segment analysis in real time and full disclosure of all leads if 
required. CPEX testing uses two main exercise modalities: the treadmill and the 
stationary cycle ergometer. The work rate can be exactly measured using the bicycle 
ergometer while it is only estimated by treadmill; therefore, the former method is 
preferred by many clinicians nowadays.  
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On the other hand, most patients are familiar with walking as it is a less threatening 
form of exercise for testing purposes than cycling. As walking treadmill provides a 
constantly moving platform, subjects may have difficulty in continually maintaining the 
required forward momentum [235]. Determination of an individual’s maximum 
exercise capacity is influenced by the mode of exercise used [416]. Walking/running 
treadmill utilises more muscle groups which in turn leads to higher oxygen 
consumption than the cycle ergometer by around 5-20% [417].  The Coefficient of 
variation for the CPEX test is less than 5.9% [418, 419]. The test consists of four 
main phases: rest, unloaded cycling, ramp and recovery. The 12 lead ECG is 
monitored continuously for the duration of the test. 
5.2.4 Rest 
The test starts with a 2-5 minutes rest period to allow patient familiarisation with the 
mouthpiece, gas exchange equipment and bicycle as well as allowing for resting 
heart rate, blood pressure (BP), ECG and gas exchange values to be established. 
The proper conduct of this stage of the test is important if valid results are to be 
obtained when exercise begins. Patients can be anxious prior to the start of the test 
and hyperventilation often then occurs once the patient is connected to the 
mouthpiece and other testing equipment. It is important for accurate conduct of the 
test to establish a regular settled resting breathing pattern before initiation of exercise 
for the measurement of the baseline respiratory exchange ratio (RER). The RER is 
the ratio of carbon dioxide output to oxygen uptake. The resting RER should ideally 
be between 0.7-0.95 [420] indicating that the patient is not hyperventilating. 
5.2.5 Unloaded Cycling 
When the patient has become used to the equipment during the rest period, 
unloaded cycling will then start, with a period of 2-3 minutes of steady pedalling at 60 
revolutions per minute with no resistance applied to the cycle ergometer. This allows 
for the oxygen cost of just turning the legs to be evaluated, provides minimum 
resistance for the particularly detrained or functionally limited and ensures that 
oxygen kinetics do not disrupt the measurement of anaerobic threshold. 
5.2.5 Ramp 
The ramp will follow from the unloaded cycling in a continuous fashion where the 
workload against which the patient must pedal is gradually increased.  
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Formulae are available to calculate the ideal rate of increase but this is often set on 
the basis of clinical judgement at a rate of increase of between 10 and 20 Watts per 
minute. The aim is to increase the workload at a rate that allows a full test to be 
completed in less than 10 minutes. The patient is asked to exercise until it is deemed 
that the anaerobic threshold has been passed or the individual can no longer 
maintain the prescribed rate of peddling or walking/running on the treadmill [235]. 
5.2.6 Recovery 
Exercise finishes with a cool down stage in which the patient pedals the bicycle for a 
brief period against zero resistance, or the treadmill is slowed to a walking pace. This 
is to prevent collapse due to hypotension and syncope if exertion is stopped 
suddenly. Blood pressure measurement is performed throughout the whole test, 
usually 3-4 times. The ECG is monitored until the heart rate is within 10 beats per 
minute of the pre test rate. 
When on the exercise bike, the patient is instructed to cycle at 50-60 RPM as 
indicated by a meter on the bicycle handlebars. The electronic braking on the bicycle 
will be programmed to allow five minutes of cycling with no resistance (unloaded 
cycling) and then five minutes of cycling with steadily increasing resistance such that 
the patient achieves anaerobic metabolism, and lactate starts to accumulate in the 
muscles. Hence, anaerobic threshold (AT) can be determined (ramp) at that point but 
the patient will continue the programmed exercise up to their VO2peak. The work rate 
increments are determined using the following equations: 
I. VO2 unloaded (ml/min) = 150 + (6 x weight (kg) 
II. Peak VO2 (ml/min) Men = height (cm) – age (years) x 20 
III. Peak VO2 (ml/min) Women = height (cm) – age (years) x 14 
IV. Work Rate increment (W/min) = (Peak VO2 –VO2 Unloaded) / 100 
 
5.2.7 Test Termination 
Possible reasons for terminating the test include: 
1. VO2peak attained- patient unable to maintain cadence of greater than 40 rpm 
on cycle one minute and doesn’t respond to encouragement.  
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2. Signs or symptoms of myocardial ischemia or dysfunction:  
a) Chest pain 
b) New S-T segment changes exceeding –2.0 mm (depression) or +3.0 
mm (elevation) 
c) New dysrythmia 
3. The patient stops pedalling due to chest pain, dizziness, feeling unwell or light 
headedness before the other criteria have been obtained. 
The CPEX test is a relatively safe procedure, with a quoted risk of death of between 
2-5 per 100,000 clinical exercise tests [416]. It is important as with all clinical tests, to 
gain informed consent prior to the procedure with appropriate discussion of risks. 
5.2.8 Peak Workload and Exercise Time 
Exercise time and peak workload as well as percentage of predicted peak workload 
are reported. 
5.2.9 VO2max and VO2 peak 
At VO2max, a subject has achieved the maximum possible oxygen consumption 
(ml/kg/min). A plateau in oxygen consumption between the final two work rate 
increments indicates that maximal oxygen uptake has been achieved and sustained 
for a brief period. As the work rate increases during exercise, one or more of the 
determinants of oxygen uptake reaches its maximum limit for that subject. In healthy 
subjects, oxygen uptake is limited by cardiovascular reserve (heart rate and stroke 
volume) rather than by respiratory reserve. Maximal oxygen uptake is dependent 
upon the mode of exercise, age, gender and body weight. Formulae for predicted 
VO2max (ml/kg/min) are: 
VO2 = W x [50.75 – 0.372(A)] (male subjects) 
VO2 = (W + 43) x [22.78 – 0.17 (A)] (female subjects) 
Where W is weight in kilograms and A is age in years. Values of 85% of predicted or 
more are considered to be within the normal range [235]. 
VO2max can be identified only in trained athletes. In most patients a clear plateau in 
oxygen uptake is not seen before exercise is limited by fatigue or terminated. 
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Generally, maximal tests in the clinical setting report the result of peak oxygen 
uptake [235]. 
VO2peak is the oxygen consumption (ml/kg/min) at the maximum level of exercise 
that a subject can attain regardless of whether a plateau in oxygen consumption is 
seen. VO2peak has the weakness that it is dependant on volition, i.e. on the subject’s 
willingness to exert themselves to their limit. However, it allows peak oxygen 
consumption to be reported in subjects in whom a true VO2max cannot be defined 
and is an important indicator of exercise capacity in subjects in the clinical setting. 
VO2peak is widely recognised as a risk stratifying measure in patients with 
cardiovascular disease [255]. It is a widely used measure in the evaluation of chronic 
heart failure [421]. 
To make this clear, patients might reach their VO2peak depending of their physical 
fitness, but this might not be their VO2max based on their body calculations.  
5.2.10 Anaerobic Threshold (AT) 
The anaerobic threshold (AT), also known as the metabolic threshold, identifies the 
point during the CPEX test where an increase in blood lactate levels during exercise 
is noted.  
The rise in circulating lactate during exercise was attributed by Wasserman and 
McIlroy to the existence of a critical threshold at which the metabolic needs for 
oxygen in the muscle exceed the capacity of the cardiovascular system to supply 
them [422]. In recent years this interpretation has been questioned and alternative 
explanations for the increase in lactate posited [423].  
The first method of measuring anaerobic threshold is the modified V-Slope method 
which is based on a graph in which carbon dioxide excretion on the y-axis is plotted 
against oxygen uptake on the x-axis (Figure 6). This produces a straight line (S1) 
with a gradient of approximately unity as oxygen uptake and carbon dioxide excretion 
increase with exercise [424].  
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As exercise intensity increases and the blood lactate concentration begins to rise 
there is a increase in the steepness of the slope (S2) as an excess of carbon dioxide 
is produced by the action of the bicarbonate buffer system.  
This inflection point identifies the anaerobic threshold. This line has a gradient of one 
when metabolism is aerobic and it increases as metabolism becomes anaerobic. The 
inflexion point of the line is taken to indicate the transition to anaerobic metabolism.  
The changes seen in respiratory gas analysis are used to identify the point at which 
the lactic acid concentration in the blood begins to increase. During the initial aerobic 
part of the CPEX test, carbon dioxide production from working muscles increases 
linearly with oxygen consumption. Blood lactate levels do not change substantially 
during this period, since muscle lactic acid production does not exceed the body’s 
capacity for removal [423].  
The second method of measuring anaerobic threshold is identified during CPEX 
testing when there is an increase in carbon dioxide excretion relative to oxygen 
uptake. The increase in carbon dioxide production is due to the buffering of lactate by 
the bicarbonate buffer system, causing a rise in CO2 carbon dioxide production.  
AT can be identified as the VO2 at which there is a systematic increase in the 
ventilatory equivalent for oxygen (VE/VO2) (see below) without an increase in the 
ventilatory equivalent for carbon dioxide (VE/VCO2) (see below). As with VO2 peak, 
anaerobic threshold is reported in ml/kg/min of oxygen uptake. 
Whilst the V-slope method is widely used, there is no clear advantage of one of the 
above methods over another [425].  
The guideline of the American Thoracic Society and the American College of Chest 
Physicians is to use both the V-slope method and ventilatory equivalents method 
(dual criteria) [416]. 
5.2.11 Respiratory Function and Ventilatory Equivalents 
Static lung function tests are performed at the outset of the test. These include forced 
expiratory volume at the first second (FEV1), forced vital capacity (FVC) and 
maximum voluntary ventilation (MVV).  
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The ventilatory equivalent for oxygen is the ratio of total expired volume to the 
volume of oxygen taken up at a given point in the test, VE/VO2. The ventilatory 
equivalent for carbon dioxide is the ratio of expired volume to the volume of carbon 
dioxide excreted at a given time point, VE/VCO2.  
These numbers give an indication of the amount of ventilation that is required to take 
up oxygen and to eliminate carbon dioxide. That is to say they are measures of 
respiratory efficiency, with higher values indicating that more ventilation (a greater 
minute volume) is required for a given amount of oxygen uptake or carbon dioxide 
excretion. The normal pattern of change in VE/VO2 is a decrease in early exercise to 
a nadir at or close to the anaerobic threshold and then an increase as maximum 
exercise capacity is approached.  
The increase in ventilation that causes this increase in VE/VO2 is caused by the 
increased carbon dioxide production due to the buffering of lactate. The ventilatory 
equivalent for carbon dioxide also decreases with the start of exercise. The upturn in 
the equivalent for carbon dioxide occurs after that for oxygen and reflects increasing 
hyperventilation with a reduction in PaCO2 to compensate for metabolic acidosis 
[235].  
5.2.12 ECG 
Baseline heart rate, peak heart rate and peak heart rate as a percentage of predicted 
are recorded. Evidence of myocardial ischemia and arrhythmia are reported. 
5.2.13 Oxygen Pulse 
The ratio of heart rate to oxygen uptake (VO2/HR) is termed the oxygen pulse and is 
a measure of oxygen extraction per heart beat. In healthy subjects oxygen uptake 
increases steadily with increasing work at lower exercise intensities. At higher 
intensities the rate of increase slows.  
Failure of the oxygen pulse to increase can be an indicator of poor left ventricular 
function and is often viewed as an indicator of myocardial ischaemia. Values reported 
are: baseline, peak value and peak value as a percentage of predicted [235]. 
A number of CPEX variables were analysed in this chapter. However, our primary 
outcome measure were AT and VO2max. AT has been measured in those patients 
as per the validated V-slope method [426-428].  
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(Modified V-slope method)        (VEVO2 and VEVCO2 method) 
 
Figure (6) shows the two methods of measuring AT 
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(Cardiopulmonary Exercise test, CPEX) 
 
 
 
 
 
 
Figures (7) show the Cardiopulmonary Exercise test 
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(Cardiopulmonary Exercise test, CPEX) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures (8) show the Cardiopulmonary Exercise test 
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5.3 Body composition  
Body composition status and changes have been assessed in this project via five 
methods. These changes are measured before the administration of APT and 14 
days within the finish of treatment. 
5.3.1 Anthropometric measurements: body weight (kg), height (m) and body mass 
index (BMI/kg.m-2) using a clinical electrical scale, clinical tape measure and a 
standard BMI chart. These measurements were obtained prior to conducting the 
CPEX testing and bioimpedance analysis.  
5.3.2 Mid-arm circumference (MAC): To obtain this dimension, the patient is asked to 
flex the elbow joint to 90 degree in a standing position. Thereafter, the distance 
between the olecranon process and the tip of the acromion process is measured on 
the non-dominant side and a mid-point is identified on the extensor surface of the 
arm (over the triceps muscle) to represent the level of the MAC. Using a tape 
measure, this arm level circumference is measured with a metric scale to the nearest 
0.1 cm. 
5.3.3 Triceps skin folds (TSF) using a (Holtain Ltd, Dyfed, UK) calliper pressure 10 
g/mm2, precise to 0.2 mm. This is performed by grasping the skin and underlying 
tissue over the mid-arm point of the triceps muscle (the same method of MAC), 
shaking it to exclude any muscle and pinching it between the jaws of the calliper. 
Triple readings were obtained within 5 minutes to improve the accuracy and 
reproducibility of the measurements with an average final reading recorded.  
5.3.4 Hand grip measurement (HG) using Takei Hand Grip Dynamometer/Digital 
A5402. This is used for measuring the flexion of the wrist and provides an accurate 
reading of grip strength. The Takei Dynamometer is also useful for estimating a 
general value for upper body strength. The dynamometer is a standard piece of 
equipment in most physiology testing labs and provides an easy and safe means of 
measuring muscular strength. It can be adjusted to fit a wide range of hand sizes and 
normative grip values are available from ages 10 to 70 years. Again, three different 
readings are obtained within 5 minutes and the mean is used as the final 
measurement.  
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(Anthropometric measurements) 
 
 
 
 
 
 
 
 
 
 
Figures (9) show the Anthropometric measurements 
Triceps skin-fold 
(TSF) 
Mid-arm 
circumference 
(MAC) 
Hand-grip 
measurements 
(GS) 
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5.3.5 Bioelectrical impedance Analysis (BIA) using a HYDRA ECF/ICF (Xitron, model 
4200). This instrument uses a microprocessor, single conversion and digital signal 
processing technology to produce a flexible, accurate and reliable measurement of 
BIA. Although the HYDRA ECF/ICF can be used without the need for a computer, we 
have opted to use a controlling computer with the BIS4200 System Utilities Software 
for easy storage of electronic data and analysis. Hence, HYDRA acquisition.exe 
enables the device to be controlled by a host compatible PC. The BIA coefficients of 
variation (represented as percentage) on repeated measurements range between 1-
5% [429, 430]. 
HYDRA mode should be set to single frequency measurement with selection of the 
ankle-wrist method. Also, FFM prediction should be turned on at the same time 
during the initial setting to get an immediate reading. Subsequently, data must be 
entered for each single individual including body weight, height and sex.  
BIA is used to measure intracellular, extracellular and total body water. It is also 
possible to obtain other data from the BIA machine such as the fat mass (FM), fat 
free mass (FFM) or lean body mass, as well as the body resistance to the two fluid 
compartments [431]. BIA measurements usually take about 1 minute to complete and 
this conventional method has been successfully validated in the literature on a variety 
of subject populations [432-437] 
The individual is placed in a supine position with legs and arms slightly abducted at 
15 degree, on a flat non-metallic bed (the same bed used for measuring bone 
densitometry body scan) for about 10-15 minutes to get a static measurement of their 
body composition [438]. HYDRA machine, computer and cables are kept away from 
the patient to avoid any possible reading interference, as the patient remains 
motionless throughout the measurement.  
The body surface between all contacts is cleaned with alcohol swab and connecting 
electrodes are attached to a non-hairy skin part of the body. The sticky connecting 
electrodes should have at least a 5cm2 of contact area to get an accurate 
measurement.  The BIA measurements are performed using four electrodes attached 
via small “alligators” clips, enabling a connection to the body electrode. The Red-
voltage detectors are placed proximally and the Black-current injectors are placed 
distally.  
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Two clips are attached at the wrist, the black clip is connected to the extensor 
surface of metacarpal-phalangeal joints and the red clip is attached to the extensor 
aspect of mid-line between the radial and ulnar heads on the right side. The other 
two wires are attached at the ankle, with the black clip attached to the dorsal aspect 
of the metatarsal-phalangeal joints and the red clip attached mid-way between the 
medial and lateral malleoli on the same side. Red and black electrodes should be at 
least 5cm away from each other to give the best results.  
For the multi-frequency measurement (ranges from 5KHz to 1MHz, typically at 50 
kHz), a weak alternating current is passed through the outer pair of electrodes, while 
the voltage drop across the body is measured using the inner pair of electrodes from 
which the body’s impedance is calculated. To convert this information to a volume 
estimate, two basic assumptions are used. First, the body can be modelled as an 
isotropic cylindrical conductor with its length proportional to the subject’s height (Ht). 
Second, the reactance (X) term contributing to the body’s impedance (Z) is small, 
such that the resistance component (R) can be considered equivalent to body 
impedance [256].  
When these two assumptions are combined, it can be shown that the conducting 
volume is proportional to the term Ht2/R, called the impedance index. It should be 
noted, however, that the human body is not a cylindrical conductor, nor are its tissues 
electrically isotropic, and the reactance component of the body’s impedance is non-
zero [439]. At 50 kHz, the body’s impedance has both resistive and reactive 
components. The reactive component is assumed to be related to the portion of the 
current that passes through cells, which act like capacitors that shift the voltage and 
current out of phase. 
3 consecutive and repeated measurement were taken from each patient within a 
period of 30 minutes to eliminate any possible errors or variations as suggested by 
Kushner in 1996 [440]. ICW, ECW and TBW were measured in litres while the FFM 
was obtained in kilograms. Adhesive conducting electrodes were placed in the exact 
position pre and post APT administration to avoid any variation made by electrode 
misplacement [441]. 
All measured data were saved electronically and on a hard copy after taking the 
mean of the ECW, ICW, TBW and FFM.  
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(Bio-electrical Impedance Analysis, BIA) 
 
 
 
Figures (10) show the Bio-electrical Impedance Analysis 
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5.4 Cytokines, albumin and CRP 
Changes in the patients inflammatory markers were measured via a plasma sample 
obtained before the administration of APT and 14 days within the finish of treatment. 
5.4.1 Processing the sample 
A total of 5mls of venous blood was taken from the patient. This blood sample was 
placed in a lithium-heparin tube and carried immediately to the laboratory after proper 
shaking. In the hospital laboratory, disposable pipettes were used to distribute the 
blood sample into 3 eppendorf tubes, each is 1.5ml size. Subsequently, these tubes 
were placed in an MSE MicroCentaur for about 8-9 minutes with a 12,000rpm speed 
to obtain the plasma samples. At the end of this centrifuge process, eppendorf tubes 
were removed from the rotor and placed on an eppendorf plastic holder for isolation 
of the plasma samples. Using another clean disposable plastic pipette, the top clear 
yellow plasma sample was aspirated from the 1st eppendorf and placed into a fresh 
and newly labelled eppendorf (1st plasma sample).  
The same process was repeated for the other two centrifuged samples to get a total 
of 3 clear plasma samples in new eppendorf tubes. These were labelled with patient 
initials, patient’s date of birth and the date of the procedure, with number 1 for a 
sample pre-APT administration and number 2 for a post-APT sample. During the 
aspiration of the top clear yellow layer of plasma from the eppendorf using the 
pipette, extra caution was directed towards avoidance of contamination of the plasma 
sample with the buffy coat layer (white cells) or the dark red sediment layer (red 
cells). If this happened, then this disturbed eppendorf was centrifuged again using 
the same process mentioned before. 
5.4.2 Storage of the sample 
Finally, the 3 eppendorf tubes containing the plasma samples were stored in a -80 
degree freezer within the same lab.  The location of the samples was recorded 
electronically on a spreadsheet, as well as on a hard copy samples map. Hence, 
each patient had  3 plasma samples pre-APT and 3 samples post-APT.  
We had a total of 32 patients who had completed their pre and post APT blood 
samples.  
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This means that 96 pre-APT samples and another 96 post-APT plasma samples 
were obtained and stored in a confidential -80 degree freezer (3 eppendorf tunes for 
each patient per single test). The plan was to use the 1st plasma sample for cytokines 
analysis, 2nd sample for CRP and albumin assay and the 3rd final plasma sample to 
be stored in the University of Leeds laboratory for future use and reference.   
About 18 months after finishing of the trial, 4 eppendorf tubes per patient (2 pre and 2 
post APT) were taken from the storage freezer making up a total of 128 plasma 
samples used for the assay of cytokines, CRP and albumin.  
Each cytokine was assayed by multiplex immunoassay on a Luminex 96 cytometer in 
duplicate. A range of pro-inflammatory markers (TNFα, IP-10, RANTES, IL-6, IL-18) 
and anti-inflammatory markers (IL-1β, IL-1ra, IL-10, MIF) as well as plasma CRP and 
albumin were measured in pg/m (picogram/microlitre).   
5.4.3 Cytokines Assay Principle 
 
The usual methods of cytokine estimation are either by bioassay or ELISA. These 
methods are limited to analysis of a single cytokine at a time and are therefore time 
consuming and require a large sample volume. The Luminex fluid-phase sandwich 
immunoassay, based on flow cytometry, has been used to quantify multiple cytokines 
at the same time from a single plasma sample. The Luminex principle utilises up to a 
hundred colours of coated polystyrene beads each having a distinct spectral address. 
Antibodies couple with the coloured bead and react with specific cytokines. A 
secondary biotinylated antibody, specific for another epitope of the cytokine, is added 
to the mixture to create an antibody sandwich. This secondary antibody is targeted in 
the final step of the process, which is the addition of Streptavidin-phycoerythrin. The 
microbeads are aligned in a single file by the cytometer where they are exposed to a 
twin LASER system in the flow cell. This uses emission spectra to quantitate the 
amount of antigen bound to each antigen specific bead. The values are compared on 
a standard curve thereby allowing a conversion of mean fluorescence to 
concentrations in picograms per microlitre. 
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Figures (11) show the LUMINEX machine for the Cytokines analysis 
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Preparation of the sample  
 
1. Preparation of plasma sample 
Plasma samples previously stored at -80°C were thaw ed at room temperature and 
diluted with equal quantities of plasma diluent. Plasma diluent is required to 
compensate for the large amounts of non-cytokine protein in the sample. Each 
eppendorf was de-iced using a Spinmix for about 40 seconds, this method is called 
Vortex. Microfuse tubes were then centrifuged again for about 4-5 minutes to remove 
any white coat that is normally precipitated at the base and contains unwanted cell 
debris, as this might clog the well and alter the cytokines analysis.  
2. Preparation of cytokine standard (master stock) 
The stock vial of the cytokine standard was reconstituted with 500µl of standard 
diluents, vortexed for 1-3 seconds and incubated on ice for 30minutes. 
3. Preparation of serial dilution of cytokine standard 
7 x 1.5ml eppendorf tubes were labelled and 150µl of standard diluent added to 
each. In the 8th tube, 187.2µl of standard diluent was pipetted. 12.8µl of the master 
stock was added to tube 8 and the tube was vortexed. This was used for serial 
dilution with 50µl of the solution being added to tube 7. Following vortexing of tube 7, 
50µl of the mixture was added to tube 6, which was then vortexed. 50µl from tube 6 
was pipetted to tube 5 and 50µl was subsequently transferred from each successive 
tube to the next with the last tube being tube 2 which had a serial 4-fold dilution. 
Tube 1 contained only standard diluent and acted as a reference zero standard. 
4. Preparation of anti-cytokine conjugated beads 
240µl of stock beads from a 25 x bead stock was prepared by diluting with 5,760µl of 
Bio-PlexTM assay Buffer, making up a total volume of 6,000ul. Following vortexing 
for 30 seconds, 50ul of bead mixture containing 2ul of beads was pipetted into each 
well. 
5. Preparation of antibody detection solution 
The 10 x stock detection antibody vial was centrifuged for 30 seconds. It was diluted 
to a 1 x concentration by adding 2,700ul of detection antibody diluent to 300ul of 10 x 
stock detection antibody. This remained stable for 4 hours at room temperature 
stored in the dark. 
6. Preparation of Streptavidin-phycoerythrin 
The Streptavidin–PE 100 x stock vial was centrifuged for 30 seconds and 60µl of the 
stock was then diluted to a 1 x solution by adding 5,940µl of Bio-PlexTM assay buffer 
to make a final volume of 6,000µl. 
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Procedure 
 
1. The 96 well plate was wetted with Bio-PlexTM assay buffer (100µl per well). 
Samples were analysed within 30 minutes from being out of the ice. 
2. The buffer was removed by vacuum filtration by placing the filter plate on a 
calibrated filter plate vacuum manifold. 
3. The filter plate was blotted with a lint-free paper towel. 
4. The multiplex bead solution was vortexed for 15-20 seconds and 50µl of solution 
pipette into each well. 
5. The solution was removed using vacuum filtration. 
6. The plate was washed twice using Bio-PlexTM wash buffer (100µl per well), which 
was removed with vacuum filtration. 
7. 50µl of standard serial dilution and samples were pipetted into separate wells. 
8. The plate was covered with sealing tape and with aluminium foil to prevent 
exposure to light and photobleaching of the beads. The plate was placed on a 
shaker; the shaker speed was slowly increased to 1,100rpm for 30seconds then 
reduced to 300rpm and incubated at room temperature for 30 minutes. 
9. The solutions were removed using vacuum filtration. 
10. The plate was washed twice using Bio-PlexTM wash buffer as in step 6 and 
stored in the dark. 
11. The antibody detection solution, prepared 10 minutes prior to usage, was 
vortexed and 25µl pipetted into each well. 
12. The plate was covered as in step 8. 
13. The solution was removed using vacuum filtration. 
14. The plate was washed thrice using Bio-PlexTM wash buffer as in step 6 and 
stored in the dark. 
15. 50µl of vortexed streptavidin-PE solution was added to each well. 
16. The plate was covered with sealing tape and aluminium foil, placed on a shaker 
and shaken at 1,100rpm for 30 seconds and then reduced to 300rpm for 10 minutes 
at room temperature. 
17. The solution was removed using vacuum filtration. 
18. The plate was washed thrice using Bio-PlexTM wash buffer as in step 6 and 
stored in the dark. The plate was blotted with a lint-free towel. 
19. 125µl of Bio-PlexTM assay buffer was pipetted into each well. 
20. The plate was sealed, placed on a shaker and shaken at 1,100rpm for 30 
seconds at room temperature. 
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21. The sealing tape was removed and the plate immediately read on the Bio-PlexTM 
system consisting of Luminex-100 cytometer and Bio-Plex Manager software 
(version 4.1). The coefficient of variation for the Luminex-100 cytometry is not more 
than 10% [442-444].   
5.4.4 Latex Immunoassay for the determination of the C-reactive protein (CRP) 
concentration in the serum and plasma 
CRP is an acute phase protein whose concentration is to increase as a result of any 
inflammatory process. This is used as a marker or general diagnostic indicator to 
detect infections and non-specific inflammation, in addition to serving as a monitor of 
patient response to pharmacological therapy and/or surgery [445]. CRP is usually 
measured via CRP Ultra, which is a latex immunoassay developed to accurately and 
reproducibly quantifies CRP levels in serum. When an antigen-antibody reaction 
occurs between CRP in a sample and anti-CRP antibody, which has been absorbed 
to latex particles, agglutination results. This agglutination is detected as an 
absorbance change, with the change in agglutination being proportional to the 
quantity of CRP in the sample. The Reagents components of the kit, stored in 2-8C in 
unopened vials, are stable up to the expiry date indicated on the package. These 
ready-made reagents are: 
Reagent 1: Glycine buffer pH 7.0, sodium azide < 0.1%. 
Reagent 2: Anti-CRP polyclonal antibodies absorbed on latex particles in a 0.2% 
suspension, sodium azide < 0.1%. 
Calibration has to be made using either the standard or the ultrasensitive method as 
per the instruction contained in the kit [446]. Serum, plasma samples (heparin, 
EDTA) are collected in accordance with the NCCLS procedure [447]. All reagents 
must reach the working temperature before being used. A proportional variation of 
the indicated reaction volumes does not change the results.  
CRP levels are calculated by plotting a calibration curve on a graph paper by tracing 
absorbance (y axis) according to corresponding mg/dL concentration (x axis) for 
each calibration. Then, absorbance values obtained from Samples and Controls are 
indicated on the calibration curve, which will eventually extrapolated to get the mg/dL 
value. The conversion factor is CRP (mg/dL) X 10 = CRP (mg/L) with a reference 
adult value of < 0.5 mg/dL [448].   
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Figures (12) show the CRP analysis machine and the Lab at the LIMM building                
(Leeds Institute of molecular Medicine) 
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Figures (13) show the centrifuge machines at the LIMM building   
  (Leeds Institute of molecular Medicine) 
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5.5 Health Related Quality of Life (HRQL) 
HRQL were assessed using 2 validated questionnaires, the European Organisation 
for Research and Treatment of Cancer (EORTC QLQ-C30) and the Patient 
Generated Subjective Global Assessment (PG-SGA). After obtaining all of the 
necessary approvals for using these questionnaires in our research, each patient 
was given a copy of both assessment tools during the first visit and another copy in 
the second visit. Before taking the individual to the CPEX or the BIA lab, each patient 
was given around 15 minutes to complete both questionnaires in a relaxed 
environment within a private room. This process is done before the APT 
administration and repeated within 14 days after the finish of the anticancer therapy.  
Both assessments tools were used to measure the following variables: 
a) Changes in the overall quality of life and psychosocial well-being 
b) Physical, emotional, cognitive and social functioning as well financial 
scales. 
c) Symptoms related to weight change (anorexia, nausea, constipation, 
mucositis, vomiting, diarrhoea, xerostomia, pain), alterations in food 
intake compared with the usual intake, and functional capacity. 
d) Changes in the daily physical activities and function. This included 
type, duration, and frequency of activities performed such as fast 
walking, moderate/slow walking, jogging, aerobics, tennis, household 
cleaning, and yard work. 
5.5.1 Patient Generated Subjective Global Assessment (PG-SGA) 
Over the last three decades, the oncology nutritional screenings have evolved 
dramatically to use information in improving the outcome.  
The evolution began in the 1980s when Detsky and Baker first showed that the 
results of clinical assessment of nutritional status correlated with results of 
assessments using laboratory tests and anthropometric measures. The major factor 
clinicians use to determine overall nutritional status is loss of subcutaneous tissue, 
muscle, and weight [449, 450]. 
Several methods of detecting nutritional deficit have been used in the past including 
anthropometrics measurements, laboratory tests and various nutritional indices [451]. 
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Patient Generated Subjective Global Assessment (PG-SGA) was developed by Faith 
Ottery, the University of Toronto in 1987 [452]. This is a reliable assessment tool 
which is easy to use, cost-effective, reproducible in several clinical settings and able 
to predict those patients who need nutritional intervention [452]. 
The PG-SGA is may be used to achieve a restoration of nutrient intake to optimal 
levels to meet requirements in order to reduce the risk of complication associated 
with malnutrition 
The first four sections of the PG-SGA are completed by the patient, with the 
remaining portions of the PG-SGA completed by the clinician (physician, nurse, or 
dietician). Each patient is classified as well-nourished (SGA A), moderately or 
suspected of being malnourished (SGA B) or severely malnourished (SGA C).  
The total PG-SGA score was calculated and all data were represented on an excel 
spreadsheets for easy analysis and assessment (full details of PG-SGA scoring 
system can be seen in the appendix section.  
 
 
 
 
 
 
 
 
 
 
Figure (14) shows the PG-SGA final stages after scoring 
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5.5.2 European Organisation for Research and Treatment of Cancer (EORTC QLQ-
C30) 
The European Organisation for Research and Treatment of Cancer (EORTC) was 
founded in 1962, as an international non-profit organisation.  The aims of the EORTC 
are to conduct, develop, co-ordinate and stimulate cancer research in Europe by 
multidisciplinary groups of oncologists and basic scientists.  Research is 
accomplished mainly through the execution of large, prospective, randomised, multi-
centre, cancer clinical trials. 
The EORTC Central Office Data Centre, created in 1974, is concerned with all 
aspects of phase II and phase III cancer clinical trials, from their design to the 
publication of the final results.  Since its inception, over 80,000 patients have been 
entered in trials handled by the EORTC Data Centre [453]. 
In 1980, the EORTC created the Quality of Life Group, which in 1986 initiated a 
research programme to develop an integrated, modular approach for evaluating the 
HRQL of patients participating in cancer clinical trials.  This led to the development of 
the EORTC QLQ-C30, a quality of life instrument for cancer patients.  To date, more 
than 2200 studies using the QLQ-C30 have been registered.  
This European questionnaire (QLQ- C30) was released in 1993 as a validated tool to 
assess the health-related quality of life (HRQL) for patients with cancer. The QLQ-
C30 is a "core questionnaire" which incorporates a range of physical, emotional and 
social health issues relevant to a broad spectrum of patients with cancer; the core 
questionnaire should be used, unmodified, in all QLQ assessments [454, 455]. 
The QLQ-C30 is composed of both multi-item scales and single-item measures. 
These include five functional scales, three symptom scales, a global health status / 
HRQL scale, and six single items.  Each of the multi-item scales includes a different 
set of items - no item occurs in more than one scale. All of the scales and single-item 
measures range in score from 0 to 100.  A high scale score represents a higher 
response level  
Thus a high score for a functional scale represents a high / healthy level of 
functioning, a high score for the global health status / HRQL represents a high 
HRQL, but a high score for a symptom scale / item represents a high level of 
symptomatology / problems. 
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The principle for scoring these scales is the same in all cases: 
1. Estimating the average of the items that contribute to the scale; this is the raw 
score. 
2. Using a linear transformation to standardise the raw score, so that scores range 
from 0 to 100; a higher score represents a higher ("better") level of functioning, or a 
higher ("worse") level of symptoms [453, 456].  
Data were saved and represented on an excel spread-sheet for easy analysis and 
assessment of answers (full details of QLQ- C30 scoring system can be seen in 
appendix 2 and 3).  
 
5.6 Patients characteristics:  
Several patients characteristics were collected on this cohort of patients. These were: 
age, type of APT with dose and duration as well as time interval between APT and 
surgery. 
 
5.7 Inclusion criteria 
A. Adenocarcinoma of rectum. 
B. Patients who received adjuvant preoperative therapy (APT). 
C. Patients who are fit to go on the CPEX test.  
D. Patients who agreed to enroll in this pilot study. 
 
5.8 Exclusion criteria 
A. Patients who are unable or decline to give consent. 
B. Patients with known malabsorption syndrome. 
C. Patients with renal failure.  
D. Patients who are not fit enough to go on the CPEX machine. 
E. Patients with colonic cancers.  
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5.9 Power calculation and Statistics  
The primary outcome of the study was to identify the impact of APT on VO2max 
measured by CPEX testing. The number of patients required for this was estimated 
based on previous findings, that suggested that a difference in VO2max of 
approximately 1.5mls/kg/min might be considered as clinically significant. .Assuming 
the difference of at least 1.5mls/kg/min [457] between the two groups (pre APT and 
post APT) in this study, it was calculated that 32 patients would have 80 per cent 
power to detect a significant difference between the two groups at a 0.05 alpha level.  
Test Normality was assessed with a Kolmogorov-Smirnova and Shapiro-Wilk tests. 
The result was in favour of using parametric test to analyse the study outcome 
measures. However, its has been recommended by expert statisticians in Leeds and 
Cardiff to use non-parametric tests to analyse the study data to avoid any statistical 
errors and to be on the safe side due to the small sample size for the whole group 
and the subgroups. Therefore, non-parametric tests were used to compare paired 
related samples (Wilcoxon Rank Sum Test). Results and data are represented in 
Median and Interquartile range pre and post therapy exposure. HRQL data was 
analysed with repeated measures analysis. A p-value < 0.05 was considered 
statistically significant. PASW Statistics 18 software was used, release 18.0.0 (UK, 
July 30, 2009), using WinWrap basic.  
 
5.10 Consent  
The right of the patient to refuse consent without giving reasons was respected. 
Furthermore, patients were able to withdraw from the study at any time without giving 
reasons and without prejudicing any further treatment. A copy of the consent was 
given to the patient and one filed in the study master file. The written consent was 
taken by a clinician, who has signed and dated the staff authorization / delegation 
log.  The process of obtaining written consent was clearly documented in the 
patient’s medical notes. 
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5.11 Ethical considerations 
 
The trial was performed in accordance with the recommendations guiding ethical 
research involving human subjects adopted by the 18th World Medical Assembly, 
Helsinki, Finland, 1964, amended at the 48th General Assembly, Somerset West 
Republic of South Africa, October 1996. Informed written consent was obtained from 
the patients prior to registration into the study.  
 
The study was submitted to and approved by a main Research Ethics Committee 
(REC) with reference number of 09/H1306/79 prior to entering patients into the study. 
In addition, The Leeds Teaching Hospitals have sponsored the project via the 
Research and Development department (R&D) with reference number of GS09/9007.  
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5.12 Trial schedule 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
                            Before Adjuvant pre-operative therapy (APT)  
 
 
 
 
 
 
 
                                 
 
        After Adjuvant pre-operative therapy (APT)                         
 
 
 
 
 
 
 
                                 
 
 
 
 
Diagram (1) shows the study design and schedule 
 
Group 1 
ChemoRadiotherapy patients 
 
MDTM 
APT for rectal cancer  
 
Group 2 
Radiotherapy only patients 
Patient informed of study aims  
Patient information leaflet provided 
Patient consent 
• CPEX test  
• Body Composition test 
• Blood test  
• Structured questionnaires about HRQL, nutritional and physical changes 
• CPEX test  
• Body Composition test 
• Blood test  
• Structured questionnaires about HRQL, nutritional and physical changes 
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5.13 Storage of venous blood sample 
 
Samples were stored in coded format within a locked location for use in future 
research projects. Storage by research team will be pending for ethical approval to 
use in another project. The researcher’s institution (Leeds General Infirmary) holds a 
storage licence from the Human Tissue Authority.  
 
 
5.14 Statement of Indemnity 
 
Clinical negligence indemnification will rest with the participating NHS Trust or Trusts 
under standard NHS arrangements. As sponsor, the Trust does not provide 
indemnification against claims arising from non-negligent harm. 
 
 
5.15 Publication Policy  
 
Results from the study will be submitted for publication to appropriate peer review 
journals specific to the area of research. It is intended that the publications will be 
produced soon after completion of the period of research in September 2014. The 
sponsor will be informed of acceptance of any and all publications. 
 
 
5.16 Methods of dissemination 
 
Data will be presented to a local audience. These will include members of the 
colorectal cancer MDT, together with anesthetists and appropriate nursing staff. It is 
hoped that sufficient data will be collected for presentation at national / international 
surgical, oncological and anaesthetic meetings, prior to publication in peer reviewed 
journals. 
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38  
 
Patients 
approached 
1 patient declined 
enrolment  
2.63% 
 
(37 patients left) 
 
1 patient was 
excluded 
2.63% 
 
(36 patients left) 
 
2 patients in Group 1 
2 patients in Group 2 
Excluded from  
 
 (32 patients left for 
Cytokines analysis only) 
6.0 RESULTS 
From January 2010 until January 2011, 38 patients were approached for this 
pragmatic pilot study. One patient had clearly declined an anticipation due to the 
disease-related overwhelming stress and another patient was excluded due to the 
presence of a unilateral below knee amputation.  
Hence, 36 patients were successfully enrolled in this study and all of them have 
completed their pre and post-therapy tests. However, 4 patients were excluded from 
the cytokines assay due to the presence of post APT haemolysed plasma samples 
despite a repeated centrifuge trials. Hence, we had only 32 pre APT and 32 post APT 
samples (2 patients from group one and 2 patients from group 2). See diagram 2. 
Patients were divided into two groups based on the type of the APT regiment 
received, combined chemoradiotherapy (24 patients) and radiotherapy only (12 
patients) groups.  
 
 
 
 
 
 
 
 
 
Diagram (2) showing patients demographics and recruitment process 
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6.1 ChemoRadiotherapy group: 
6.1.1 Demographics  
This group had 24 patients who had combined chemoradiotherapy. Out of these 24 
patients, 11 of them had intravenous chemotherapy and pelvic radiotherapy and the 
rest of the 13 patients had oral chemotherapy and pelvic radiotherapy.  
Chemoradiotherapy group mean age was 59.4 years, SD 13.7 (23.00-80.00) and the 
length of adjuvant pre-operative treatment (APT), in days, had a mean of 46 days, 
SD 18.6 (25.00-92.00). The length of time, in days, between finish of the APT and the 
day of surgery had a mean of 36.6 days, SD 13 (14.00-56.00). This group had 18 
males and 6 females. 
ChemoRadio (n=24) Variables 
Mean SD Min Max 
Age (Pre-APT) 59.4 13.7 23.00 80.00 
Length of APT (days) 46.0 18.5 25.00 92.00 
APT to Surgery window (days) 36.5 12.9 14.00 56.00 
Gender Male= 18                         Female= 6 
 
Table (3) shows descriptive figures for age, length of APT, window to surgery and gender for 
the chemoradiotherapy group 
 
6.1.2 CPEX 
Different variable were measured during CPEX testing before and after APT 
treatment to best reflect the functional capacity in patients with rectal cancer. Out of 
many CPEX variables obtained from the test, only few parameters were compared 
before and after APT administration due to their relevance in clinical practice and our 
study hypothesis.  
These are: Work load (Watts) at the maximum oxygen consumption, oxygen 
consumption (ml/kg/min) at anarobic threshold and at peak (or maximum), the 
ventilatory equivalent ratio for carbon dioxide at anaerobic threshold in addition to the 
maximum pulse oxygen consumption. 
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Below is an example of the CPEX test result showing different variables measured 
during the examination period of a patient.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Table (4) shows a full summary output from CPEX test from which only few variables were 
selected for their hypothesis and clinical relevance. These are Work (Watts) at VO2max, VO2 
(ml/kg/min) at AT and VO2max, VO2/HR (ml/beat) at VO2 as well as VE/VCO2 at AT 
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There was a significant decline in the VO2max after APT exposure with a p-value of 
0.005. In addition, there was a significant increase in the VEVCO2AT with a p-value 
of 0.001, which clinically represent more pulmonary dead space, and/or reduction in 
the cardiac reserve (cardiac failure). VO2AT dropped in most of the patients but this 
difference in median values did not reach significance.  
 
 
 
 
Table (5) above shows the result of the CPEX test for the ChemoRadiotherapy group before 
and after the administration of APT represented in medians, IQR and Ranges together with 
their p- values. Results in bold are significant 
 
 
 
 
 
 
 
Variable 
Pre APT 
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
z- 
value  
p-
value 
 
Work VO2max 
 
68.5, (46.0), 91.0 61.0, (41.0), 120.0 -1.308 0.191 
VO2AT 
 
13.45, (3.65), 11.2 12.3, (3.5), 19.6 -1.843 0.065 
VO2max 
 
19.35, (6.83), 28.30 17.05, (5.6), 31.90 -2.802 0.005 
VEVCO2AT 
 
29.5, (6.0), 32.0 32.50, (8.75), 37.0 -3.428 0.001 
VO2HRmax 
 
29.5, (6.0), 32.0 10.5, (6.75), 11.0 -0.706 0.480 
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Figures (15) above show the changes in VO2max and VEVCO2AT (before and after APT 
adminstration) in the chemoradiotherapy group. Both of these results are significant. 
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Figures (16) above show the changes in Work (Watts) at VO2 Max, VO2 (ml/kg/min) at AT, 
VO2/HR (ml/beat) at VO2 (before and after APT adminstration) in the chemoradiotherapy 
group. These results are not significant 
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6.1.3 Body composition 
There was no significant change in the body weight and body mass index post APT 
exposure. However, a significant decline in the median value of the triceps skin fold, 
mid-arm circumference and grip strength was noticed after the therapy (p-value of 
0.007, 0.006 and 0.01 respectively). Moreover, there was a significant (p<0.001) 
reduction in total body water post APT.  
 
 
 
 
Table (6) above shows the result of the body composition tests for the ChemoRadiotherapy 
group before and after the administration of APT represented in medians, IQR and Ranges 
together with their p- values. Results in bold are significant 
 
 
 
 
Variable 
Pre APT 
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
 
z- 
value 
p-
value 
 
Weight Kg 
 
68.58, (19.83), 70.60 66.5, (22.55), 74.10 -1.100 0.271 
BMI kg/m2 
 
25.97, (7.11), 20.42 25.44, (6.93), 21.64 -0.386 0.700 
TSF 
 
13.0, (8.33), 27.90 10.5, (5.87), 32.30 -2.709 0.007 
MAC 
 
28.5, (6.13), 19.50 27.60, (6.12), 16.0 -2.755 0.006 
GS 
 
31.15, (18.48), 29.70 30.1, (18.08), 28.4 -2.586 0.010 
ECW 
 
15.78, (5.4), 16.12 15.86, (6.46), 14.38 -0.814 0.415 
ICW 
 
19.08 (8.63), 23.60 17.24, (9.17), 27.83 -0.857 0.391 
TBW 
 
34.76, (14.98), 42.05 18.04, (10.34), 38.8 -4.143 0.000 
FFM 
 
44.81, (18.89), 50.70 42.43, (19.86), 52.39 -0.171 0.864 
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Figures (17) above show the changes in GS, TSF, MAC and TBW (before and after APT 
adminstration) in the chemoradiotherapy group. These results are significant 
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6.1.4 Cytokines 
The patients inflammatory status usually reflect a balance between plasma levels of 
pro-inflammatory markers (TNFα, IP-10, RANTES, IL-6, IL-18) and anti-inflammatory 
markers (IL-1β, IL-1ra, IL-10, MIF) as well as plasma CRP and albumin.  
Cytokines behaviours and their effects were explained in the introduction chapter and 
will be discussed further in the discussion section. There was no distinct changes in 
median cytokine levels following the APT treatment. Some of them had increased, 
others decreased and some of them showed no changes post therapy. 
 
 
Table (7) above shows the result of the cytokines tests for the ChemoRadiotherapy group 
before and after the adminstration of APT represented in medians, IQR and Ranges together 
with their p- values. No significant results were found 
 
 
 
 
 
Variable Pre APT 
Median, (iqr), range 
Post APT 
Median, (iqr), range 
z- 
value 
p- 
value 
IL1β 0.65, (0.45), 30.86 0.5750, (0.61), 78.33 -1.079 0.281 
IL1RA 17.87, (66.6), 12582.06 11.01, (77.81), 44252.5 -1.651 0.099 
IL6 7.99, (37.6), 380.4 10.7, (25.0775), 952.93 -1.120 0.263 
IL10 2.5, (39.07), 1404.82 2.16, (37.02), 799.19 -0.633 0.527 
IP10 304.0, (209.0), 636.7 366.2, (256.11), 682.53 -1.802 0.072 
RANTES 1595.1, (768.8), 2188.4 1506.2, (555.4), 1734.7 -1.315 0.189 
IL18 143.8, (109.8), 393.9 178, (111.6), 376.2 -0.016 0.987 
MIF 91.8, (96.2), 8219.3 87.1, (78.4), 179.87 -1.932 0.053 
TNF-α 7.27, (9.21), 1951.56 3.94, (14.96), 3653.05 -1.700 0.089 
CRP 0.52, (0.6), 5.99 0.26, (0.6), 9.29 -1.721 0.085 
ALBUMIN 3.96, (0.67), 1.41 3.8, (0.5), 1.2 -1.364 0.172 
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Figures (18) above show the changes in different cytokine levels (before and after APT 
adminstration) in the chemoradiotherapy group 
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Figures (19) above show the changes in different cytokines, albumin and CRP levels (before 
and after APT adminstration) in the chemoradiotherapy group 
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6.1.5 HRQL 
There was a significant worsening of all of the health related quality of life (HRQL) 
endpoints measured with EROTC QLQ C-30 questionnaire. Scoring system used 
was explained in the Method chapter and is included in the appendices section of this 
thesis.  
 
Table (8) shows the significant result of the different HRQL variables measured with EROTC 
QLQ C-30 questionnaire in the chemoradiotherapy group. Global health status (QL), physical 
function (PF), role function (RF), emotional function (EF), cognitive function (CF), social 
function (SF), fatigue (FA), pain (PA), appetite loss (AP), constipation (CO), diarrhoea (DI), 
financial difficulties (FI) 
 
 
Variable 
Pre APT 
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
z- 
value 
p- 
value 
 
 
QL 94.0, (0.0), 13.0 25.0, (23.0), 30.0 
 
-4.299 
 
0.000 
 
PF 97.0, (6.0), 13.0 50.0, (28.2), 61.0 
 
-4.290 
 
0.000 
 
RF 94.0, (0.0), 13.0 54.0, (14.0), 61.0 
 
-4.298 
 
0.000 
 
EF 94.0, (11.5), 13.0 50.0, (28.2), 61.0 
 
-4.292 
 
0.000 
 
CF 94.0, (4.5), 13.0 54.0, (28.2), 61.0 
 
-4.299 
 
0.000 
 
SF 94.0, (11.2), 13.0 50.0, (14.0), 61.0 
 
-4.292 
 
0.000 
 
FA 94.0, (11.2), 13.0 50.0, (33.0), 61.0 
 
-4.292 
 
0.000 
 
NV 11.0, (11.0), 33.0 50.0, (14.0), 61.0 
 
-4.207 
 
0.000 
 
PA 5.50, (15.5), 33.0 50.0, (14.0), 61.0 
 
-4.206 
 
0.000 
 
DYSPNEA 0.0, (33.0), 33.0 50.0, (28.2), 42.0 
 
-4.213 
 
0.000 
 
INSOMNIA 0.0, (11.0), 33.0 50.0, (14.0), 61.0 
 
-4.210 
 
0.000 
 
AP 0.0, (17.0), 33.0 50.0, (20.2), 61.0 
 
-4.267 
 
0.000 
 
CO 5.5, (17.00, 33.0 54.0, (28.2), 61.0 
 
-3.952 
 
0.000 
 
DI 0.0, (11.0), 33.0 50.0, (14.0), 61.0 
 
-4.167 
 
0.000 
 
FI 5.5, (17.0), 33.0 50.0, (14.0), 61.0 
 
-4.291 
 
0.000 
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There was also a significant worsening in the final health related quality of life score 
measured with PG-SGA questionnaire. Scoring system used was explained in the 
Method chapter and is included in the appendices section of this thesis.  
 
 
 
Table (9) shows the significant result of the different HRQL variables measured with PG-SGA 
questionnaire in the chemoradiotherapy group. This is the final result after using the scoring 
formula 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Pre APT 
Median, (iqr), range  
 
Post APT 
Median, (iqr), range  
z- 
value 
p- 
value 
 
 
PGSGA 
 
1.0, (1.0), 1.0 
 
4.5, (3.0), 5.0 
 
 
-4.308 
 
0.000 
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Figures (20) above show the changes in (HRQL) endpoints measured with EROTC QLQ C-30 
questionnaire (before and after APT adminstration) in the chemoradiotherapy group. These 
results are significant 
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Figures (21) above show the changes in (HRQL) endpoints measured with EROTC QLQ C-30 
questionnaire (before and after APT adminstration) in the chemoradiotherapy group. These 
results are significant 
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6.1.6 Correlation 
Spearman correlation tests were performed between research variables to detect any 
possible relations among the study end outcomes. Any correlations that appear 
significant are candidates for subsequent multiple linear regression analysis. Positive 
correlation means both dependent and independent variables increase together while 
negative correlation means one increases and the other decreases. 
 
Primary correlations (Hypothesis One): 
In this hypothesis, we have assumed that the chosen CPEX variables have an 
impact on Demographics, Body composition, Cytokines and HRQL variables in the 
chemoradiotherapy group.  
• Independent variables: Changes in CPEX variables 
• Dependent variables: Changes in demographics, Body composition, 
Cytokines and HRQL variables. 
Work at VO2max had a positive correlation with both the individual weight and grip 
strength. While other CPEX variables had a negative correlation with IL1β, FFM, role 
and emotional functions.    
 
Independent 
variables  
Dependent 
variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
Work (Watts) VO2max Weight Kg 0.409 0.047 Positive 
Work (Watts) VO2max GS 0.414 0.044 Positive 
VO2max IL1β -0.435 0.034 Negative 
VEVCO2AT RF -0.583 0.003 Negative 
VEVCO2AT EF -0.439 0.032 Negative 
VO2HRmax FFM -0.416 0.043 Negative 
Table (10) shows only significant correlations (positive and negative) with regard to 
hypothesis one in the chemoradiotherapy group 
 
Any correlations between this hypothesis variables not included in the above table 
are not significant. They can be found in the appendix section of this thesis.   
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Secondary correlations (Hypothesis Two): 
In this hypothesis, we have assumed that HRQL variables measured with QLQ-C30 
and PG-SGA have an impact on Body composition variables. 
• Independent variables: Changes in HRQL variables  
• Dependent variables: Changes in Body composition variables. 
 
Please see table below for more details about this hypothesis correlations.  
Independent 
variables  
Dependent 
variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
QL TSF -0.569 0.004 Negative 
CF Weight Kg -0.552 0.005 Negative 
CF BMI kg/m2 -0.659 0.000 Negative 
CF TBW .552 0.005 Positive 
SF TSF 0.407 0.048 Positive 
FA ECW 0.413 0.045 Positive 
NV MAC 0.518 0.010 Positive 
DYSPNEA GS 0.407 0.049 Positive 
DYSPNEA FFM 0.427 0.037 Positive 
CO Weight Kg 0.415 0.043 Positive 
PGSGA ECW 0.437 0.033 Positive 
Table (11) shows only significant correlations (positive and negative) with regard to 
hypothesis two in the chemoradiotherapy group 
 
Any correlations between this hypothesis variables not included in the above table 
are not significant. They can be found in the appendix section of this thesis.   
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6.2 Radiotherapy group: 
6.2.1 Demographics 
This group included 12 patients who had only pelvic radiotherapy. Their mean age 
was 71.8, SD 8.9 (55.00-88.00) and the length of adjuvant pre-operative treatment 
(APT), in days, had a mean of 5.7 days, SD 1.1 (4.00-7.00). The length of time, in 
days, between finish of the APT and the day of surgery had a mean of 22.1 days, SD 
17.6 (8.00-58.00). This group had 10 males and 2 females. 
 
Radio (n=12) Variables 
Mean SD Min Max 
Age (Pre-APT) 71.8 8.9 55.00 88.00 
Length of APT (days) 5.7 1.1 4.00 7.00 
APT to Surgery window (days) 22.1 17.5 8.00 58.00 
Gender Male= 10                                Female= 2 
Table (12) shows descriptive figures for age, length of APT, window to surgery and gender for 
the radiotherapy group 
 
 
6.2.2 CPEX 
Different variable were measured during CPEX testing before and after APT 
treatment to best reflect the functional capacity in patients with rectal cancer. Out of 
many CPEX variables obtained from the test, only few parameters were compared 
before and after APT administration due to their relevance in clinical practice and our 
study hypothesis. These are: Work load (Watts) at the maximum oxygen 
consumption, oxygen consumption (ml/kg/min) at anarobic threshold and at peak (or 
maximum), the ventilatory equivalent ratio for carbon dioxide at anaerobic threshold 
in addition to the maximum pulse oxygen consumption. 
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In this group, no significant changes were found in the CPEX variables post APT. 
 
Table (13) above shows the result of the CPEX test for the Radiotherapy group before and 
after the adminstration of APT represented in medians, IQR and Ranges together with their p- 
values 
 
 
 
 
 
 
 
 
 
 
 
 
Figures (22) above show the changes in the CPEX variables (before and after APT 
adminstration) in the radiotherapy group 
 
Variable 
Pre APT 
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
 
z- value p-value 
 
Work VO2max 89.5, (70.25), 118 81, (61.25), 121 -1.926 0.054 
AT 11.55, (4.575), 12.5 10.95, (2.8), 16.9 -1.177 0.239 
VO2max 18.35, (9.15), 15.6 16.25, (7.975), 17.3 -0.845 0.398 
VEVCO2AT 33, (12), 29 34.5, (12), 37 -1.340 0.180 
VO2HRmax 10, (3), 7 9.5, (3.5), 7 -1.027 0.305 
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Figures (23) above show the changes in the CPEX variables (before and after APT 
adminstration) in the radiotherapy group 
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6.2.3 Body composition 
There was a significant decline in the triceps skin fold and mid arm circumference 
post APT exposure with p- values of 0.013 and 0.013 respectively. In addition, total 
body water and fat free mass were also reduced significantly post APT with p-values 
of 0.002 and 0.034 respectively.  
 
 
 
Table (14) above shows the result of the body composition tests for the Radiotherapy group 
before and after the administration of APT represented in medians, IQR and Ranges together 
with their p- values. Results in bold are significant 
 
 
 
 
 
Variable 
Pre APT  
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
 
z- 
value 
p-
value 
 
 
Weight Kg 70.6, (28.3), 45.1 71.5, (28.8), 46.46 
 
-0.078 
 
0.937 
 
BMI kg/m2 25.8, (6.03), 12.4 25.5, (5.79), 12.76 
 
-1.255 
 
0.209 
 
TSF 12.35, (13.75), 17.8 9.2, (10.8), 16 
 
-2.477 
 
0.013 
 
MAC 29.5, (4.9), 9.5 28.5, (5), 7.5 
 
-2.494 
 
0.013 
 
GS 34.5, (8.7), 23.7 33.7, (6.8), 26.8 
 
-1.413 
 
0.158 
 
ECW 16.7, (4.7), 11.51 16.94, (4.66), 11.18 
 
-0.392 
 
0.695 
 
           ICW 18.02, (7.38), 12.71 17.7, (5.5), 10.11 
 
-0.981 
 
0.327 
 
TBW 36.16, (11.67), 24.22 20.6, (16.4), 23.98 
 
-3.059 
 
0.002 
 
FFM 48.14, (14.06), 31.56 44.19, (14.6), 24.63 
 
-2.118 
 
0.034 
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Figure (24) above shows the changes in MAC, TSF, FFM and TBW (before and after APT 
adminstration) in the radiotherapy group. These results are significant 
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6.2.4 Cytokines 
The patients inflammatory status usually reflect a balance between plasma levels of 
pro-inflammatory markers (TNFα, IP-10, RANTES, IL-6, IL-18) and anti-inflammatory 
markers (IL-1β, IL-1ra, IL-10, MIF) as well as plasma CRP and albumin. 
Cytokines behaviours and their effects were explained in the introduction chapter and 
will be discussed further in the discussion section. There was no distinct change in 
median cytokine levels following the APT treatment. Some of them had increased, 
others decreased and some of them showed no changes post therapy. 
 
 
Table (15) above shows the result of the cytokines tests for the Radiotherapy group before 
and after the adminstration of APT represented in medians, IQR and Ranges together with 
their p- values. No significant results were found 
 
 
Variable 
Pre APT 
Median, (iqr), range 
 
Post APT 
Median, (iqr), range 
 
z- 
value 
p-
value 
 
 
IL1β 0.53, (0.79), 1.39 0.53, (0.33), 1.07 
 
-1.820 
 
0.069 
 
IL1RA 9.8, (16.76), 212.39 8.6, (7.3), 22.31 
 
-0.534 
 
0.594 
 
IL6 5.85, (4.73), 9.47 6.75, (14.97), 102.16 
 
-1.956 
 
0.050 
 
IL10 1.55, (1.26), 2.98 1.82, (1.63), 6.49 
 
-1.156 
 
0.248 
 
IP10 318.46, (125.94), 878.44 223.1, (333.2), 996.8 
 
-0.622 
 
0.534 
 
RANTES 1353.03, (884.4), 1561.6 1447.2, (988.3), 1590.4 
 
-0.711 
 
0.477 
 
IL18 150.18, (92.46), 190.05 139.17, (105.04), 202.8 
 
-0.089 
 
0.929 
 
MIF 123.8, (182.2), 1357.2 66.05, (184.39), 455.23 
 
0.000 
 
1.000 
 
TNF-α       3.94, (3.29), 11.5      3.00, (1.88), 8.14 
 
  -1.481 
 
 0.139 
 
CRP 0.14, (0.72), 1.22 0.29, (0.39), 2.82 
 
-1.468 
 
0.142 
 
ALBUMIN 4, (0.42), 1.12 3.89, (0.53), 1.2 
 
0.000 
 
1.000 
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Figures (25) above show the changes of the cytokines tests for the Radiotherapy group 
before and after the administration of APT represented in medians, IQR and Ranges together 
with their p- values. No significant results were found 
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Figures (26) above show the changes in different cytokines, albumin and CRP levels (before 
and after APT adminstration) in the radiotherapy group 
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6.2.5 HRQL 
There was a significant worsening of all of the health related quality of life (HRQL) 
endpoints measured with EROTC QLQ C-30 questionnaire. Scoring system used 
was explained in the Method chapter and is included in the appendices section of this 
thesis.  
 
 
 
Table (16) shows the significant result of the different HRQL variables measured with EROTC 
QLQ C-30 questionnaire in the radiotherapy group. Global health status (QL), physical 
function (PF), role function (RF), emotional function (EF), cognitive function (CF), social 
function (SF), fatigue (FA), pain (PA), appetite loss (AP), constipation (CO), diarrhoea (DI), 
financial difficulties (FI) 
 
 
 
 
 
Variable 
Pre APT  
Median, (iqr), range 
 
Post APT  
Median, (iqr), range 
 
z- 
value 
p-
value 
 
QL 94, (0), 6 25, (17), 17 -3.081 0.002 
PF 94, (7), 13 34.5, (31), 61 -3.065 0.002 
RF 94, (0), 13 50, (28.25), 61 -3.063 0.002 
EF 94, (6), 13 58, (8), 52 -3.066 0.002 
CF 94, (0), 13 50, (12.5), 61 -3.065 0.002 
SF 94, (5.25), 13 58, (8), 52 -3.069 0.002 
FA 94, (11.25), 13 54, (14), 61 -3.062 0.002 
NV 0, (11), 11 50, (39.75), 61 -3.066 0.002 
PA 0, (15.5), 33 34.5, (40), 61 -2.828 0.005 
DYSPNEA 11, (15.5), 33 50, (31.75), 61 -2.827 0.005 
INSOMNIA 5.5, (11), 11 50, (33), 42 -3.068 0.002 
AP 0, (11), 11 47, (42), 61 -3.065 0.002 
CO 0, (11), 33 47, (28.25), 61 -2.910 0.004 
DI 5.5, (11), 17 34.5, (34), 61 -2.983 0.003 
FI 5.5, (11), 33 37.5, (40), 42 -3.068 0.002 
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There was also a significant worsening in the final health related quality of life score 
measured with PG-SGA questionnaire. Scoring system used was explained in the 
Method chapter and is included in the appendices section of this thesis.  
 
 
 
Table (17) shows the significant result of the different HRQL variables measured with PG-
SGA questionnaire in the radiotherapy group. This is the final result after using the scoring 
formula 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Pre APT 
Median, (iqr), range  
 
Post APT 
Median, (iqr), range  
z- 
value 
p- 
value 
 
PGSGA 
 
1, (1), 1 
 
4, (2), 4 
 
-3.077 0.002 
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Figures (27) above show the changes in (HRQL) endpoints measured with EROTC QLQ C-30 
questionnaire (before and after APT adminstration) in the chemoradiotherapy group. These 
results are significant 
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Figures (28) above show the changes in (HRQL) endpoints measured with PG-SGA and 
EROTC QLQ C-30 questionnaire (before and after APT adminstration) in the 
chemoradiotherapy group. These results are significant 
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6.2.6 Correlation 
Spearman correlation tests were performed between research variables to detect any 
possible relations among the study outcomes. Any correlations that appear 
significant are candidates for subsequent multiple linear regression analysis. Positive 
correlation means both dependent and independent variables increase together while 
negative correlation means one increases and the other decreases. 
Primary correlations (Hypothesis One): 
In this hypothesis, we have assumed that the chosen CPEX variables have an 
impact on Demographics, Body composition, Cytokines and HRQL variables in the 
radiotherapy group.  
• Independent variables: Changes in CPEX variables. 
• Dependent variables: Changes in demographics, Body composition, 
Cytokines and HRQL variables. 
 
Please see table below for hypothesis one. 
Independent 
variables 
 
Dependent 
variables  
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
Work (Watts) VO2max INSOMNIA -0.653 0.021 Negative 
AT Weight Kg -0.615 0.033 Negative 
AT GS 0.726 0.007 Positive 
VO2max FA 0.589 0.044 Positive 
VEVCO2AT TBW 0.612 0.035 Positive 
VEVCO2AT PF 0.681 0.015 Positive 
VO2HRmax CRP -0.628 0.029 Negative 
Table (18) shows only significant correlations (positive and negative) with regard to 
hypothesis one in the radiotherapy group 
 
Any correlations between this hypothesis variables not included in the above table 
are not significant. They can be found in the appendix section of this thesis.   
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Secondary correlations (Hypothesis Two): 
In this hypothesis, we have assumed that HRQL variables measured with QLQ-C30 
and PG-SGA have an impact on Body composition variables in the radiotherapy 
group. 
 
• Independent variables: Changes in HRQL variables. 
• Dependent variables: Changes in Body composition variables. 
 
Please see table below for hypothesis two. 
 
 
Table (19) shows only significant correlations (positive and negative) with regard to 
hypothesis two in the radiotherapy group 
 
Any correlations between this hypothesis variables not included in the above table 
are not significant. They can be found in the appendix section of this thesis.   
 
 
Independent 
variables  
Dependent 
variables  
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
QL BMI kg/m2 -0.621 0.031 Negative 
QL FFM -0.603 0.038 Negative 
PF FFM 0.642 0.024 Positive 
RF ECW 0.662 0.019 Positive 
NV TBW 0.654 0.021 Positive 
PA Weight Kg 0.577 0.049 Positive 
AP FFM -0.593 0.042 Negative 
DI ECW 0.770 0.003 Positive 
DI ICW -0.674 0.016 Negative 
FI FFM 0.598 0.040 Positive 
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6.3 Measure of changes for the full cohort of patients  
Mixed ANOVA test was performed to find out if the changes of both 
chemoradiotherapy and radiotherapy groups were constant or not. This is a robust 
test and can deal with non-normally distributed data, in order to detect whether type 
of therapy acts as an effect on the different variables measured.  
A repeated measures ANOVA was performed using Therapy Type as a between 
subjects effect. The results in the table show the outcome for the interaction effect 
between time and Therapy Type. 
It does show that there are no significant changes in the 36 patients after exposure to 
either of the APT regimes.  
This means that both types of therapies (chemoradiotherapy and radiotherapy alone) 
have nearly similar effect and trend on study outcomes, ie: either cause an increase 
or decrease of the variables measured. See table and figures below for more 
information.  
 
 
 
 
 
 
 
Table (20) below shows the outcome for the interaction effect between time and Therapy 
Type (Chemoradiotherapy and Radiotherapy). No significant results were found 
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Interaction: 
Time*Therapy Type 
Variable ChemoradioRx Start ChemoradioRx End RadioRx Start RadioRx End F p 
WorkWatts 
VO2Max 112.292 115.500 97.000 89.750 1.495 0.230 
AT  14.075 12.879 11.850 11.025 0.121 0.730 
VO2Max 10.708 10.458 9.917 10.250 1.038 0.315 
VEVCO2AT 31.750 34.167 36.667 38.000 0.900 0.349 
VO2HRMax 20.083 18.608 17.000 16.317 0.962 0.334 
Weight 72.564 71.817 75.121 75.095 0.537 0.469 
BMI 25.474 25.483 26.173 26.059 0.148 0.703 
TSF 13.475 12.008 14.508 11.958 1.016 0.321 
MAC 28.171 27.339 29.500 28.433 0.066 0.799 
GS 34.035 31.736 33.125 32.342 10.337 0.256 
ECW 16.145 16.194 17.342 17.355 0.007 0.934 
ICW 18.444 18.109 19.073 18.638 0.019 0.890 
TBW 34.153 20.365 37.233 23.174 0.006 0.937 
FFM 45.036 44.824 48.883 46.912 2.220 0.145 
IL1BETA 3.623 4.519 .835 .675 0.045 0.833 
IL1RA 779.937 2163.985 30.623 10.945 0.440 0.512 
IL6 59.141 73.354 6.734 20.485 0.433 0.515 
IL10 57.544 72.354 1.779 2.724 0.181 0.674 
IP10 328.072 364.441 387.424 383.414 0.499 0.485 
RANTES 1614.711 1390.320 1256.635 1449.759 0.013 0.911 
IL18 180.803 178.698 127.711 130.505 0.001 0.972 
MIF 524.296 88.631 235.761 141.257 0.970 0.332 
CRP .863 .764 .409 .634 0.045 0.833 
ALBUMIN 3.884 3.756 3.901 3.822 1.671 0.206 
QL 94.167 21.792 95.000 25.333 0.636 0.431 
PF 95.542 47.125 91.583 39.083 0.364 0.550 
RF 94.375 51.875 93.833 47.583 0.364 0.550 
EF 93.167 47.417 95.333 54.167 0.469 0.498 
CF 94.333 46.583 93.833 50.417 0.474 0.496 
SF 94.250 50.000 93.250 55.250 1.098 0.302 
FA 94.000 44.958 94.750 50.500 0.499 0.485 
NV 8.958 46.667 3.667 43.667 0.102 0.751 
PA 8.333 47.833 7.417 37.583 1.573 0.218 
DYSPNEA 11.250 44.208 9.250 41.833 0.002 0.961 
INSOMNIA 6.917 50.375 5.500 43.750 0.548 0.464 
AP 9.458 44.333 4.583 44.167 0.416 0.523 
CO 9.250 47.333 6.417 46.583 0.054 0.818 
DI 7.125 48.583 6.000 36.417 2.059 0.160 
FI 10.167 47.625 7.333 35.750 2.065 0.160 
PGSGA .708 4.417 .583 3.917 0.437 0.513 
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Figures (29) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the CPEX variables:  Work (Watts) at 
VO2Max, AT, VO2Max, VEVCO2AT, and VO2HRMax  
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Figures (30) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the body composition variables:  weight, BMI, 
TSF, MAC, GS and ECW 
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Figures (31) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the body composition variables:  ICW, TBW 
and FFM 
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Figures (32) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the cytokines variables:  IL1beta, IL1RA, IL6, 
IL10, IP10 and RANTES 
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Figures (33) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the cytokines variables: IL18, MIF, CRP and 
Albumin 
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Figures (34) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the HRQL variables as measured with 
EROTC QLQ C-30 and PG SGA questionnaires 
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Figures (35) above show the changes in the estimated marginal means in both 
chemoradiotherapy and radiotherapy groups for the HRQL variables as measured with 
EROTC QLQ C-30 and PG SGA questionnaires 
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7.0 DISCUSSION  
7.1 Overview 
Colorectal Cancer (CRC) is the second commonest cancer causing death from 
malignant disease in the United Kingdom. Approximately 35,000 new cases and over 
16,000 deaths each year related to CRC with an overall 5 year survival of 
approximately 55% [1].  
The behaviour of colorectal neoplasia varies and depends on many pre and 
postoperative factors that can play an important role in its pathway. This study did not 
concentrate on tumour behaviour; however, we looked mainly at the possible 
physiological changes, in patients with rectal cancer, which might occur during the 
course of the disease incurred by the preoperative neoadjuvant treatment.   
Modern CRC management combines surgical resection with or without an adjuvant 
preoperative therapy (APT) represented by long course chemoradiotherapy (rectum), 
short course radiotherapy (rectum) or chemotherapy with immuno-modulators 
(colonic) such as the FOXTROT trial.  
APT could potentially reduce the peri-operative natural shedding of the tumour cells.  
This shedding might contribute to dissemination of tumour cells at the time of 
operation [62]. 50% of patients with recurrent CRC disease have peritoneal 
metastases which have a poor response to systemic therapy once established [458]. 
In 2009, Berardi et al showed in a detailed literature review that in the last two 
decades, new development in the multimodality treatments have improved the 
prognosis of locally advanced rectal cancer with local recurrences decreasing from 
40% to < 10% and overall survival increasing from 50% to 75%. Hence, continuous 
research is needed to improve these regiments efficacy with minimal patients-related 
adverse events in clinical practice [459].  
APT has a potential impact on the patient’s ability to cope with the physiological 
stress from surgery. This could be due to the cardiotoxic effect of chemotherapy 
agents, which might reduce myocardial function leading to a reduced cardiac output 
and so oxygen delivery. This is well documented in the literatures and an indication 
to discontinue the treatment [460]. However, effects of APT on the functional capacity 
have not been explored properly yet.  
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Moreover, subclinical heart failure may produce a degree of pulmonary congestion, 
which will eventually influence the oxygen uptake during stress [461]. 
In addition, the neurotoxic effects of APT may insult the autonomic nervous system 
and interfere with the cardiovascular adaptation to increased oxygen demand and 
blood flow at tissue level [462]. Finally, changes at the cellular and mitochondrial 
level might interfere with the cellular respiration and cause tissue hypoxia [463].  
Mak et al has found that despite widespread and rapid adoption of preoperative 
radiotherapy for locally advanced rectal cancer, it is still underused in certain 
sociodemographic groups [464]. 
Patients with poor physiological reserve preoperatively are more likely to have 
postoperative complications. These patients are at more risk of having poor short-
term outcome after major colorectal resection such as anastomotic leak, infection 
and other cardiopulmonary events [465, 466]. 
Patients who are subjected to one-week course of preoperative radiotherapy have 
significantly shorter period of insult from APT compared to those who are undertaking 
5-6 weeks course of combined chemoradiotherapy. However, radiotherapy may still 
induce an inflammatory response caused by cellular death and ultimately affect 
fitness for surgery especially in view of shorter interval between the end of APT and 
surgery in this group of patients [315].   
There is a subjective impression among surgeons and anaesthetists that aggressive 
APT can significantly reduce the physiological reserve of patients awaiting cancer 
resection and this may account for the uncertain benefits of such treatment in some 
settings.  
In our study, only patients with rectal cancer were recruited as those with colonic 
cancer were already randomised to the FOXTROT trial. We had two main groups, 
chemoradiotherapy (24 patients) and radiotherapy only groups (12 patients).  
We have found that patients who had chemoradiotherapy were around the age of 59 
years while radiotherapy regime was given to older patients with a mean of 72 years. 
This might explain the selection process by the oncologist at the MDT meetings to 
recruit younger and fitter patient for long course chemoradiotherapy. All of the 
radiotherapy patients had T3 rectal tumour.  
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The mean duration of chemoradiotherapy regime was 46 days and patients in this 
group waited for a mean of 36.5 days to have their surgical resection while the mean 
length of radiotherapy treatment was 5.7 days and patients waited for an average of 
22 days to have their operation. There were more men than women in both groups. 
Cardiopulmonary reserve, as measured with CPEX testing, was significantly 
compromised in the chemoradiotherapy group of patients, as there was a significant 
decline in the VO2max and a significant increase in the pulmonary dead space 
represented by VEVCO2AT after APT exposure with p-value of 0.005 and 0.001 
respectively. However, CPEX variables had minimal changes in the radiotherapy 
group post APT. This may be due to the small number of patients recruited in this 
group or might be related to the regime itself of having less toxic and systemic effects 
on the cardiopulmonary function.  
With regard to the body composition data, both groups showed significant changes in 
different variables, which indicate the major effect of APT on different body 
compartments.  
In the chemoradiotherapy group, there was a significant decline in the TSF, MAC and 
GS giving p-values of 0.007, 0.006 and 0.010 respectively. There was also a 
significant decrease in the TBW with p-value of 0.000 post APT.  
In the radiotherapy group of patients, there was also a significant decline in the TSF, 
MAC and TBW with p-values of 0.013, 0.013 and 0.002 respectively. In addition, 
there was a significant reduction in the FFM in this group with p-value of 0.034 post 
APT exposure. No significant changes were noticed in the BMI values of both 
groups.  
Different pro and anti-inflammatory cytokines together with CRP and albumin were 
compared before and after APT exposure. We could not find any particular trend in 
the cytokines behaviours. Some of them increased, others decreased and few did not 
show any changes post therapy exposure. However, in the radiotherapy group, IL6 
was nearly significant with a p-value of 0.050. Larger cohort of patients might have 
an effect on the result of the cytokines behaviours. In addition, the timing of taking 
the serum samples from patients after finishing the anti-cancer surgery might have 
an impact on the cytokines levels and trends.  
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Multiple questions and assessments were applied to measure the health related 
quality of life and physical wellbeing in both groups of patients pre and post APT 
using EROTC QLQ C-30 and PG-SGA questionnaires. There had been an 
impressive significant worsening of all of the endpoints measured with these two 
validated questionnaires giving a p-value of less than 0.000 post APT exposure.  
The body physiological changes are interacting with each other. We have therefore 
tried to link between the study outcomes to get a possible correlation among these 
physiological parameters. Hence and in addition to the primary aims of this study to 
assess functional capacity post APT, Spearman correlation tests were performed to 
look for any possible interaction among the research variables. Positive correlation 
means both dependent and independent parameters increase or decrease together 
while negative correlation means one increases and the other decreases and vice 
versa.  
In chemoradiotherapy group, the work load (watts) at VO2max of patients are directly 
proportional to their body weight and grip strength (positive correlation). Moreover, 
VO2max, VEVCO2AT and VO2HRmax are adversely proportional to IL1β, RF, EF 
variables and FFM (negative correlation). On the other hand, HRQL variables are 
positively correlated with most of the body composition endpoints (except TSF) while 
it is negatively associated with TSF and BMI.  
In the radiotherapy group, Work (Watts) at VO2max, AT and VO2HRmax are 
negatively correlated with insomnia, body weight and CRP respectively. While AT, 
VO2max and VEVCO2AT are positively correlated with GS, fatigue and (TBW + 
physical function) respectively.  
On the other hand, HRQL variables had different correlations with body composition 
endpoint based on the specific physical function assessed with the two 
questionnaires.  
Additionally, mixed ANOVA test was performed to find out if the changes of both 
chemoradiotherapy and radiotherapy groups were constant or not. This test did not 
show any significant results which means that both groups of patients had the same 
trend of changes in their CPEX, body composition, cytokines and HRQL variables 
after any type of APT exposure.  
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Whilst APT has shown an overall benefit in a number of settings, there is also 
evidence that it may harm patients in different ways. This project allowed us to 
identify patients at risk of functional deterioration following APT in order to develop 
certain interventions to obviate the adverse effects of APT. These intervention may 
include exercise training, nutritional interventions with or without supplements, 
modifying the interval between APT and surgery, modulation of the inflammatory 
cascade and, in some cases, modifying the APT regime for a particular patient with 
careful selection [467].  
Our aims in this project were mainly observational to find out the possible 
physiological deterioration in colorectal cancer patients after APT administration. We 
did not explore any methods of intervention to optimise this cohort of patients pre-
operatively. This might be the next step of the study to select the best way to 
optimise these patients before the tumour resection in order to reduce the surgical 
morbidity.  
It is currently evident from previous literatures that the pre-operative physiological 
status of patients with colorectal cancer predicts long and short term outcomes after 
surgical resection [228, 468]. Hence, multimodal preoperative optimisation with 
supervised exercise programmes [469], smoking cessation [470], nutritional support, 
anti-inflammatory treatment (ex: aspirin) [471] and intensive cardiopulmonary support 
with medication is presently the hot topic drawing the emphasis on improving the 
postoperative mortality and morbidity in this cohort of patients. Future research work 
is needed to figure out the interaction of these treatments and their impact on human 
body physiology.  
Further work is needed to explore the effect of APT on a large cohort of patients with 
advanced colorectal cancer in homogenous population depending on age, type of 
cancer as well as type and duration of APT as our study was performed on a mixed 
population. Full biological and physiological mechanism needs to be understood 
behind the effect of APT on patients with neoplastic tumours.  
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7.2 The glory of Cardiopulmonary exercise testing (CPEX) 
In 1993, Older and colleagues demonstrated an association between cardiovascular 
mortality and anaerobic threshold as determined by CPEX testing in 187 elderly 
patients undergoing major intra-abdominal surgery [245]. Patients who had an 
anaerobic threshold of less than 11 ml/kg/min were identified as being at a higher risk 
of post-operative death. In a subsequent study, the same group examined risk 
stratification of patients presenting for major non-cardiac surgery and postoperative 
outcome. Patients with an anaerobic threshold of greater than 11 ml/kg/min with no 
inducible ischemia and a ventilatory equivalent for oxygen of less than 35 were 
considered to be at low risk of complications and were managed on the ward after 
surgery.  
Patients with an adequate anaerobic threshold (AT) but with an elevated ventilatory 
equivalent for oxygen or evidence of myocardial ischemia received high dependency 
care in the postoperative period. Those with an AT of less than 11 ml/kg/min were 
cared for in intensive care after their surgery [252]. The authors pointed out the value 
of CPEX testing for identifying patients at low risk of complications who are 
candidates for ward management after surgery. 
A review by Smith and colleagues examined the value of CPEX in predicting 
perioperative complications in non-cardiopulmonary surgery [472]. They reviewed all 
studies comparing the predictive value of maximum oxygen consumption 
(VO2max/peak) or anaerobic threshold, and analysed nine studies in further detail.  
They concluded the majority of studies demonstrated that CPEX variables, especially 
VO2peak, are associated with periperative morbidity and mortality in non-
cardiopulmonary surgery. Six out of the seven studies which reported sufficiently 
detailed findings on peak oxygen consumption [457, 473-477] and four out of six 
reporting anaerobic threshold [245, 457, 473, 477] found these variables to be 
associated with perioperative complications. 
In most of the United Kingdom clinical centres, VO2peak of less than 15 ml/kg/min 
and/or an AT of less 11 ml/kg/min is considered as clinically significant and carries 
high risk of mortality and morbidity. Hence, careful patient counselling, MDT 
selections, considering other non-surgical modality of treatments with pre, peri and 
postoperative intensive management is vital to meet this poor cardiopulmonary 
reserve. 
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An association between poor performance during CPEX testing and mid-term 
outcome has also been reported for aortic surgery. Carlisle and colleagues found 
reduced 30 day survival and mid term (2 year) survival in patients who performed 
less well on preoperative CPEX testing [457]. On multivariable analysis, greater 
values of the ventilatory equivalent for CO2 (VE/VCO2) at anaerobic threshold were 
found to be associated with both 30 day mortality and worse mid-term survival.  
More recently Swart and Carlisle have conducted a randomised control trial of risk 
stratification based on CPEX criteria in patients undergoing major non-cardiac 
surgery [457]. Patients with an AT of less than 11 ml/kg/min were randomly allocated 
to receive either high dependency care or normal ward postoperative care. Patients 
with an AT greater than >10.9 ml/kg/min were sent back to the ward for their 
postoperative care. The number of cardiac events (acute LVF and acute coronary 
syndromes) and length of hospital stay were measured in each group of patients. No 
reported cardiac events and lowest hospital stay occurred in the patients with an AT 
of greater than 10.9 ml/kg/min. 
In their review, Smith and colleagues speculated that adverse outcomes following 
different types of surgery might be associated with altered CPEX variables. In 
addition, the strength of the association between exercise capacity and perioperative 
risk may be different for different types of surgery as the pre-existing morbidity might 
affect the predictive value of CPEX results. They also concluded that CPEX testing 
needs to be validated for each surgical procedure [472]. 
Our project data showed a significant reduction in the cardiac reserve, represented 
by VO2max, of those patients exposed to chemoradiotherapy. In fact, we have 
measured the VO2peak for these patients as none of them has reached his/her 
maximum oxygen consumption (only reached their peak oxygen consumption). This 
drop in VO2peak or VO2max is a marked limiting factor affecting the cardiopulmonary 
function and might contribute to peri and postoperative morbidity. CPEX testing can 
be used to quantify the cardiopulmonary aspect of physiological reserve. This is 
mainly seen in colorectal cancer patients exposed to combined chemoradiotherapy.  
The previously mentioned “Dual” method of measuring AT may not be reliable in an 
anxious subject who has been hyperventilating prior to the start of exercise. 
Hyperventilation before the start of exercise leads to depletion of body stores of 
carbon dioxide and may lead to inaccurate estimation of anaerobic threshold with a 
“pseudo-threshold” being seen before the onset of metabolic acidosis [478].  
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Such hyperventilation which often occurs in stressed patients subjected to any form 
of testing procedure.  
To obviate this problem, the respiratory rate, respiratory exchange ratio and end-tidal 
carbon dioxide should be allowed to settle to normal values before the start of 
exercise. If this cannot be achieved the anaerobic threshold as determined by non-
invasive testing has to be regarded as unreliable. The AT represents the exercise 
intensity that can be sustained indefinitely and is dependent on exercise modality 
[235]. Values from cycle ergometry are 5-10% less than those obtained from 
treadmill testing. Exercise intensities above AT are associated with a limited exercise 
tolerance. AT expressed as a percentage of VO2max increases with age and it 
generally occurs at 50-60% of VO2max but there is a wide range and values between 
40% and 85% of VO2max are considered to be within normal range. Values of 
anaerobic threshold below 40% of predicted VO2max are indicative of significant 
exercise limitation [416]. 
Furthermore, our study showed a significant increase in the VEVCO2 post 
chemoradiotherapy. This is an objective measurement of the pulmonary dead space 
(means more un-recruited alveoli) and strongly associated with poor ventilatory 
function, pulmonary arterial hypertension and cardiac failure [479]. This parameter 
had significantly increased at both of the critical point, anaerobic threshold and 
maximum oxygen consumption. However, this value did not change post 
radiotherapy regime.   
CPEX testing is not suitable for determination of functional capacity in all groups of 
patients. Those severely limited by musculoskeletal or neuromuscular diseases will 
find any sort of exercise difficult.  
In patients with lower limb weakness it can be possible to gain an estimate of 
functional capacity using a hand cycle ergometer. However, VO2peak values 
obtained from arm ergometry are only about 70% of those obtained from leg exercise 
and an increase in lactate is often seen early in exercise [480, 481]. 
Although, both the European Society of Cardiology (ESC) and the American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines on cardiac 
assessment for non-cardiac surgery highlight the importance of estimating exercise 
capacity in assessing perioperative risk [482]. The value of CPEX testing lies in the 
insights about cardiopulmonary function offered by the data obtained.  
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The test may be used to direct patients to the appropriate level of post-operative 
care. It may also be used to direct the pre-operative preparation of the patient. The 
presence of inducible myocardial ischemia may indicate the need for appropriate 
cardiac medications and further cardiological investigation. Poor cardiac function may 
be manifest by a low oxygen pulse. Elevated ventilatory equivalents throughout a test 
may represent respiratory insufficiency and suggest a need for preoperative 
medication changes and for vigorous physiotherapy in the post operative period 
[235]. 
As it is well established that there is an association between a limited exercise 
capacity and the risk of post-operative complications, various risk scores such as the 
revised cardiac risk index are also available for the pre-operative risk stratification of 
patients [483]. The logical next stage in the development of pre-operative risk 
stratification is the development of tools, which integrate the results of pre-operative 
stress testing, pre-operative risk scoring and biomarkers such as brain natriuretic 
peptide to give a comprehensive tool for pre-operative risk stratification [484].  
This will require the prospective study and follow up of large numbers of patients but 
has the potential to offer better tools for preoperative risk prediction that either risk 
scoring or exercise testing alone. In the meantime, preoperative CPEX can 
reasonably be supported on the basis of an established relationship between 
exercise capacity and outcome and plausible scientific arguments to support its 
validity. 
In a cancer rehabilitation programme, De Backer et al have found that high-intensity 
strength training was well tolerated by CRC patients with a significant improvement in 
muscle strength and significant increase in the VO2max by 10% in men and 13% in 
women.  
It has been concluded that a supervised, high-intensity strength training programme 
was an effective means to improve muscle strength, cardiopulmonary function, and 
HRQL and should be incorporated in cancer rehabilitation programmes [485]. 
Chemotherapy agents, such as 5-Fluorouracil (5FU), are known to cause coronary 
endothelium toxicity and spasm, myocardium hypoxia and toxicity as well as toxic 
myocarditis [486, 487]. These systemic agents circulate in the body and cause 
microvascular damage as well as tissue hypoxia at cellular level leading to an end-
organ mal-function or dysfunction.  
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This explains the proven disturbance in body physiology after the neoadjuvant 
therapy in our study. Only one patient out of 36 had a witnessed and documented 
myocardial toxicity post APT exposure. He was a 64 years old who was previously fit 
and well with no significant past medical history of note. This patient had the first 
CPEX testing which was normal (AT=13 and VO2max=18.2 ml/kg/min), then had a 5-
week course of 1150mg Capecitabine (oral 5FU chemotherapy agent) and pelvic 
radiotherapy. Only 1 week after finishing the APT regime, this patient had his second 
CPEX test at the Cardiology laboratory, as per the study protocol, when he started to 
have ventricular tachycardia (VT) and fibrillation (VF) only 1 minute after exercising 
on the CPEX bicycle with a significant drop of AT to 11 and VO2max to 15 ml/kg/min.  
According to the study protocol, a consultant anaesthetist, the senior author (surgical 
trainee) as well as two trained cardiac physiology personnel must be present all time 
during the CPEX testing. This patient had a successful cardiopulmonary resuscitation 
and was reverted to normal sinus rhythm. He was admitted to CCU and had all of the 
necessary investigation done including blood test, Troponin T, Transthoracic Echo 
and coronary angiography. They were all normal and did not show any sings of an 
existing disease. Two experienced cardiologists have labelled this event clearly as 
5FU-myocardial toxicity. Subsequently this patient was optimised with Statin, Aspirin, 
Clopidogrel and Bisoprolol plus all of the Surgical, Oncological and Anaesthetic 
teams were informed and an HDU bed booked. Thereafter, his surgery was delayed 
by 8 weeks after finishing his neoadjuvant treatment and he had his surgical 
resection with no unexpected peri and postoperative complications and discharged 
home one week later. If this patient did not have his second CPEX test done, he 
would have been at a high risk of developing these events peri or postoperatively 
which will increase the surgical mortality and morbidity. This is a clear example about 
the effect of APT on the cardiopulmonary reserve and the whole idea about this 
study. 
In another study, it has been suggested that although the prognosis of recovery from 
this myocardial toxicity is good, the mortality rate still ranges between 2.2 and 13% in 
case of symptomatic cardiotoxicity [488]. 
Hence, the dose of the chemotherapy agents must be adjusted precisely and the 
oncologists should carefully select patients prior to the administration of any chemical 
agents.  
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In addition, we should frankly point to the invaluable role and importance of the pre-
operative CPEX testing as a way of diagnosing and identifying high-risk individuals to 
avoid any unexpected complications and improve postoperative outcomes.  
 
7.3 Body compartments value in managing colorectal cancer patients 
Abnormal fluid balance can affect the cardiovascular function and subsequently alter 
the end-organ perfusion. Changes in the body composition compartments could be 
tested by various methods. Body composition techniques subdivide the body into 
compartments based on differing physical properties. The different compartments 
reflect hydration, nutrition/wasting, body fat, and bone mineral content. In our study, 
we have used Bioelectrical impedance analysis (BIA) and anthropometric 
measurements. BIA is a safe, cheap and acceptable technique by most patients. 
Multiple serial measurements are important to identify changes in hydration or 
nutrition earlier than would occur with the ward routine monitoring and charts, 
allowing appropriate intervention and management to improve patient clinical service 
and outcomes. BIA information can confirm the clinical impression of some patients 
as well as detecting changes in others with subclinical manifestation.  
This technique has some limitation when used between different individuals, but in 
our research, the same method was used before and after the administration of APT, 
hence, reliable results were obtained with comparison of the pre and post APT 
values. 
A wrist-ankle measurement using HYDRA ECF/ICF machine assumes the body is 
one perfect cylinder when in fact the body is comprised of five imperfect cylinders 
(two arms, two legs and trunk) with arms and legs contributing to 90% of the 
measurement [437] as the trunk has a large cross-sectional area [299]. 
Fluid volume tends to be evenly distributed in healthy subjects, thus the wrist-ankle 
measurement is useful and accurate [489]. As such, the relationship between a wrist-
ankle measurement and total body water is a function of the body water being evenly 
distributed. However, assuming even distribution of the body fluid is not true in 
certain medical conditions and between different populations, hence; segmental 
measurement of body composition might be of good value here [438].  
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BIA can give wide ranges of normality in the body composition of normal individuals, 
with wide variation in body fat and skeletal muscle among healthy individuals. 
However, this technique limitation is not of a great value in this research programme 
as individuals were controlling themselves plus we measured the mean of three 
readings pre and post APT exposure. This possible error was even more reduced by 
excluding patients with renal disease and nutritional deficits of any kind.  
Changes in body composition readings could be greatly influenced by the vascular 
perfusion of the limb. Hence, impaired cardiac function which might result from the 
APT administration can alter body fluid compartment volumes when measured with 
the wrist-ankle method [440]. This is actually true as this study demonstrated a 
significant fluid depletion and generalised body dehydration with a significant drop in 
the total body water in both groups of patients, which clearly indicates a clinically 
significant level of dehydration pre-operatively (post APT exposure). This could be 
explained by the impaired cardiopulmonary function and poor tissue perfusion 
happening after the anti-cancer therapy. Furthermore, FFM was reduced in the 
radiotherapy group, which is reflecting a reduced level of nutrition and wasting post 
neoadjuvant treatment.  
Although the HYDRA ECF/ICF technology has been repeatedly used to measure an 
accurate FFM, the prediction of FMM with impedance is subjected to a significant 
error as it is directly linked to the ECF volume [432, 490]. An increase in the ECF 
would result in a large predicted FFM and higher percentage of fat estimation.  
ECW can be further split into intravascular volume (has an effect on blood pressure, 
development of left ventricular hypertrophy, and cardiac dysfunction) and 
extravascular fluid (affecting tissue hydration and oedema) [270]. Therefore, even 
subtle changes within these sub-compartments for a given ECW can affect the 
cardiac reserve and varying the oncotic pressure. Therefore, this might have an 
effect on the CPEX data and the functional capacity post APT exposure.  
Moreover, the overall patients triceps skin fold (TSF) and mid-arm circumference 
(MAC) showed a significant decline after the neoadjuvant therapy. TSF and MAC are 
active components in the postoperative rehabilitation programme as both forms the 
basis of the lean body mass. By this, we mean having more muscle and less fat bulk 
is important for early mobility, prevent of thrombo-embolic phenomena, prevent chest 
infection and early hospital discharge.  
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Recent work and research have suggested that when the HYDRA ECF/ICF 
technology of measuring TBW is combined with densitometry, the prediction of FFM 
and fat estimation is greatly improved [491-493].  
Gupta et al have evaluated the nutritional status of CRC patients using BIA, serum 
albumin, prealbumin and transferrin, subjective global assessment (SGA) and QLQ-
C30. It has been showed that the prevalence of malnutrition, as determined by SGA, 
was 41%. Well-nourished patients had statistically significantly better quality if life 
(QoL) scores on the global, physical, and role functions compared to malnourished 
patients. Interestingly, the median role function score in well-nourished patients was 
41.6 points higher than the corresponding score in malnourished patients, indicating 
a "much better" functioning from a patient's perspective. Similarly, QoL scores on 
multiple symptom scales were statistically significantly better among well-nourished 
patients. Hence, malnutrition is a significant cause of morbidity and mortality in 
advanced colorectal cancer and is associated with poor QoL [494]. 
We have also found that the individual muscle power, represented by the grip 
strength (GS), had reduced post chemoradiotherapy. This again is an important and 
determining factor to tackle any postoperative complications and enhance quick 
recovery.  
Interestingly, BIA can also be used to verify 5-Fluro-Uracil (5FU) clearance and 
volume of distribution in CRC patients undergoing combined APT. The 
pharmacokinetic of this chemotherapy is better predicted by BIA; which will lead to an 
improved dosing with the 5FU [495]. 
Surprisingly, creatine oral supplementation can improve the deranged BIA 
parameters resulted from the adjuvant pre-operative therapy but has failed to 
improve muscle mass or function and QoL in patients with colorectal cancer [496]. 
Body weight and body mass index (BMI) did not show significant changes after APT. 
We might need a bigger sample to show changes and make a conclusion. Despite 
this, individuals body weight had a strong and significant correlations to the 
cardiopulmonary reserve and HRQL. Hence, neoadjuvant treatment can also 
indirectly affect the body physiology of CRC patients via its direct effects on the BMI 
as changes in body weight is strongly linked to the cardiopulmonary function and the 
patients psychological status.  
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Interestingly, many studies in the literatures have indicated a reasonable association 
between obesity and risk of colorectal adenomas and cancer. A recent pooling study 
by Jacobs et al from 8213 patients was performed in 2009 to highlight the association 
between body mass index (BMI) and metachronous neoplasia varied by the lesions 
characteristic, family history, sex and colorectal manifestations. Exploratory analyses 
indicated that BMI was significantly related to most histological characteristics of 
metachronous adenomas among men but not among women. They have also 
concluded that body size, mainly in men, may affect colorectal carcinogenesis at 
comparatively early stages [497].  
Our project has confirmed noticeable changes in the body composition after the APT 
administration and these changes in the body fluid and fat distribution can affect the 
CRC course and behaviour after the anti-cancer therapy which could be linked to peri 
and postoperative complications [498].  
BIA does not measure fat directly, but in a patients where body weight is changing 
without corresponding changes in ECW or ICW, it is most likely that there is a 
change in their body fat that can be calculated [270].  
BIA data suggested changes that may not have been clinically apparent. To give a 
clear image about the individual body composition, we recommend serial BIA 
measurements over a period of time pre and post APT exposure rather than one-day 
readings. This is much revealing as there is a normal physiological fluctuation of 
body weight and composition over time, especially when there is an active colorectal 
cancer within the body. BIA is a technique that is acceptable to patients and can be 
readily performed in clinical situations. Therefore, changes in body composition, as 
tested by BIA and anthropometric tests, are multifactorial and could be caused by 
direct or indirect insults.  
Neoadjuvant treatment itself can have a direct impact affecting the body composition 
changes represented by fluid depletion, end-organ tissue hypoxia and a significant 
increase in the catabolic rate [499].  
In addition, APT can also have a direct non-specific adverse reactions such as such 
as nausea, vomiting, weight and appetite loss (the cancer anorexia-cachexia 
syndrome). These systemic symptoms can indirectly affect the body physiology via 
different mechanisms involving the cardiopulmonary system, inflammatory cascade 
and the HRQL status.   
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On the other hand, the composition of the body compartments could be changed by 
the indirect effect of the APT such as poor tissue perfusion (impaired 
cardiopulmonary function), induction of immune response (SIRS, CARS) as well as 
the psychological impact of the therapy (poor physical and nutritional well-being).  
Detecting statistically significant changes for patients can often require serial 
measurements over a long period especially if the changes are occurring at relative 
slow rates. Hence, the statistical ability to identify a significant change in body 
composition is dependent on not only the measurement precision, but also the 
biological variability of the body composition parameter in the research population 
and the sample size of the study group. 
The limitation and complexity of the BIA dictate careful interpretation of results and 
data, which should be taken in conjunction with other components of clinical 
assessment rather than as an alternative technique. Further systematic studies, to 
evaluate the ability of BIA to alter and improve clinical management compared with 
conventional standard clinical assessment, are important to refine the BIA ability to 
define normality within an individual. 
7.4 Nutrition in CRC patients; role and methods 
It is well known, for years, that malnutrition in patients with neoplastic diseases is 
associated with a poor prognosis and that weight loss is an important predictor of 
mortality [500-502]. 
Cancer patients usually suffer from cachexia because of anorexia and metabolic 
alterations, such as inflammation, increased muscle proteolysis, as well as changes 
in the metabolism of lipids, carbohydrates and proteins.  
To date, no nutritional, pharmacological or metabolic intervention has proved 
effective in preventing these metabolic changes [503]. 
As for energy metabolism, an imbalance between pro-inflammatory and anti-
inflammatory cytokines, which is typical of cancer patients, may lead to an increase 
in resting energy expenditure (REE) and contribute to the development of cachexia. 
More recently, it has been recognized that the metabolic response to a tumour may 
differ, leading to a hypometabolic state in some patients. 
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Malnutrition has been shown to affect post-operative outcome from previous studies, 
so it would be beneficial to identify those who are malnourished or who are at risk of 
becoming so preoperatively. In a recent study in 2010 by Burden et al, 87 patients 
were enrolled and over half of these patients had lost weight prior to surgery and one 
in five were malnourished. Body composition measurements with bioelectrical 
impedance analysis and anthropometric measurements have demonstrated 
malnourished patients with significantly less fat free mass compared to patients who 
were not clinically malnourished. Hence, nutritional screening would be beneficial 
preoperatively to identify weight-losing patients at an early stage in the care pathway 
when they initially enter the secondary care system [504]. In addition, Garth et al 
have found that malnutrition and its associated complications are considerable issues 
for surgical patients with colorectal cancer. Poor nutritional status coupled with 
delayed and inadequate post-operative nutrition practices are associated with worse 
clinical outcomes [505]. 
In our study, we have used the PATIENT-GENERATED SUBJECTIVE GLOBAL 
ASSESSMENT (PG-SGA) to assess nutritional changes post APT exposure. This 
tool is reproducible in several clinical settings (inpatient, outpatient, home care and 
hospice), cost-effective, easy to use, able to predict those patients who need 
nutritional intervention and who will benefit from nutritional intervention, and have 
little inter-observer variability. We have found that patients started with stage A 
(normal and well nourished) and ended up with stage B (moderately mal-nourished) 
after the chemoradiotherapy regime. This reduction in the SGA rating was obtained 
via assessing the PGSGA questionnaire parameters as well as the anthropometric 
measurements (Weight, BMI, TSF, MAC, GS) [506]. 
Few evidences are available in the literatures supporting the importance of 
postoperative nutritional support in CRC patients. Chen et al have showed that "non-
risk" patients who did not receive postoperative nutrition support had a higher rate of 
postoperative complications than patients who received postoperative nutrition 
support with a longer postoperative hospital stay. Hence, appropriate and moderate 
nutritional intervention can improve the postoperative outcome of colorectal cancer 
patients [507]. 
A recent in vitro study showed that a lipid emulsion containing fish oil (FO) slows the 
growth of colorectal cancer cells and enhances their sensitivity to 5-fluorouracil (FU).  
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A lipid emulsion containing FO has a growth inhibitory effect on a human colon 
adenocarcinoma cell line, an effect not due to the induction of apoptosis, and 
potentiated the S phase-halting effect of FU. Thus, an FO lipid emulsion may be of 
benefit in colorectal cancer [508]. This is a useful evidence to show the importance of 
preoperative nutritional support in improving the outcome of CRC patients.  
Post APT patients awaiting CRC surgical resection might benefit from supportive 
counselling via meetings with a dietician or specialised nurse about the importance of 
nutrition and ways to optimise the body nutritional requirements to minimise surgical 
related complications. Many studies are available in the literatures to support the 
significance of preoperative individualized nutritional care, based on each patients 
energy needs, to prevent surgical sites infections, cardiopulmonary events, 
anastamotic leak and long hospital stay. All these factors will eventually reduce the 
peri and postoperative mortality and morbidity [509-511].  
Recent evidences showed that individualised intervention could improve the overall 
food intake and the quality of life as well as reducing postoperative complications in 
cancer patients undergoing chemoradiotherapy. This personalised intervention needs 
a close collaboration and monitoring with the patient to assess their dietary 
compliance [203, 308, 512]. 
Early nutritional support, with proper protocols, is very important in patients with 
severe malnutrition. Therefore, specific screening tools were developed and 
validated for malnourished patients such as Patient Generated Subjective Global 
Assessment, Subjective Global Assessment, Nutrition Risk Index and Malnutrition 
Universal Screening Tools for cancer patients [513, 514]. 
If this dietary counselling fails and patients food intake remains below their calories 
requirements, then the next step will be the provision of oral nutritional supplements 
(ONS) which is less invasive than other forms of artificial feeding [512].  
ONS’s are end-products that are ready to use as a supplement to the main intake or 
as a sole source of food. Successful supplementation depends on the palatability and 
the volume of these products, which are determining factors for compliance in 
patients who often experience changes in their sense of taste and smell [515-517].  
Oral nutritional supplements are used for patients with variable level of nutritional 
needs in the clinical practice.  
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These supplements are only effective in patients with a high risk of malnutrition or in 
those who are already malnourished, whereas the benefits appear to be uncertain or 
only slightly visible clinically when used for patients with a low risk of malnutrition or 
with mild malnutrition [518]. There are no specific guidelines for the use of ONS, 
however, patients at risk of malnutrition with anorexia and/or partial dysphagia not 
resolvable within 2 weeks with a calorie intake of less than 50% of requirements 
should have ONS. Also, it should be given to malnourished patients with a BMI < 18 
kg/m2, anorexia and/or partial dysphagia, who have already lost 5% of their normal 
weight in the last 6 months, with a calorie intake of less than 50% of total 
requirements [499]. 
The total energy requirements for cancer patients is normally calculated using the 
Harris-Benedict formula multiplied by the stress factor (1.2–1.4) according to the 
clinical condition of the patient [519, 520]. This should include 20% protein (1.2–2 
g/kg/day), 20% fats and 50–60% carbohydrates [512]. 
In a recent study by Stratton et al, ONS has been found to increase body weight and 
improve body composition (increased lean body mass or fat free mass). It can also 
improve body function such as muscle strength, walking distance, well being, 
physical and mental health; hence reducing the peri and postoperative mortality and 
morbidity [518]. 
The next step up the feeding ladder is Enteral Nutrition (EN), which requires a shift 
from the concept oral consumption of food to the infusion of calories and nutrients via 
nasogastric, nasojejunal tubes, percutaneous endoscopic gastrostomy (PEG) and 
surgical jejunostomy. Few issues need to be considered before commencing this 
type of feeding as EN is more invasive and can affect patient’s cultural, social and 
emotional environment [521]. 
Despite the above, EN is considered as the chosen method when artificial feeding is 
required and the gastrointestinal tract is intact. It is physiological way of feeding, less 
prone to complications, less expensive and easier to monitor compared to parenteral 
nutrition. Moreover, the passage of nutrients through the intestinal tract maintains 
intact and restores the absorption surface [513, 522]. 
EN is indicated and prescribed when ONS is failing to meet 50% of the nutritional 
requirements of the body, severe anorexia as well as more than 5% loss of body 
weight [499].  
 160 
EN formula is divided into two main categories: elementary and semi-elementary 
formulas. In addition, there are formulas enriched with immunonutrients (e.g. 
glutamine, omega-3, branched amino acids or nucleotides) and special formulas for 
specific diseases [523].  
The use of enteral nutrition in cancer patients has demonstrated an improvement in 
their appetite, energy intake and nutritional status especially when used 
preoperatively [524]. It has also showed a noticeable reduction in the gastrointestinal 
toxicity from the anticancer therapy, due to a better response to treatment [523, 525, 
526]. Furthermore, EN was associated with a significant improvement in the quality of 
life, was cost-effective and had a good compliance for the use at the home [527-530]. 
If previous nutritional supports fail to meet the individual calories requirements then 
Total Parenteral Nutrition (TPN) is the next step forward to prevent malnutrition and 
its associated morbidities. TPN is expensive, invasive and needs a close monitoring 
with multidisciplinary team involvement and associated with wide range of possible 
complications. TPN in cancer patients is used when there is high risk of 
undernutrition, malabsorption, severe mucositis, enteritis and in patients with short 
bowel syndrome. Studies involving patients treated for short periods of time (normal 
less than 1 week) have produced poor results or have shown the same efficacy as 
enteral nutrition [531-534].  
A lot of interest has been developed over the last decade about the importance of 
Omega3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), on the immune system and the inflammatory response 
as both can potentially reduce the pro-inflammatory and immunosuppressive effects.  
EPA and DHA can increase the T-helper/T-suppressor cell ratio and stimulating 
lymphocyte proliferation leading to a higher natural killer cell activity with benefits at a 
biochemical, clinical and functional level [533-539]. Interestingly, recent studies 
showed that preoperative administration of parenteral Omega3 fatty acids have 
reduced the APT-associated immunosuppression as well as a decrease in the length 
of hospital stay [535, 536]. 
Future studies focusing on the importance of early nutritional interventions in cancer 
patients with caloric optimisations are needed and would be an important topic for 
subsequent phases of this study.  
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We strongly think that preoperative nutritional optimisation can improve the APT 
efficacy and potentiate patients functional capacity by modulating the 
cardiopulmonary reserve and the cytokines balance, hence, reducing the peri and 
postoperative morbidity associated with malnutrition.  
Patients with colorectal cancer usually have an increase demand for a special protein 
called Glutamine, which is an amino acid used as a source of energy and nitrogen by 
the rapidly dividing tumour cells. Hence, CRC patients can be affected by its 
deficiency, which may lead to changes in their immune status, the integrity of the 
intestinal mucous membrane and protein-energy metabolism, contributing to cancer 
cachexia [540, 541]. In addition, branched amino acids (BCAAs) are used as 
regulators of protein synthesis and degradation, and as a source of energy for the 
muscles and other tissues. Moreover, they are precursors of glutamine and alanine, 
which might improve functional capacity and reduce the length of hospital stay. Thus, 
glutamine and BCAAs supplementation is important for CRC patients especially after 
APT administration [542-545].  
Chemotherapy can cause microvascular ischemia leading to significant damage to 
the mucous membrane lining the gastrointestinal tract. This could be subclinical or 
can be associated with nausea, vomiting, diarrhoea, stomatitis and mucositis. 
Radiotherapy can also cause a direct damage to the small and large bowels named 
as radiation enteritis. The extent of damage depends on the location and size of the 
radiation port, size and frequency of fractionation and whether the treatment is part of 
a multimodality treatment regimen.  
In conclusion, nutritional treatment and support should always be linked to the ‘time 
factor’, because even a good calorie-protein intake is inadequate for cancer patients 
undergoing chemoradiotherapy, if not timely and early administered.  
 
7.5 Health related quality of life (HRQL) and physical activity in CRC patients 
We establish the need for further investigation in specific areas of this field, such as 
considering the role of exercise in patients with colorectal cancer undergoing 
preoperative adjuvant therapy. 
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Many types of exercise programme were tried in the clinical practice, such as: 
aerobic exercise, resistive exercise, high intensity and low intensity programmes, 
group or individual programmes, institution based or home based programmes, and 
programmes with additional components such as dietary advice and relaxation 
techniques. No consensus has been reached to an 'ideal programme' and there have 
been no studies comparing different programmes and no published study in favour of 
one programme on another.  
Studies employing home based or self directed exercise programmes have 
encountered problems with members of the control group initiating their own exercise 
programme during the trial period despite being advised not to [413]. A formal 
structure with group based sessions at a health or fitness facility seems to diminish 
this problem [410].   
'Physical' or 'physical role' is a sub-category of most health related quality of life 
(HRQL) tools. Physical role has been shown by several studies to show 
improvements after patients have participated in exercise programmes [405, 408, 
546-549].  
Unfortunately, several studies show positive but non-significant results; with fewer 
well designed studies showing significant results. Courneya et al [413] performed a 
2-group study with a home based exercise programme but unfortunately many of 
their control group (51%) also began exercising at home during the study period.  
This meant that their initial analysis showed no difference in physical scores between 
their intervention group and control group. However, they then performed an ancillary 
analysis separating the patients into 2 groups according to whether they had 
improved their fitness or not.  
This showed more positive results with a statistically significant difference in HRQL 
and physical role scores between the 2 groups [413]. Not everyone has been able to 
show a positive relationship between exercise and physical role improvement.  
Stephenson et al [407], did not find a positive association between physical activity 
levels and HRQL in their cross sectional survey, however, they had a largely 
metastatic/palliative cohort (60%) and their data came from patient reported activity 
logs. This cohort is very likely to have affected their results and their study design 
makes the evidence provided weak [407].  
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Overall, the literature supports that improvement or avoidance of deterioration is 
seen in the physical role domain of HRQL following exercise. It is reasonable to 
assume an improvement in physical role would confer a HRQL advantage; as for 
patients; this reflects less limitation in their ability to independently perform daily 
acitivities and spend time performing social and hobby functions.   
Fatigue, as a symptom, is a component of many HRQL scores. Several studies 
investigate the role of exercise in improving fatigue amog patients with cancer 
undergoing adjuvant therapy; and some relate this to overall HRQL scores [408, 410, 
550, 551]. The trend of the literature is towards supporting the use of physical activity 
for cancer related fatigue. The later can be the result of many factors such as 
treatment or malignancy related anaemia, de-conditioning due to adopting a 
sedentary lifestyle, insomnia and anxiety [551]. One-way exercise is thought to help 
by preserving or improving fitness, meaning less energy is required to perform 
normal daily tasks; and therefore patients can achieve more before their fatigue 
becomes insurmountable. These results in lower fatigue scores are often translated 
in the higher HRQL scores [405, 410]. An alternative theory is that fatigue associated 
with doing exercise is felt in a positive manner, and is justifiable and satisfying for 
patients who experience it, whilst fatigue experienced when following a sedentary life 
style results in negative feelings of fatigue [550].  
In our study, we have used version 3.0 of the EORTC QLQ-C30 questionnaire to 
assess different parameters of the global health status, functional and symptoms 
scales. Significant deterioration was found in the physical role, emotional, cognitive 
and social functioning in both groups of patients after the neoadjuvant therapy. In 
addition, significant worsening symptoms (Fatigue, Nausea, vomiting, Pain, 
Dyspnoea, Insomnia, Appetite loss, Constipation, Diarrhoea, Financial difficulties) 
was noted after the anticancer treatment in both groups of patients post APT.  
Although theories as to the reason for improved fatigue scores are variable, there is a 
strong agreement that exercise leads to positive results [405, 408, 410, 550, 551].  
Young-McCaughan et al suggest that exercise has the strongest evidence base for 
treating fatigue over all other therapies [405]. Whilst this may be true, post 
intervention patients still return poorer scores compared to the general population 
[410].  
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In fact, Dimeo et al were unable to show a significant reduction in fatigue in their 
intervention group however, their control group showed a significant increase in 
fatigue so with this in mind their intervention still had a positive result for their patients 
[408]. However, a Cochrane review of women with breast cancer performing exercise 
whilst undergoing adjuvant therapy also only showed a statistically non-significant 
reduction in fatigue scores across the studies they included but this was not 
compared to a control group [552]. 
Symptom profiles are also measured as a sub-category of many HRQL tools and 
there is evidence to suggest an improvement in symptom profiles for some patients. 
The meta-analysis performed by Conn et al [553] showed a significant improvement 
in symptom scales for single group studies but not for studies with 2-group 
comparison. They did not provide a breakdown of the symptom scale, therefore, it is 
possible that few symptoms were responsible for this positive result or whether 
improvements were seen across the board [553]. Adamson et al [410] highlighted 
insomnia, pain and diarrhoea as the responsible components for returning an 
improved score in their study. On the other hand, there are studies where no 
improvement in the symptom scale is seen in the exercise group but when compared 
to a control group there is a prevention of worsening of some symptoms [408, 553].  
As well as considering physical and symptom changes, HRQL is also concerned with 
emotional and mental functioning. It is relatively common to see emotional responses 
improve hand in hand with physical scores. This could be because an increase in 
physical capacity allows for more independence and ability to perform enjoyable 
activities as well as essential daily tasks [408, 413, 554]. Anxiety showed to be 
improved after exercise in several chronic conditions and is not exclusive to cancer 
[408]. The mechanism by which this is achieved is not known but it is statistically 
significant in several studies [408, 554].  
In breast cancer studies, anxiety is often assessed in combination with depression 
and excellent results were seen in this area [555-560]. Corneya et al showed 
improvements in depression scores specific to patients with colorectal cancer [408, 
413].   
Many patients experience problems with insomnia during treatment for cancer; this 
may be a primary symptom, a treatment side effect or due to anxiety. Some positive 
response to insomnia has been seen after an exercise intervention. The best 
example of this is in the study performed by Adamsen et al [410].  
 165 
They showed an improvement in insomnia; but their study included relaxation and 
massage as well as exercise. As such, it is difficult to know if this improvement is 
attributable to the exercise or other elements of their intervention. 
Exercise has repeatedly been shown in the literature to result in positive physical and 
emotional improvements for patients with cancer. However, the relationship between 
these elements may not be straightforward. It is possible that positive results in these 
studies come from the sub group of patients in the intervention cohorts who actually 
increase exercise levels from their pre-morbid levels [405, 561, 562]. Some evidence 
seams to suggest that it is not the absolute amount of exercise that a patient is doing 
that is important, but the change in exercise levels from pre diagnosis to post 
diagnosis [562].  
In other words, those who did little exercise prior to diagnosis that subsequently 
started exercising showed better results than those who already had active lives.  It is 
possible that this is due to the fact that HRQL is related to the degree of change 
caused by the cancer experience. The patient with sedentary pre-morbid lifestyle 
may improve their HRQL score whilst the active patient may have seen a significant 
decline in their ability to perform their normally daily activities despite participating in 
an exercise programme and thus return a poorer score [408, 550].  
This was well shown by Courneya et al [413] who were disappointed to find that 
many of their control group began exercising during the study period using advice 
from patients in the intervention group. They performed an ancillary analysis by 
separating their patients into those who had improved their fitness during the study 
period and those who had not. They were able to show that improved fitness 
correlated with improved HRQL [413]. 
On the other hand, Courneya et al [561] also showed a positive effect on HRQL after 
low intensity exercise intervention despite no measurable improvement in fitness 
[561]. This could be interpreted as a psychosocial mechanism where patients find 
that they are distracted from negative thoughts and feel like they have taken some 
personal responsibility for their recovery. It is also possible that they enjoy the 
interaction with peers and health professionals that formal group exercise 
programmes offers as suggested by Adamsen et al [410]. The literature cannot 
provide evidence of this theory as none of the current studies provide alternative non-
physical programmes for the control arm of their studies.  
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Thus, it cannot be assessed if there is an effect from group interaction and attention 
from health professionals leading to improved HRQL [410]. 
An isolated finding by Stephenson et al [407] is that performing physical exercise is 
negatively correlated with family wellbeing and social wellbeing. The hypothesis that 
this is due to the time taken to perform physical activities; and that this is considered 
to take away from valuable time with family or socialising. This is not reported 
elsewhere and indeed, there is little mention in other papers about the negative 
effects of performing exercise. Whether this is a publication bias or a simple 
reflection on the norm findings is difficult to assume.   
Despite there being little evidence regarding the negative effects of physical exercise 
on HRQL some studies do highlight concerns or criteria for excluding patients from 
completing exercise programmes. The literature is consistent in its support of 
exercise as a feasible and safe intervention for patients with cancer; however, some 
studies have highlighted specific exclusions. For example exclusion of patients with 
brain metastasis, bone metastasis, and platelets <50,000 [546]; others excluded 
patients with psychiatric disorders, and all those with muscular, cardiovascular or 
pulmonary disease were excluded as well. Immunocompromised patients secondary 
to treatment, for example, may limit location of exercise. Public gyms and exercise 
facilities should be avoided until blood counts are within normal limits. Patients with 
anaemia may experience dizziness, shortness of breath and angina type pains, 
which may lead to a significant medical event. Medical appendages such as 
intravenous lines and catheters should not be exposed to excess risk of infection 
such as saunas and swimming pools; furthermore care is required to ensure they are 
not dislodged in the process of performing exercise [547].  
Therefore, although exercise seams to be beneficial for patients, these specific 
concerns should be born in mind before promoting such programmes in order to 
prevent harm in other ways. The design of studies has improved more recently but 
the literature suffers from a lack of randomised trials or even two group comparison 
studies with the majority being single group studies.  
It is understandably difficult to perform a randomised trial in this era and the ability to 
perform double blinded trials is lacking, however, single blinding of the assessors 
should be attempted. Many studies also have recruitment problems and find that only 
motivated people who want to perform exercise join the study. 
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In general, people do not join an exercise study because they want to be in the 
control group [413]. This has been in part the source of difficulties experienced by 
some early studies where control group patients pursued their own exercise regimes. 
It would also be valuable to perform a study that includes a non-exercise based 
programme for the control group and see if there is any effect from group dynamics 
or attention from health professionals. There are no multicentre trials performed on 
subjects other than those with breast cancer.  There are some further studies in this 
area currently being carried out, the results of which will hopefully improve our 
understanding of exercise as a moderator of HRQL and improved outcomes for 
patients [563, 564]. 
A valuable area of study for those concerned with colorectal cancer is that of the role 
of exercise programmes in patients who receive preoperative adjuvant therapy. This 
is an ideal target for investigation which could show promising results in terms of 
preoperative optimisation of patients. Considering the side effects and sequelae of 
chemotherapy and radiotherapy, it is likely that patients experience a reduction in 
fitness during their treatment.  
A period of recuperation and healing is provided for patients receiving long course 
combined treatment, and medical optimisation is sought with multiple patients visiting 
cardiologists or respiratory physicians in the preoperative period. However, it is rare 
that support is given to them in terms of physical exercise and nutrition excluding 
some basic advice in clinic. Investigation into this area could provide promising data 
in support of exercise, both in terms of preoperative optimisation and improved 
HRQL, which in turn leads to motivated patients who will be more likely to aim for a 
prompt recovery post operatively. In short, there is a growing body of evidence which 
points towards a positive effect of exercise for patients with cancer undergoing 
adjuvant therapies.  
A proportion of the literature suggest little benefit is afforded to those performing 
exercise along side their cancer treatment but there very little to support that it 
actually has a negative effect.  
The current literature suffers from a lack of randomised and multicentre trials and 
often the small studies currently published are unable to provide statistically 
significant results. Overall, the literature supports that patients either experienced an 
improvement in their HRQL after participating in an exercise programme, or in some 
cases avoided deterioration.  
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Programmes in a formal class setting at a hospital or similar facility appear more 
successful in improving HRQL that other forms of programme offered. The effect of 
exercise is more successful in some categories than others; physical and emotional 
wellbeing return better result than social and mental wellbeing in most studies. There 
is still work that needs to be done to confirm that findings from early studies are 
correct.  A particular area of interest which could have dramatic results in coming 
years is that of pre-habilitation of surgical patients after preoperative adjuvant 
therapy. 
Preoperative exercise training proved to be feasible in other setting and may be 
practical in colorectal cancer patients depending on the APT regimes [565]. Exercise 
training has significant effect on the cardiopulmonary function and HRQL in 
postmenopausal breast cancer survivors who had completed surgery, radiotherapy 
and/or chemotherapy with or without hormonal treatment [399].  
Another study by Morikawa et al showed that activation of the WNT signalling 
pathway and cadherin-associated protein beta 1 (CTNNB1 or beta-catenin) was 
associated with better colorectal cancer-specific survival and overall survival in obese 
patients only. Post-diagnosis physical activity was associated with better colorectal 
cancer-specific survival only among patients with negative status for nuclear 
CTNNB1. These molecular, pathological and epidemiology findings suggest that the 
effects of alterations in the WNT-CTNNB1 pathway on outcome are modified by BMI 
and physical activity [566]. 
Both CRC and chemoradiotherapy are associated with fatigue. Our data indicate a 
loss of fat free mass over the course of APT which implies a loss of muscle bulk. This 
may not be sufficient of itself to explain the fatigue and the loss of the functional 
capacity associated with the anticancer therapy. It is possible that fatigue 
experienced by patients may reflect changes within the muscles themselves. 
Chemoradiotherapy can cause tissue hypoxia at muscular level, can induce an 
inflammatory process mediated by different cytokines as well as affect the patient 
cardiopulmonary reserve.  
These adverse events will have a direct impact on the body functional capacity and 
deteriorate all of the above endpoints of the EORTC QLQ-C30 questionnaire. 
Therefore, further studies to look for the muscle changes at cellular level are required 
to explain this limited functional capacity of poet therapy patients.  
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Little evidence is available on patient-reported outcomes after APT for colorectal 
cancer patients. In a recent multicenter prospective observational trial, HRQL was 
assessed using (EORTC) QLQ-C30 questionnaire before and 2-3 weeks after 
completion of APT as well as at 6 and 12 months after surgery. Primary analysis of 
selected scales included: global quality of life, physical functioning, social functioning, 
fatigue, body image, future prospective, and gender-related sexual problems. This 
showed that 78% of patients reported stool fractionation and 72% sensation of 
incomplete defecation. Only 14% of patients had optimal continence. Physical/social 
functioning, fatigue, and body image showed a decrease just after APT and returned 
to baseline levels at 1 year after treatment. Global quality of life was stable over time. 
Male sexual problems were greatly impaired throughout the study period (P < 0.001) 
with major clinically meaningful changes between baseline and 1 year after treatment 
[567]. 
Haydon et al have confirmed the beneficial effects of physical activity in reducing 
colorectal cancer mortality and improving the outcome through interactions with the 
insulin-like growth factor and insulin-like growth factor binding protein 3 axis [568]. 
Although this trial was performed on postoperative CRC patients, it clearly shows the 
importance of supervised exercise programmes to improve patients functional status 
and QoL. This could be easily used at the post APT stage in order to optimise CRC 
patients preoperatively.  
No trend difference was noted between both chemoradiotherapy and radiotherapy 
only groups as there was a significant deterioration of functional and symptoms 
scales post APT exposure in all of the patients. This means that even radiotherapy 
alone can cause alteration of the body functional capacity, which could be explained 
by triggering the systemic inflammatory response, nutritional deficit as well as 
alteration to the body compartment compositions.  
 
7.6 Colorectal cancer markers of inflammation  
Colorectal cancer is an immunologic challenge and can modify the systemic immune 
response in different ways that may causally affect both the preoperative and 
postoperative clinical outcomes.  
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Cancer-related malnutrition is associated with the presence of a systemic 
inflammatory response, as reflected by enhanced levels of pro-inflammatory 
cytokines. Systemic inflammatory response leads to hypermetabolism-associated 
malnutrition, which is a common feature of metabolic derangement in patients with 
neoplasia [569, 570]. 
The patients inflammatory status usually reflect a balance between plasma levels of 
pro-inflammatory markers (TNFα, IP-10, RANTES, IL-6, IL-18) and anti-inflammatory 
markers (IL-1β, IL-1ra, IL-10, MIF) [571]. 
 
 
 
 
 
 
 
 
Figure (36) shows the balance of different pro and anti-inflammatory markers and how they drive the 
inflammatory response [571] 
 
Any imbalance between pro- and anti-inflammatory cytokines or any uncontrolled 
production of cytokines can result in an inflammatory response [571].  
An old concept indicate that septic patients usually begin with systemic inflammatory 
response syndrome (SIRS), then they transfer to mixed anti-inflammatory response 
syndrome (MARS) and end up with compensatory anti-inflammatory response 
syndrome (CARS) [572, 573].  
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Previous studies showed the presence of proinflammatory status is septic patients 
could be significant and can predict clinical outcomes [574]. Other studies have 
demonstrated the presence of anti-inflammatory cytokines at the onset of sepsis 
[575]. 
                 
 Table (21) shows the sensitivity and specificity of pro and anti inflammatory cytokines [572] 
Tumour-related changes in the inflammatory response in humans have been largely 
ignored, and their relationships with the clinical outcome have not been well 
discussed, especially in colorectal cancer.  
Serum cytokines are accepted mediators of host immune response. It is still a debate 
that these inflammatory markers influence postoperative morbidity and long-term 
survival in patients with CRC as their exact role is still unknown.  
It has been found that there is a significant correlation between plasma IL-6 and IL-
10 concentrations and survival as well as between IL-12 and toxicity [576]. 
Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with 
tumour cell invasion and stromatogenesis, i.e. the formation of specific connective 
tissue stroma amenable to easy penetration by endothelial and tumour cells. 
Angiogenesis is a multistep process in which many growth factors and cytokines 
have an essential role. Vascular endothelial growth factor (VEGF) is a potent 
angiogenic agent that acts as a specific mitogen for vascular endothelial cells 
through specific cell surface receptors. IL-6 pathway is another mechanism linking 
angiogenesis to malignancy. CRP is a representative marker for inflammation and is 
associated with disease progression in many cancer types [577-579].  
Cytokine Value 
Proinflammatory cytokines 
  
IL-6  Sensitivity (%) 82 
 Specificity (%) 86 
Anti-inflammatory cytokines 
  
IL-1ra Sensitivity (%) 71 
 Specificity (%) 84 
IL-10 Sensitivity (%) 84 
 Specificity (%) 82 
IL-6R  Sensitivity (%) 64 
 Specificity (%) 76 
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Preoperative serum VEGF and CRP level increased in colorectal cancer patients 
after APT administration and has been proposed as a poor prognostic factor for 
overall survival in patients with colorectal cancer [580]. 
Hatada et al have found that a marked activation of the pro-inflammatory cytokine 
network associated with a decreased antagonistic reaction and an increased 
consumption of IL-6 became prominent in malnourished CRC patients when they 
underwent intense surgical stress. These immunological disturbances may be 
relevant to protein energy malnutrition and subsequent clinical outcome [338]. 
In 1998, Nozoe has found that a preoperative serum elevation of CRP was an 
indicator of the malignant potential of the tumours as well as a predictor of the 
prognosis of patients with colorectal cancer [383]. 
Subsequently and in a study performed by Chung et al to investigate the prognostic 
significance of preoperative serum CRP, it has been shown that preoperative 
elevation of this inflammatory marker does not have the independent prognostic 
significance reported by earlier studies. Whether the elevated CRP can predict the 
development of cachexia or whether this association characterizes a pattern in 
tumour behaviour remains to be determined [393]. 
Kaminska et al have investigated serum cytokines (TNFalpha, IL-1ra, IL-6, IL-8, IL-10 
as well as CRP) in patients with colorectal cancer, prior to the adjuvant preoperative 
therapy (APT) and postoperatively. Most of these serum cytokines were raised 
postoperatively regardless of the tumour stage. On day 10 and 42 after surgery, the 
levels of cytokines followed various patterns [344]. 
In our study, looking at both groups of patients undergoing either pre-operative 
chemoradiotherapy or radiotherapy, various and non-significant pattern of changes 
were seen in plasma cytokines. However, 21 patients had a reduced plasma level of 
IL1β and 22 patients had reduced plasma level of IL1ra post therapy exposure in the 
full cohort of 36 patients. Therefore, there was a general trend of reduction in IL1β 
and IL1ra [348]. This slightly agreed with one oesophageal cancer study that showed 
levels of IL-1ra and IL1β significantly decreased after a cetuximab enhanced Folfox 
chemoradiotherapy neoadjuvant regimen. In this study it was found that there was no 
significant difference in these changes between responders and non-responders.  
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However, a further oesophageal cancer study using a different neoadjuvant 
chemoradiotherapy regimen also found tissue IL-1β to significantly decrease after 
treatment in complete responders, and remain unchanged in non-responders [581]. 
We have also found that IL-10 had a very non-specific pattern of change with nearly 
half of the patients had increased and the other half had reduced plasma levels of 
IL10. Considerable further investigation of IL-10 is thus required before it can be 
used as a biomarker in clinical practice. 
Whilst a number of cytokines also have the potential to be used as prognostic 
markers, a considerable amount of further research needs to be conducted before 
they are useful in clinical practice. Large colorectal cancer studies that measure a 
multiplicity of cytokine levels before and after each treatment modality (neoadjuvant 
therapy, surgery, and any adjuvant treatment), and compare levels to traditional 
staging and morbidity and mortality, are needed in the first instance. Further studies 
examining elements of the acute inflammatory response as therapeutic targets may 
also be useful in determining further prognostic elements. 
Previous human studies have investigated the influences of nutritional interventions 
on the body serum cytokines. However, it is unclear whether preoperative nutritional 
routes influence responses of systemic cytokines in patients after surgery. 
Lin et al have investigated whether preoperative total parental nutrition (TPN) 
influences systemic interleukin-6 (IL-6) and interleukin-8 (IL-8) responses in patients 
following surgery for colorectal cancer. Plasma IL-6 and IL-8 levels were marginally 
higher before the operation and were significantly higher on the first post-operative 
day in the TPN group than in the oral group. It has been concluded that routes of 
nutritional supply have an impact on the production of systemic cytokines after insult 
and plasma CRP levels did not differ between the two groups. The postoperative 
systemic IL-6 and IL-8 responses in patients who received standard TPN 
preoperatively were greater than in patients who received an oral diet. Preoperative 
nutrition via the enteral route may provide better regulation of cytokine responses 
after surgery than parenteral nutrition [582].  
While our data showed no significant changes of IL8 and CRP with no specific trend 
in the behaviour of these cytokines post APT exposure.  
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IL-6 and IL-8 were observed at 24-72 hours postoperatively in patients with colorectal 
cancer and this indicated a high risk of early postoperative septic complications and 
anastomotic leak [583]. In addition, low preoperative IL-1Ra is associated with 
postoperative infection frequently seen in the malnourished patients due to the 
defective immunoinflammatory adaptation system [584]. 
Moreover, Ll’yasova has investigated the relationship between circulating levels of 
the inflammatory markers and the presence of cancer with its outcome. It has been 
found that the presence of raised IL-6 and CRP are associated with colorectal 
neoplasia and very much correlated to the tumour behaviour [585]. This is actually a 
useful piece of information as IL-6 and CRP can be used in the clinical practice to 
determine the CRC activity post APT that could be modulated by different 
interventions such as exercise, nutrition, anti-inflammatory and optimisation.   
We couldn’t get a clear image from the cytokines behaviours in our study as there 
was no statistical significant difference noted for the plasma levels of IL10, IP10, 
RANTES, IL18 and MIF after finishing the neoadjuvant treatment. However, all of the 
above cytokines showed similar trends in both chemoradiotherapy and radiotherapy 
only groups. Although we have shown some subjective and objective evidences of 
nutritional deficits, serum albumin levels did not show significant changes after the 
neoadjuvant treatment as some patients had increased levels and others had 
dropped their serum albumin post APT exposure. 
Cancer-associated immunodeficiency is seriously worsened by surgical trauma. It 
has been found that short-term preoperative interleukin-2 (IL-2) immunotherapy 
abolishes postoperative immunodeficiency and can induce immunological control of 
the growth of minimal residual disease. This amplification of the immune response in 
the post-operative period is capable of controlling minimal residual disease after 
radical surgery, of reducing the progression rate, and of improving the prognosis and 
overall survival [586]. 
Previous research has showed a correlation between various psychosocial factors, 
particularly cancer-related concerns and depression, and pre/postoperative level of 
serum cytokines in patients with newly diagnosed colorectal cancer. However, the 
clinical significance of these findings needs to be addressed in longitudinal follow-up 
studies of recurrence and survival [587].  
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Although cytokines analysis did not provide this study with a clear message about 
their trends post APT, further studies with larger number of CRC patients might give 
a better power calculation to show significant changes, which will be useful to 
understand their roles in SIRS, MARS and CARS. The chosen cytokines in this 
research are the most relevant pro and anti-inflammatory markers related to 
colorectal cancer studies in the literatures.  
We have previously explained the role of chemotherapy agents on myocardial toxicity 
and the way 5FU can impair the patients cardiopulmonary reserve by causing 
mycocardial toxicity.  
This is an understandable way of pathophysiology, as the circulating chemical agents 
have a direct impact on tissue oxygenation and can cause microvascular ischemia. 
However, health professionals in clinical practice might enquire about why localised 
pelvic radiotherapy can alter the body physiology and reserve.  
This is an interesting argument as we think that targeted radiotherapy can induce a 
systemic inflammatory response with the production of systemic circulatory pro and 
anti-inflammatory cytokines (induction of SIRS or CARS) leading to these alteration 
in body physiology. This was clearly noted in our study as the radiotherapy group 
showed some derangements of the body cytokines, although not statistically 
significant, but might be clinically relevant in the disease process and progression as 
certainly cytokines levels were altered in some way post APT exposure.  
In addition, pelvic radiotherapy had a significant impact on psychological well-being, 
as shown on the HRQL questionnaires, as well as the body compartment 
distributions, as shown by the body composition parameters. These adverse events 
will eventually impair the body physiological reserve. Some experiments are still 
being held to explore the effect of anti-inflammatory medications, such as statins and 
aspirin to modulate the inflammatory cascade in patients with systemic inflammatory 
response syndrome.  
Previous studies have showed a strong relation between post-operative infective 
complications and long-term survival in patients with colorectal caner. Poor prognosis 
is usually associated with anastamotic leak as the later can trigger an inflammatory 
cascade, including the release of pro inflammatory cytokines and vascular growth 
factors, which promotes tumour growth, dissemination and even future local 
recurrence [588, 589].  
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However, there is enough evidence in the literatures that strong inflammatory cell 
infiltrate within and around the tumour has a protective effect on disease progression 
in colorectal cancer [590, 591]. Further work is needed to clarify these relations and 
its impact of postoperative outcome.  
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7.8 Brief summary of the study with a suggested hypothesis  
Post APT deterioration of the body physiological reserve in patients with CRC is 
multifactorial as there is a clear interaction between various aspect of body 
physiology such as cardiopulmonary fitness, body composition, cytokines level and 
HRQL. Direct and indirect impact of neoadjuvant treatment can alter the patients 
functional capacity and affect outcomes. This was shown clearly in the above thesis 
as most of our study variables were inter-linked together causing an overall 
deterioration in the body physiological reserve of CRC patients pre-operatively. 
We strongly think post APT patients awaiting surgical resection have a significant 
dterioration in their physiological reserve represented by: 
 
1. Reduced VO2max & AT (Impaired cardiovascular function) 
2. Increased VE/VCO2 (Impaired pulmonary function) 
3. Reduced  ECW, ICW & TBW (Fluid depletion) 
4. Reduced MAC, TSF & FFM (Reduced lean body mass) 
5. Impaired HRQL, (poor physiological and psychological well-being) 
6. Deranged Cytokines, CRP and Albumin (Triggered SIRS, MARS and CARS) 
 
We also think these patients are not given enough time to fully recover from the APT 
insult and they are not eminently ready for a major surgical resection. We therefore 
recommend the following points to be addressed and explored in more details at 
future studies to optimise CRC patients pre-operatively in order to reduce the 
possible postoperative mortality and morbidity in colorectal cancer patients.  
1. Prolong the window between finishing the APT regime and surgical resection 
until full recovery is made. 
2. Change of APT regime as per individual needs with rigid selection criteria.  
3. Supervised exercise training programme to improve physical wellbeing. 
4. Supervised dietary programme with or without targeted supplements.  
5. Psychological support and appropriate counselling.  
6. Anti-inflammatory agents that modulate pathway of SIRS or CARS.  
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7.9 Limitation of the study and future recommendations  
 
Despite of the hard work done to explore the possible changes at the physiological 
reserve among colorectal cancer patients, there are still some areas to be improved 
and needs to be explored in depth with future research and studies.  
1. This was only a pilot study on 36 patients with rectal cancer to explore the 
possible presence of physiological changes after adjuvant pre-operative 
therapy. Larger sample of patients is needed for future studies with a control 
group of patients who do not receive any kind of APT in order to eliminate any 
possible cause of physiological deterioration caused by the course of the 
neoplastic disease itself. 
2. We have used a mixed population to identify the possible trend of changes in 
patients with rectal cancer undergoing neoadjuvant treatment and awaiting 
surgical resection. Further studies on homogenous populations are needed 
as the two types of the APT regiments have different physiological impact on 
patients with colorectal cancer and might produce different results. 
3. As most of the study end-points were inter-linked, we recommend a detailed 
exploration of the study variables to find any relevant correlations among the 
study results and their clinical effects on CRC patients.  
4. Planning for a multi-centre study to recruit a large number of patients from 
different background over a short period of time. 
5. Our study end-points were measured before the administration and 2 weeks 
within the finish of APT regiment. We recommend future studies to measure 
our variables at the following points of time: anytime pre APT, 72 hours post 
APT, 72 hours pre-operative as well as careful recording of all of the post-
operative complications up to 30 days. This will give a clear explanation of the 
body behaviour during different disease stages. 
6. Co-ordinatation with the FOXTROT trial group in order to recruit patients with 
colonic cancer into a different group and compare outcomes with the rectal 
cancer group of patients.  
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8.0 APPENDICES  
 
Appendix 1 (Patient-Generated Subjective Global Assessment, PGSGA)           
 
STANDARDIZED NUTRITIONAL ASSESSMENT 
 
History 
 
1. Weight 
In summary of my current and recent weight: 
 
I currently weigh about ----------------- pounds 
I am about ----------- feet ---------------- tall 
A year ago I weighed about --------------- pounds 
Six months ago I weighed about ---------------- pounds 
During the past two weeks my weight has: 
□ decreased □ not changed □ increased 
 
2. Food Intake 
As compared to my normal, I would rate my food intake during the past month 
as either: 
□ Unchanged 
□ More than usual 
□ Less than usual 
 
I am now taking:  
 
□ Little solid food 
□ Only liquids 
□ Only nutritional supplements 
□ Very little of anything 
 
3. Symptoms 
 
I have had the following problems that kept me from eating enough (check all 
that apply): 
□ No problem eating 
□ No appetite, just did not feel like eating 
□ Nausea  
□ Vomiting 
□ Constipation  
□ Diarrhoea 
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□ Mouth sores  
□ Dry mouth 
□ Pain; where? ----------------------------------- 
□ Things taste funny or have no taste 
□ Smells bother me 
□ Other --------------------------------------------- 
 
4. Functional Capacity  
 
Over the past month, I would rate my activity as generally: 
□ Normal with no limitations  
□ Not my normal self, but able to be up and about with fairly normal activities 
□ Not feeling up to most things, but in bed less than half the day 
□ Able to do little activity and spend most of the day in bed or chair 
□ Pretty much bedridden, rarely out of bed 
 
 
THE REMAINDER OF THIS FORM WILL BE COMPLETED BY YOUR 
DOCTOR, NURSE, OR THERAPIST. THANK YOU. 
 
5. Disease and Its Relation to Nutritional Requirements 
 
Primary diagnosis (specify) -------------------------------- 
Stage, if known ---------------------------------------- 
Metabolic demand (stress):  
□ no stress □ low stress □ moderate stress □ high stress 
 
Physical  
 
For each trait specify: 0 = normal, 1 =mild, 2 = moderate, 3 = severe 
 
loss of subcutaneous fat (triceps, chest) ----------------------------- 
muscle wasting  (quadriceps and deltoids) -------------------------- 
ankle oedema ----------------- 
sacral oedema ------------------  
ascites --------------------- 
 
SGA rating 
 
Select one 
□ Well nourished  
□ Moderately (or suspected of being) malnourished  
□ Severely malnourished 
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Appendix 1 continue (Scoring sheet for PG-SGA questionnaire)  
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Appendix 1 continue (Outcome/stages of PG SGA questionnaire) 
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Appendix 2 (EORTC QLQ-C30 questionnaire, version 3) 
 
We are interested in some things about you and your health. Please answer 
all of the questions yourself by circling the number that best applies to you. 
There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
 
Please fill in your initials: 
 
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year):  
 
 
 
Not at all (1) 
A little bit (2) 
Quite a bit (3) 
Very much (4)  
 
1. Do you have any trouble doing strenuous activities, like carrying a heavy 
shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, dressing, washing yourself or using the 
toilet? 1 2 3 4 
 
 
During the past week:  
 
 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other leisure time activities? 1 
2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
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During the past week:  
  
 
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentration, like reading a newspaper or 
watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment interfered with your 
family life? 1 2 3 4 
27. Has your physical condition or medical treatment interfered with your 
social activities? 1 2 3 4 
28. Has your physical condition or medical treatment caused you financial 
difficulties? 1 2 3 4 
 
 
 
 
For the following questions please circle the number between 1 and 7 
that best applies to you 
 
 
29. How would you rate your overall health during the past week? 
                               1 2 3 4 5 6 7 
    Very poor Excellent 
 
30. How would you rate your overall quality of life during the past week? 
    1 2 3 4 5 6 7 
                               Very poor Excellent 
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Appendix 2 continue (Scales and items for the QLQ C30 questionnaire) 
 
 Scale Number 
of items 
Item 
range* 
Version 3.0 
Item 
numbers 
Function 
scales 
Global health status / 
QoL 
 
     
Global health status/QoL 
(revised)† 
QL2 2 6 29, 30  
Functional scales 
 
     
Physical functioning (revised)† PF2 5 3 1 to 5 F 
Role functioning (revised)† RF2 2 3 6, 7 F 
Emotional functioning EF 4 3 21 to 24 F 
Cognitive functioning CF 2 3 20, 25 F 
Social functioning SF 2 3 26, 27 F 
Symptom scales / items 
 
     
Fatigue FA 3 3 10, 12, 18  
Nausea and vomiting NV 2 3 14, 15  
Pain PA 2 3 9, 19  
Dyspnoea DY 1 3 8  
Insomnia SL 1 3 11  
Appetite loss AP 1 3 13  
Constipation CO 1 3 16  
Diarrhoea DI 1 3 17  
Financial difficulties FI 1 3 28  
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Appendix 2 continue (scoring of QLQ C30 questionnaire) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Technical Summary 
 
In practical terms, if items I1, I2, ... In are included in a scale, the procedure is as follows: 
 
 Raw score 
Calculate the raw score  
RawScore = ( ) nIIIRS n+++= ...21  
  
 Linear transformation 
Apply the linear transformation to 0-100 to obtain the score S, 
 
Functional scales:  ( ) 10011 ×





 −
−=
range
RSS  
Symptom scales / items: ( ){ } 1001 ×−= rangeRSS  
 
Global health status / QoL: ( ){ } 1001 ×−= rangeRSS  
 Range is the difference between the maximum possible value of RS and the minimum possible 
value.  The QLQ-C30 has been designed so that all items in any scale take the same range of 
values.  Therefore, the range of RS equals the range of the item values.  Most items are scored 1 
to 4, giving range = 3.   
    The exceptions are the items contributing to the global health status / QoL, which are 7-point 
questions with range = 6, and the initial yes/no items on the earlier versions of the QLQ-C30 
which have range = 1. 
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Version 2.0                                                                                                      
Centre Number: GS09/9007 
Study Number: 09/H1306/79 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Study Title:        
Physiological effect of adjuvant pre-operative chemotherapy 
and/or radiotherapy on patients undergoing colorectal cancer 
resections 
                
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. Thank you for reading this. 
 
• Part 1 tells you purpose of this study and what will happen to you if you 
take part.  
• Part 2 gives you more detailed information about the conduct of the study.  
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Part 1 
What is the purpose of the study? 
Cancers of the bowel (colon and rectum) are usually treated by surgical 
removal, but when the cancers are large, it can be difficult to removal all the 
cancer. The size of a cancer is shown on a scan, which a patient has once the 
cancer is diagnosed. This scan is then seen and discussed by all specialists 
at a weekly team meeting. When the cancer is seen to be large, the 
specialists will often recommend a course of either chemotherapy, or 
radiotherapy, and occasionally both therapies, to be given before surgery. The 
aim being is to shrink the cancer, to make it easier to operate on. 
These treatments have been shown previously to improve the results of 
surgery for rectal cancer and currently being studied, in a national trial, for 
colonic cancer. However, there is concern that these treatments can actually 
weaken you and so affects the individual’s fitness for a major surgery 
afterwards. Although enabling better treatment of the cancer, it might increase 
the risks of the operation. The aim of this study is to look for the possible 
effects of chemotherapy and radiotherapy on an individual’s general health. 
This is a pilot study on 40 patients. If our study shows that these important 
physiological functions are badly affected by chemotherapy or radiotherapy, 
then the next step will be to focus on how to improve such patients before 
they undergo a major operation, so that the risk of complications is reduced. 
Pre-operative chemo and radiotherapy offer several advantages such as 
better control of the tumour locally, an increase in the overall survival time and 
a possible increase in the proportion of patients having surgery without 
affecting the function of the anus to control defecation.  
Preoperative chemotherapy for colonic cancer may improve the likelihood of 
complete surgical removal of the tumour, and so improve survival. 
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Nowadays, some surgeons consider that pre-operative chemo and 
radiotherapy increases the incidence of early postoperative complications, 
especially causing a higher incidence of anastomotic leakage (join leak). 
Potential problems related to preoperative radiotherapy (RT) are wound 
infection (sepsis), delayed healing and a higher rate of anastomotic leak or 
dehiscence  
Chemotherapy (CT) affects nutritional status directly by lowering the body 
protein production and has indirect general effects such as nausea, vomiting, 
loss of weight and appetite, diarrhoea.  
Radiotherapy can also cause diarrhoea, taste changes, nausea, vomiting, 
loss of appetite and may further compromise nutrition and functional ability.  
Anti-cancer treatment with CT and/or RT may compromise both nutritional 
status and functional ability which in turn, impacts Quality of life (QoL). 
The resulting nutritional problems occur through direct effects on cancerous 
and healthy tissues, which may induce loss of weight and appetite, nausea or 
vomiting, and diarrhoea, leading to physical discomfort and a variety of poor 
absorption diseases. 
Heart and Lung exercise test (Cardiopulmonary exercise test / CPEX 
test) 
CPEX test adds very important additional information to that provided by the 
standard exercise test such as a precise determination of the actual heart ad 
lung reserve. CPEX testing closely mimics the postoperative situation, as it 
requires an increased heart function to satisfy the increased oxygen demand. 
People identified as having poor oxygen delivery on the CPEX bicycle would 
be expected to have a poor ability to increase heart function following surgery. 
The results of CPEX have a very high predictive value for patients at risk of 
major complications in the postoperative period. Therefore, it is a reliable 
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method of detecting patients who are fit to have this major tumour resection 
surgery. 
The CPEX test is non-invasive, it requires minimal preparation, and it may be 
performed on an outpatient basis. During the test you will be closely 
monitored by a Consultant anaesthetist and a heart technician.  
During your CPEX test, you will be required to perform mild exercise on an 
upright bicycle whilst breathing through a mouthpiece. Each breath will be 
measured to assess how the body is performing. The capacity and strength of 
the lungs is measured before and during exercise. Your heart tracing (ECG) 
will also be recorded prior to, during and post exercise. 
The CPX test will lasts for a total of 60 minutes; however you will only be 
required to exercise for approximately 10 minutes. The amount of exercise is 
modest - it does not require you to exert yourself to maximum effort. During 
the test you will be continuously monitored by the medical team. Results are 
generally available at the end of the consultation. In the extremely unlikely 
event that you become unwell, full resuscitation facilities will be available. 
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Body composition and fluid distribution test 
Changes in body composition reflect hydration, nutrition, and body fat, are all 
important elements reflecting well-being and efficacy of therapy. 
Body composition can be measured indirectly through changes in body 
weight, body mass index (BMI), and subcutaneous sum of skin folds (biceps, 
triceps, subscapular, suprailiac, and medial calf). 
To optimise fluid balance, a number of techniques have been investigated to 
measure body composition in clinical practice. Of these, bioelectrical 
impedance analysis (BIA) has attracted most interest and seems to be of 
greatest promise. This will be used in this study to measure the fluid and fat 
distribution in your body. It is very similar to have a heart tracing test (ECG). 
The BIA measurements are performed using four electrodes: usually two are 
attached at the wrist and two at the ankle which will take about 10 minutes to 
do the readings. It is not painful at all and has no recorded adverse effects. 
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Inflammatory and septic markers 
A number of blood markers could be affected after the administration of 
adjuvant chemotherapy or radiotherapy. We are interested in those related to 
inflammation. We will obtain a venous blood sample of 15ml to measure the 
level of inflammation in your body. 
 
Why have you been chosen? 
You have a cancer of the bowel. The multidisciplinary team meeting has 
decided to offer you a pre-operative treatment (chemotherapy or radiotherapy 
or both) to improve the post-operative outcomes and make the tumour 
operable. The aim of this study is to find out your overall body changes before 
and after having this treatment set by the oncologists.  
We hope you will be able to help us answer the above question. In order to 
help us we would ask you to go on the bicycle exercise machine to test you 
heart and lung as well as measuring your body fluid and contents by a tracing 
machine placed on your wrists.  
In addition, we will need to take a blood sample from your vein plus 
completing only one questionnaire relating to your current quality of life, 
physical and nutritional status. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take 
part, you will be given this information sheet to keep and be asked to sign a 
written consent form before or during your clinic visit. 
If you decide to take part you are still free to withdraw at any time without 
giving a reason. A decision to withdraw at any time or a decision not to take 
part will not affect the standard of care you receive. If you do decide to 
withdraw from the study at any point we will destroy all your identifiable 
samples, but we will need to use the data collected up to your withdrawal. 
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What would happen to me if I didn’t take part? 
Your treatment will not be affected in any way and your results will not be 
included into the study. 
What would happen to me if I took part? 
You will meet the principal investigator (SR) and have the study explained to 
you. A brief 10 minutes face to face interview will be conducted between the 
main study investigator and yourself after finishing your oncology 
appointment. The project aims and methods will be briefly explained and you 
will be provided with a written covering letter explaining the aims and methods 
of the study, a patient information sheet, a consent form and a single 
questionnaire in a prepaid self-addressed envelope. You will be given at least 
24 hours to decide about the study recruitment and participation in the above 
project. We shall then proceed to contact you by phone to enquire about your 
final decision.  
If you enter into the study, we will advise you to sign the provided written 
consent and return it together with the fulfilled questionnaires in your assigned 
clinic appointment. A helpline number will be provided in the covering letter to 
allow you to ask any questions you feel relevant before agreeing to consent to 
the study, or if you have difficulty completing the questionnaire. 
You will have 2 assessments. The first assessment will be 2 weeks before, 
and the second assessment 2 weeks after, the therapy. Assessments to be 
made include: heart and lung fitness on an exercise bike, body composition 
(fluid, fat and muscle distribution) and  nutritional status, blood tests to 
examine for inflammation within the body, and quality of life by 2 
questionnaires. 
You will be provided with a single appointment (arranged with the participant 
by telephone) to attend the project-specific outpatient clinic. During this visit, 
cardiopulmonary fitness (measured with CPEX test) and body composition 
analysis (measured with BIA) will be carried out as well as taking a venous 
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blood sample. This clinic is located at the cardiology physiology department of 
Leeds General Infirmary and the CPEX test will be carried out under the 
supervision of a consultant anaesthetist and a cardiopulmonary technician. In 
addition, measurements will be also done in the same visit to measure body 
weight, height, body mass index, skin folds and hand grip measurements.  
A single venous blood sample of 5ml will be obtained to check for 
inflammatory markers. 
You can bring the fulfilled questionnaires to you first clinic visit. These are 2 
validated instruments (EORTC QLQ-C30 and PG-SGA questionnaires) used 
to figure out patient’s QoL, physical and nutritional status which should take 
approximately 15 minutes to complete the 34 questions. 
The same procedure will happen again after finishing the assigned pre-
operative chemo and radiotherapy (adjuvant pre-operative 
chemoradiotherapy/APT). Patient will be contacted via post or telephone and 
invited for the second study visit to repeat the same procedures above in 
order to compare the findings pre and post pre-operative chemo and 
radiotherapy.  
The study-specific two clinic visits (pre and post adjuvant therapy) will be 
carried out two weeks before and two weeks after the administration of the 
anticancer treatment.  
This is to give the best reflection of the adjuvant chemoradiotherapy on the 
body physiology of colorectal cancer patients.  
If a patient deemed to need further adjuvant treatment from the MDT meeting, 
then the second visit should occur prior to this intervention.  
Patients will be provided with travel expenses as well as drinks and snacks 
during their visit and stay for the tests. 
A research team member will be present at the outpatient clinic and be able to 
go through any potential issues you may have. A helpline number to the 
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Research Office will provide a point of contact for any questions between 
0800hrs - 1700hrs Monday to Friday. 
The study requires that you complete the questionnaire as fully as possible 
and return it to a member of the research team either in clinic or via the 
Research Office addressed envelope provided. 
There is only one short questionnaire to fill in which covers many aspects of 
your Nutritional and Physical status as well as your current quality of life 
(QoL).  
This project will be conducted within the John Goligher Colorectal Unit, 
Department of Colorectal Surgery at the General Infirmary at Leeds. Ethical 
approval has been sought from the Leeds East Regional Ethics Committee.  
As a patient within the study you will be recruited into one of the three groups: 
 
Group 1 (Chemoradiotherapy patients) 
Group 2 (Radiotherapy patients only) 
There will be no difference in your diagnosis or treatment by taking part in this 
study. You will receive standard care, as any other patient would do.  
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A flow chart to help you understand the study and a time line of events is 
provided below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
                            Before Adjuvant pre-operative therapy (APT)  
 
 
 
 
 
 
 
                                 
 
        After Adjuvant pre-operative therapy (APT)                         
 
 
 
 
 
 
 
                                 
 
 
 
 
Diagram showing the study design and schedule 
Group 1 
ChemoRadiotherapy patients 
 
MDTM 
APT for rectal cancer  
 
Group 2 
Radiotherapy only patients 
Patient informed of study aims  
Patient information leaflet provided 
Patient consent 
• CPEX test  
• Body Composition test 
• Blood test  
• Structured questionnaires about HRQL, nutritional and physical changes 
• CPEX test  
• Body Composition test 
• Blood test  
• Structured questionnaires about HRQL, nutritional and physical changes 
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What if you have a low score in the questionnaire or you want to discuss 
issues raised by the questionnaire? 
In some cases we anticipate that patients may demonstrate poor scores in the 
questionnaire survey. In such cases, or in individuals wishing to discuss 
issues raised by the questionnaire, we shall arrange a further outpatient 
appointment. Further investigation and referral may be advised to liaison 
services (Leeds General Infirmary). 
 
Part 2 
What are the possible disadvantages and risks of taking part? 
With regard to this research, the only potential risk is when you go onto the 
heart and lung (cardiopulmonary) exercise machine as you might, 
occasionally, develop chest pain during the procedure. If this happens, the 
procedure will be immediately stopped and you will be managed as per the 
hospital protocol to treat a patient with chest pain. You will be in the 
cardiology department anyway and all of the other needed investigations and 
interventions are ready there to use if required. The procedure will be done by 
a cardiology technician with the presence of a consultant anaesthetist to deal 
with such adverse events if happened. CPEX testing is now routinely 
performed in Leeds Hospitals for patients about to undergo major abdominal 
surgery, who are considered high risk e.g. patients with an abdominal aortic 
aneurysm. The incidence of adverse events as reported in the literature is 2 to 
5 per 100.000 patients going onto the CPEX machine. 
What are the possible benefits of taking part? 
There are no benefits conferred to you by taking part in this study other than 
the potential to find out the possible downsides of chemo and radiotherapy in 
the treatment of bowel cancer.  
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What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about our findings. In the event that these findings affect you, your 
research doctor will inform you about it.  
What happens when the research study stops? 
Your care will not be affected in any way. 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it. Regardless of this, if you wish to complain about any aspect of 
the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms are available to 
you. 
Would my taking part in this study be kept confidential? 
All information collected about you during the course of the research would be 
kept strictly confidential. Any information about you, which leaves the hospital 
or surgery, would have your name and address removed so that you cannot 
be recognized from it.  
Only responsible health professionals from the Department of Surgery at 
Leeds General Infirmary or regulatory authorities from the NHS trust, involved 
in the trial, will be allowed to view your medical notes in the context of this 
study. 
All data that is collected throughout the trial will be treated with the strictest 
confidence. 
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What will happen to the results of the research study? 
Results of the study will be collected and stored on a secure database for the 
duration of the study (24 months). The results will then be analysed as soon 
as possible and we aim to publish our findings in peer reviewed medical 
journals towards the end of 2010. You will be able to obtain a copy of the final 
publication from most medical libraries. Most libraries will hold copies of the 
journal and in some instances these journals maybe available on the internet. 
Results from this study will be used by the researcher as data for further 
educational research qualification with the University of Leeds.     
Who has reviewed the study? 
The Leeds East Research and Ethics Committee. 
Who is funding this research? 
This research will be funded by the Yorkshire Cancer research (YCR) as the 
award grant has been approved in November 2009. The project will be 
organised and implemented via John Goligher Colorectal Research 
Unit/Account at the Leeds General Infirmary.  
Who can I contact if I would like to discuss the study or questionnaires 
in greater detail? 
The following number has been provided to help assist patients considering 
participation or participating in the study: 
Mr. Samir Rahmani, Colorectal Research Fellow, Contact No. 0113 392 3557, 
Monday – Friday 0800 – 1700hrs. 
Thank you for reading and participating in this study. Please note that a copy 
of this information sheet and a copy of the completed consent form will be 
given to you for your safekeeping.  
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CONSENT FORM 
 
VERSION 2.0 
 
 
 
 
 
 
 
 
Name of Researcher   Samir Rahmani 
Centre Number              GS09/9007 
Study Number               09/H1306/79 
Patient Identification Number   ……………………… 
 
Statement of Agreement to Participate in the Trial 
 
 
1. I confirm that I have read and understand the information sheet 
dated...........(version 2) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these 
answered satisfactorily. Please place your initials in the box of you agree. 
     
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. Please place your initials in the box of you 
agree. 
 
3. I agree to allow the team running the above study offering the 
necessary help and intervention when I am on the cardiopulmonary 
exercise testing machine if needed. Please place your initials in the box of you 
agree.  
4. I agree to take part in the above study by completing the questionnaire.              
Please place your initials in the box of you agree. 
5. I agree to allow the team informing my doctor (GP) about participation 
in this study, a subsequent letter will be sent to the surgery.              
Please place your initials in the box of you agree. 
………………………………………………      ………………………………           …. /…./……..      
Name of Patient (BLOCK CAPITALS)            Signature                Date 
 
                 
…………………………………………………     ………………………………          …. /…./……..      
Name of Researcher (BLOCK CAPITALS)       Signature     Date 
 
 
Project Title 
Physiological effect of adjuvant pre-operative chemotherapy and/or 
radiotherapy on patients undergoing colorectal cancer resections 
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Centre Number: GS09/9007 
Study Number: 09/H1306/79 
Version:  1 
Letter to the Patient General Practitioner (GP) 
Study Title:        
Physiological effect of adjuvant pre-operative chemotherapy and/or 
radiotherapy on patients undergoing colorectal cancer resections 
 
Dear Doctor,  
 
There is the potential that pre-operative treatment with chemotherapy or radiotherapy 
before surgery for bowel cancer can debilitate the patient and so affect the 
individual’s fitness for major surgery. Although enabling better treatment of the 
cancer, such treatment might increase the risks of the operation. The aim of this 
study is to look for the possible effects of chemotherapy and radiotherapy on an 
individual’s general health. 
 
The above named patient, who is registered in your general practice, has been 
invited to take part in this research study as he/she has a bowel cancer that needs 
treatment.  
The patient has been approached by the principle investigator of the research and 
was provided with a covering letter, a patient information leaflet and a consent form.  
We will appreciate your help and support to the patient, if needed, to clarify any 
issue.  
However, our full contact details have been provided and full communication will be 
maintained with the patient throughout the study.  
Thank you very much for your time.  
 
Yours truly, 
Mr. Samir Rahmani, Colorectal Research Fellow 
Contact No. 0113 392 3557 
Monday – Friday 0800 – 1700hrs 
 
Patient name: 
Patient date of birth: 
Patient hospital number: 
Patient address:  
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Centre Number: GS09/9007 
Study Number: 09/H1306/79 
Version: 2 
Patient invitation letter 
 
Study Title:        
Physiological effect of adjuvant pre-operative chemotherapy and/or 
radiotherapy on patients undergoing colorectal cancer resections 
 
 
Dear participants,  
 
There is the potential that pre-operative treatment with chemotherapy or radiotherapy 
before surgery for bowel cancer can be weakening and so affect the a person’s 
fitness for major surgery. Although enabling better treatment of the cancer, such 
treatment might increase the risks of the operation. The aim of this study is to look for 
the possible effects of chemotherapy and radiotherapy on an individual’s general 
health. 
 
You are being invited to take part in this research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the patient information leaflet carefully and discuss 
it with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
Thank you very much for your time.  
 
Yours truly, 
Mr. Samir Rahmani 
Colorectal Research Fellow 
Contact No. 0113 392 3557 
Monday – Friday 0800 – 1700hrs 
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Result Chapter 
 
 
These following boxplots showing the changes in score between the start and finish 
for all study variables (pre and post APT for the full cohort of patients). These charts 
show the medians, maximum and minimum.  
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Result Chapter (Chemoradiotherapy group): Primary correlations (Hypothesis One) 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
Work (Watts) VO2max Age at start -.294 .162 Not Significant 
Work (Watts) VO2max Length of treatment  .100 .641 Not Significant 
Work (Watts) VO2max Weight Kg  .409 .047 Positive 
Work (Watts) VO2max BMI kg/m2 .380 .067 Not Significant 
Work (Watts) VO2max TSF .157 .463 Not Significant 
Work (Watts) VO2max MAC -.072 .739 Not Significant 
Work (Watts) VO2max GS .414 .044 Positive 
Work (Watts) VO2max ECW .070 .746 Not Significant 
Work (Watts) VO2max ICW .285 .177 Not Significant 
Work (Watts) VO2max TBW -.187 .382 Not Significant 
Work (Watts) VO2max FFM .242 .254 Not Significant 
Work (Watts) VO2max IL1β -.131 .542 Not Significant 
Work (Watts) VO2max IL1RA -.057 .791 Not Significant 
Work (Watts) VO2max IL6 -.115 .593 Not Significant 
Work (Watts) VO2max IL10 .094 .661 Not Significant 
Work (Watts) VO2max IP10 .178 .404 Not Significant 
Work (Watts) VO2max RANTES -.041 .848 Not Significant 
Work (Watts) VO2max IL18 -.222 .297 Not Significant 
Work (Watts) VO2max MIF -.128 .550 Not Significant 
Work (Watts) VO2max CRP .015 .945 Not Significant 
Work (Watts) VO2max ALBUMIN .131 .543 Not Significant 
Work (Watts) VO2max QL -.346 .098 Not Significant 
Work (Watts) VO2max PF .398 .054 Not Significant 
Work (Watts) VO2max RF .087 .685 Not Significant 
Work (Watts) VO2max EF .147 .492 Not Significant 
Work (Watts) VO2max CF -.195 .361 Not Significant 
Work (Watts) VO2max SF .067 .756 Not Significant 
Work (Watts) VO2max FA -.109 .611 Not Significant 
Work (Watts) VO2max NV -.025 .907 Not Significant 
Work (Watts) VO2max PA -.133 .535 Not Significant 
Work (Watts) VO2max DYSPNEA .005 .981 Not Significant 
Work (Watts) VO2max INSOMNIA .022 .919 Not Significant 
Work (Watts) VO2max AP .198 .354 Not Significant 
Work (Watts) VO2max CO .158 .462 Not Significant 
Work (Watts) VO2max DI .093 .666 Not Significant 
Work (Watts) VO2max FI .164 .444 Not Significant 
Work (Watts) VO2max PGSGA -.181 .399 Not Significant 
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Independent 
Variables 
Dependent Variables Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VO2max  Age at start -.303 .150 Not Significant 
VO2max  Length of treatment  .190 .374 Not Significant 
VO2max  Weight Kg  -.044 .840 Not Significant 
VO2max  BMI kg/m2 .195 .361 Not Significant 
VO2max  TSF .253 .234 Not Significant 
VO2max  MAC .258 .224 Not Significant 
VO2max  GS -.214 .316 Not Significant 
VO2max  ECW .099 .645 Not Significant 
VO2max  ICW .168 .433 Not Significant 
Independent 
Variables 
Dependent Variables 
 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
AT  Age at start -.141 .512 Not Significant 
AT  Length of treatment  -.209 .327 Not Significant 
AT  Weight Kg  -.175 .414 Not Significant 
AT  BMI kg/m2 -.017 .938 Not Significant 
AT  TSF -.143 .505 Not Significant 
AT  MAC -.082 .705 Not Significant 
AT  GS .144 .503 Not Significant 
AT  ECW .109 .613 Not Significant 
AT  ICW .269 .204 Not Significant 
AT  TBW .272 .198 Not Significant 
AT  FFM .297 .159 Not Significant 
AT  IL1β .078 .715 Not Significant 
AT  IL1RA .095 .658 Not Significant 
AT  IL6 .141 .513 Not Significant 
AT  IL10 .059 .786 Not Significant 
AT  IP10 -.194 .364 Not Significant 
AT  RANTES -.013 .953 Not Significant 
AT  IL18 .073 .736 Not Significant 
AT  MIF -.068 .753 Not Significant 
AT  CRP .023 .916 Not Significant 
AT  ALBUMIN -.202 .343 Not Significant 
AT  QL .044 .840 Not Significant 
AT  PF -.353 .091 Not Significant 
AT  RF .118 .582 Not Significant 
AT  EF -.091 .673 Not Significant 
AT  CF .126 .559 Not Significant 
AT  SF -.240 .259 Not Significant 
AT  FA .182 .394 Not Significant 
AT  NV .073 .734 Not Significant 
AT  PA .004 .984 Not Significant 
AT  DYSPNEA .015 .945 Not Significant 
AT  INSOMNIA .096 .657 Not Significant 
AT  AP -.017 .936 Not Significant 
AT  CO -.135 .530 Not Significant 
AT  DI -.067 .754 Not Significant 
AT  FI .085 .692 Not Significant 
AT  PGSGA -.177 .409 Not Significant 
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VO2max  TBW -.004 .984 Not Significant 
VO2max  FFM .086 .690 Not Significant 
VO2max  IL1β -.435 .034 Negative 
VO2max  IL1RA -.189 .378 Not Significant 
VO2max  IL6 -.213 .317 Not Significant 
VO2max  IL10 -.067 .757 Not Significant 
VO2max  IP10 -.073 .734 Not Significant 
VO2max  RANTES .252 .234 Not Significant 
VO2max  IL18 -.017 .937 Not Significant 
VO2max  MIF .019 .931 Not Significant 
VO2max  CRP .009 .968 Not Significant 
VO2max  ALBUMIN -.045 .836 Not Significant 
VO2max  QL -.063 .770 Not Significant 
VO2max  PF .208 .329 Not Significant 
VO2max  RF .082 .704 Not Significant 
VO2max  EF -.127 .555 Not Significant 
VO2max  CF -.238 .262 Not Significant 
VO2max  SF -.192 .370 Not Significant 
VO2max  FA .215 .313 Not Significant 
VO2max  NV .189 .378 Not Significant 
VO2max  PA -.018 .932 Not Significant 
VO2max  DYSPNEA -.259 .222 Not Significant 
VO2max  INSOMNIA -.167 .435 Not Significant 
VO2max  AP -.119 .581 Not Significant 
VO2max  CO -.386 .063 Not Significant 
VO2max  DI -.214 .315 Not Significant 
VO2max  FI -.089 .680 Not Significant 
VO2max  PGSGA -.281 .184 Not Significant 
 
 
Independent 
Variables 
Dependent Variables 
 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VEVCO2AT Age at start .182 .396 Not Significant 
VEVCO2AT Length of treatment  .098 .648 Not Significant 
VEVCO2AT Weight Kg  -.200 .350 Not Significant 
VEVCO2AT BMI kg/m2 -.136 .525 Not Significant 
VEVCO2AT TSF .254 .231 Not Significant 
VEVCO2AT MAC .361 .083 Not Significant 
VEVCO2AT GS -.030 .888 Not Significant 
VEVCO2AT ECW -.211 .321 Not Significant 
VEVCO2AT ICW -.153 .474 Not Significant 
VEVCO2AT TBW -.008 .969 Not Significant 
VEVCO2AT FFM -.279 .187 Not Significant 
VEVCO2AT IL1β .073 .734 Not Significant 
VEVCO2AT IL1RA .147 .494 Not Significant 
VEVCO2AT IL6 .055 .799 Not Significant 
VEVCO2AT IL10 .173 .419 Not Significant 
VEVCO2AT IP10 .127 .553 Not Significant 
VEVCO2AT RANTES -.291 .168 Not Significant 
VEVCO2AT IL18 .086 .690 Not Significant 
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VEVCO2AT MIF -.102 .636 Not Significant 
VEVCO2AT CRP .230 .280 Not Significant 
VEVCO2AT ALBUMIN .159 .459 Not Significant 
VEVCO2AT QL -.163 .447 Not Significant 
VEVCO2AT PF -.029 .893 Not Significant 
VEVCO2AT RF -.583 .003 Negative 
VEVCO2AT EF -.439 .032 Negative 
VEVCO2AT CF .093 .666 Not Significant 
VEVCO2AT SF .319 .129 Not Significant 
VEVCO2AT FA .025 .908 Not Significant 
VEVCO2AT NV .158 .461 Not Significant 
VEVCO2AT PA -.109 .611 Not Significant 
VEVCO2AT DYSPNEA -.202 .345 Not Significant 
VEVCO2AT INSOMNIA .259 .221 Not Significant 
VEVCO2AT AP -.212 .321 Not Significant 
VEVCO2AT CO -.274 .196 Not Significant 
VEVCO2AT DI -.135 .528 Not Significant 
VEVCO2AT FI -.440 .031 Negative 
VEVCO2AT PGSGA .118 .583 Not Significant 
 
 
Independent 
Variables 
Dependent Variables 
 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VO2HRmax Age at start -.208 .329 Not Significant 
VO2HRmax Length of treatment  -.025 .909 Not Significant 
VO2HRmax Weight Kg  .009 .967 Not Significant 
VO2HRmax BMI kg/m2 .044 .840 Not Significant 
VO2HRmax TSF -.107 .618 Not Significant 
VO2HRmax MAC .243 .253 Not Significant 
VO2HRmax GS -.193 .365 Not Significant 
VO2HRmax ECW -.119 .579 Not Significant 
VO2HRmax ICW -.364 .081 Not Significant 
VO2HRmax TBW .260 .220 Not Significant 
VO2HRmax FFM -.416 .043 Negative 
VO2HRmax IL1β .185 .386 Not Significant 
VO2HRmax IL1RA .035 .871 Not Significant 
VO2HRmax IL6 .039 .858 Not Significant 
VO2HRmax IL10 .067 .755 Not Significant 
VO2HRmax IP10 -.055 .798 Not Significant 
VO2HRmax RANTES -.134 .532 Not Significant 
VO2HRmax IL18 .200 .349 Not Significant 
VO2HRmax MIF -.177 .408 Not Significant 
VO2HRmax CRP -.104 .630 Not Significant 
VO2HRmax ALBUMIN -.026 .905 Not Significant 
VO2HRmax QL .004 .987 Not Significant 
VO2HRmax PF .133 .535 Not Significant 
VO2HRmax RF -.294 .163 Not Significant 
VO2HRmax EF -.063 .770 Not Significant 
VO2HRmax CF -.068 .751 Not Significant 
VO2HRmax SF .010 .962 Not Significant 
VO2HRmax FA -.140 .515 Not Significant 
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VO2HRmax NV .187 .382 Not Significant 
VO2HRmax PA -.142 .507 Not Significant 
VO2HRmax DYSPNEA -.480 .018 Negative 
VO2HRmax INSOMNIA .018 .935 Not Significant 
VO2HRmax AP -.057 .791 Not Significant 
VO2HRmax CO -.316 .133 Not Significant 
VO2HRmax DI -.152 .479 Not Significant 
VO2HRmax FI .028 .898 Not Significant 
VO2HRmax PGSGA -.113 .600 Not Significant 
 
 
Secondary correlations (Hypothesis Two) 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
PF Weight Kg  .288 .172 Not Significant 
PF BMI kg/m2 .264 .213 Not Significant 
PF TSF -.085 .692 Not Significant 
PF MAC .201 .347 Not Significant 
PF GS -.015 .943 Not Significant 
PF ECW -.077 .721 Not Significant 
PF ICW -.055 .797 Not Significant 
PF TBW1 -.200 .350 Not Significant 
PF FFM -.185 .386 Not Significant 
 
 
 
 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
RF Weight Kg  .132 .538 Not Significant 
RF BMI kg/m2 .179 .401 Not Significant 
RF TSF -.116 .590 Not Significant 
RF MAC -.030 .890 Not Significant 
RF GS -.074 .730 Not Significant 
RF ECW .044 .838 Not Significant 
RF ICW .068 .753 Not Significant 
RF TBW1 -.042 .845 Not Significant 
RF FFM .078 .718 Not Significant 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
QL Weight Kg  -.017 .937 Not Significant 
QL BMI kg/m2 -.031 .885 Not Significant 
QL TSF -.569 .004 Negative 
QL MAC -.251 .237 Not Significant 
QL GS -.109 .612 Not Significant 
QL ECW .212 .319 Not Significant 
QL ICW .296 .160 Not Significant 
QL TBW1 -.102 .635 Not Significant 
QL FFM .309 .141 Not Significant 
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Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
EF Weight Kg  .191 .372 Not Significant 
EF BMI kg/m2 -.067 .757 Not Significant 
EF TSF -.269 .204 Not Significant 
EF MAC -.231 .278 Not Significant 
EF GS -.037 .865 Not Significant 
EF ECW .074 .730 Not Significant 
EF ICW -.117 .585 Not Significant 
EF TBW1 .014 .948 Not Significant 
EF FFM .003 .990 Not Significant 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
CF Weight Kg  -.552 .005 Negative 
CF BMI kg/m2 -.659 .000 Negative 
CF TSF -.005 .981 Not Significant 
CF MAC -.182 .394 Not Significant 
CF GS -.068 .754 Not Significant 
CF ECW -.159 .458 Not Significant 
CF ICW -.137 .523 Not Significant 
CF TBW1 .552 .005 Positive 
CF FFM -.056 .794 Not Significant 
 
 
 
 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
SF Weight Kg  .021 .923 Not Significant 
SF BMI kg/m2 -.172 .421 Not Significant 
SF TSF .407 .048 Positive 
SF MAC .096 .654 Not Significant 
SF GS .131 .543 Not Significant 
SF ECW .030 .889 Not Significant 
SF ICW -.170 .427 Not Significant 
SF TBW1 -.055 .799 Not Significant 
SF FFM -.159 .459 Not Significant 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
FA Weight Kg  -.056 .795 Not Significant 
FA BMI kg/m2 -.168 .432 Not Significant 
FA TSF .021 .921 Not Significant 
FA MAC -.023 .914 Not Significant 
FA GS .045 .834 Not Significant 
FA ECW .413 .045 Positive 
FA ICW .245 .248 Not Significant 
FA TBW1 .038 .859 Not Significant 
FA FFM .266 .209 Not Significant 
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Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
NV Weight Kg  .274 .195 Not Significant 
NV BMI kg/m2 .380 .067 Not Significant 
NV TSF -.029 .892 Not Significant 
NV MAC .518 .010 Positive 
NV GS -.115 .594 Not Significant 
NV ECW .087 .685 Not Significant 
NV ICW .326 .121 Not Significant 
NV TBW1 -.053 .806 Not Significant 
NV FFM .251 .236 Not Significant 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
PA Weight Kg  -.258 .224 Not Significant 
PA BMI kg/m2 -.089 .680 Not Significant 
PA TSF -.225 .291 Not Significant 
PA MAC -.191 .372 Not Significant 
PA GS .151 .481 Not Significant 
PA ECW .020 .926 Not Significant 
PA ICW .121 .573 Not Significant 
PA TBW1 .304 .148 Not Significant 
PA FFM .078 .716 Not Significant 
 
 
 
 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
DYSPNEA Weight Kg  .048 .822 Not Significant 
DYSPNEA BMI kg/m2 -.078 .718 Not Significant 
DYSPNEA TSF -.225 .290 Not Significant 
DYSPNEA MAC -.342 .102 Not Significant 
DYSPNEA GS .407 .049 Positive 
DYSPNEA ECW .323 .124 Not Significant 
DYSPNEA ICW .287 .174 Not Significant 
DYSPNEA TBW1 .200 .349 Not Significant 
DYSPNEA FFM .427 .037 Positive 
 
 
 
 
Independent Variables Dependent 
Variables 
 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
INSOMNIA Weight Kg  .024 .912 Not Significant 
INSOMNIA BMI kg/m2 -.023 .916 Not Significant 
INSOMNIA TSF -.206 .335 Not Significant 
INSOMNIA MAC .024 .912 Not Significant 
INSOMNIA GS .205 .336 Not Significant 
INSOMNIA ECW -.256 .227 Not Significant 
INSOMNIA ICW .212 .320 Not Significant 
INSOMNIA TBW1 -.200 .349 Not Significant 
INSOMNIA FFM .047 .829 Not Significant 
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Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
AP Weight Kg  .070 .744 Not Significant 
AP BMI kg/m2 .085 .694 Not Significant 
AP TSF -.367 .078 Not Significant 
AP MAC -.116 .591 Not Significant 
AP GS .203 .342 Not Significant 
AP ECW .015 .945 Not Significant 
AP ICW -.028 .896 Not Significant 
AP TBW1 .064 .767 Not Significant 
AP FFM .013 .953 Not Significant 
 
 
 
 
 
 
Independent Variables Dependent 
Variables 
 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
DI Weight Kg  .244 .251 Not Significant 
DI BMI kg/m2 .014 .947 Not Significant 
DI TSF -.078 .716 Not Significant 
DI MAC .036 .867 Not Significant 
DI GS .282 .182 Not Significant 
DI ECW .183 .392 Not Significant 
DI ICW .215 .312 Not Significant 
DI TBW1 .255 .230 Not Significant 
DI FFM .150 .485 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
FI Weight Kg  .073 .733 Not Significant 
FI BMI kg/m2 -.041 .848 Not Significant 
FI TSF -.372 .073 Not Significant 
FI MAC -.209 .326 Not Significant 
FI GS .070 .745 Not Significant 
FI ECW -.152 .478 Not Significant 
FI ICW .274 .195 Not Significant 
FI TBW1 .153 .476 Not Significant 
FI FFM .217 .308 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
CO Weight Kg  .415 .043 Positive 
CO BMI kg/m2 .215 .314 Not Significant 
CO TSF -.275 .194 Not Significant 
CO MAC -.158 .460 Not Significant 
CO GS .280 .186 Not Significant 
CO ECW .141 .510 Not Significant 
CO ICW .355 .089 Not Significant 
CO TBW1 -.260 .220 Not Significant 
CO FFM .386 .063 Not Significant 
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Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
PGSGA Weight Kg  .388 .061 Not Significant 
PGSGA BMI kg/m2 .266 .208 Not Significant 
PGSGA TSF -.048 .823 Not Significant 
PGSGA MAC .208 .331 Not Significant 
PGSGA GS .151 .482 Not Significant 
PGSGA ECW .437 .033 Positive 
PGSGA ICW .236 .267 Not Significant 
PGSGA TBW1 -.175 .415 Not Significant 
PGSGA FFM .315 .134 Not Significant 
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Result Chapter (Radiotherapy group): Primary correlations (Hypothesis One) 
 
 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
AT  Age at start -.288 .364 Not Significant 
AT  Length of treatment  -.240 .452 Not Significant 
AT  Weight Kg  -.615 .033 Negative 
AT  BMI kg/m2 -.420 .175 Not Significant 
AT  TSF -.377 .226 Not Significant 
AT  MAC .523 .081 Not Significant 
AT  GS .726 .007 Positive 
Independent Variables Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
Work (Watts) VO2max Age at start .475 .119 Not Significant 
Work (Watts) VO2max Length of treatment  .071 .826 Not Significant 
Work (Watts) VO2max Weight Kg  -.217 .498 Not Significant 
Work (Watts) VO2max BMI kg/m2 .074 .820 Not Significant 
Work (Watts) VO2max TSF .316 .317 Not Significant 
Work (Watts) VO2max MAC .142 .661 Not Significant 
Work (Watts) VO2max GS .181 .573 Not Significant 
Work (Watts) VO2max ECW -.109 .736 Not Significant 
Work (Watts) VO2max ICW .333 .291 Not Significant 
Work (Watts) VO2max TBW .305 .336 Not Significant 
Work (Watts) VO2max FFM -.004 .991 Not Significant 
Work (Watts) VO2max IL1β -.071 .826 Not Significant 
Work (Watts) VO2max IL1RA -.091 .778 Not Significant 
Work (Watts) VO2max IL6 .203 .527 Not Significant 
Work (Watts) VO2max IL10 -.060 .854 Not Significant 
Work (Watts) VO2max IP10 -.462 .130 Not Significant 
Work (Watts) VO2max RANTES -.161 .617 Not Significant 
Work (Watts) VO2max IL18 .336 .285 Not Significant 
Work (Watts) VO2max MIF .081 .803 Not Significant 
Work (Watts) VO2max CRP .270 .397 Not Significant 
Work (Watts) VO2max ALBUMIN .033 .918 Not Significant 
Work (Watts) VO2max QL -.237 .458 Not Significant 
Work (Watts) VO2max PF -.293 .355 Not Significant 
Work (Watts) VO2max RF -.211 .510 Not Significant 
Work (Watts) VO2max EF -.366 .241 Not Significant 
Work (Watts) VO2max CF -.131 .685 Not Significant 
Work (Watts) VO2max SF .014 .965 Not Significant 
Work (Watts) VO2max FA .533 .075 Not Significant 
Work (Watts) VO2max NV -.034 .917 Not Significant 
Work (Watts) VO2max PA .106 .743 Not Significant 
Work (Watts) VO2max DYSPNEA .530 .076 Not Significant 
Work (Watts) VO2max INSOMNIA -.653 .021 Negative 
Work (Watts) VO2max AP -.293 .355 Not Significant 
Work (Watts) VO2max CO -.048 .883 Not Significant 
Work (Watts) VO2max DI -.390 .210 Not Significant 
Work (Watts) VO2max FI -.078 .810 Not Significant 
Work (Watts) VO2max PGSGA .475 .119 Not Significant 
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AT  ECW -.116 .721 Not Significant 
AT  ICW .524 .080 Not Significant 
AT  TBW -.322 .308 Not Significant 
AT  FFM .021 .948 Not Significant 
AT  IL1β .164 .611 Not Significant 
AT  IL1RA .172 .594 Not Significant 
AT  IL6 -.119 .713 Not Significant 
AT  IL10 .287 .366 Not Significant 
AT  IP10 -.035 .914 Not Significant 
AT  RANTES .196 .542 Not Significant 
AT  IL18 -.336 .286 Not Significant 
AT  MIF .028 .931 Not Significant 
AT  CRP -.210 .513 Not Significant 
AT  ALBUMIN .567 .054 Not Significant 
AT  QL .076 .815 Not Significant 
AT  PF -.159 .622 Not Significant 
AT  RF -.123 .703 Not Significant 
AT  EF .442 .151 Not Significant 
AT  CF .138 .670 Not Significant 
AT  SF -.255 .423 Not Significant 
AT  FA .119 .712 Not Significant 
AT  NV -.353 .260 Not Significant 
AT  PA -.359 .252 Not Significant 
AT  DYSPNEA -.186 .562 Not Significant 
AT  INSOMNIA -.039 .904 Not Significant 
AT  AP -.483 .111 Not Significant 
AT  CO .018 .956 Not Significant 
AT  DI -.256 .422 Not Significant 
AT  FI .312 .324 Not Significant 
AT  PGSGA -.288 .364 Not Significant 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VO2max  Age at start .128 .691 Not Significant 
VO2max  Length of treatment  -.101 .756 Not Significant 
VO2max  Weight Kg  -.354 .259 Not Significant 
VO2max  BMI kg/m2 -.025 .940 Not Significant 
VO2max  TSF .269 .399 Not Significant 
VO2max  MAC .071 .827 Not Significant 
VO2max  GS .429 .164 Not Significant 
VO2max  ECW -.260 .415 Not Significant 
VO2max  ICW .567 .054 Not Significant 
VO2max  TBW .182 .571 Not Significant 
VO2max  FFM -.214 .505 Not Significant 
VO2max  IL1β .039 .904 Not Significant 
VO2max  IL1RA .063 .845 Not Significant 
VO2max  IL6 .011 .974 Not Significant 
VO2max  IL10 -.032 .923 Not Significant 
VO2max  IP10 -.102 .753 Not Significant 
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VO2max  RANTES .105 .745 Not Significant 
VO2max  IL18 .161 .617 Not Significant 
VO2max  MIF .063 .846 Not Significant 
VO2max  CRP -.011 .974 Not Significant 
VO2max  ALBUMIN .253 .428 Not Significant 
VO2max  QL -.049 .880 Not Significant 
VO2max  PF -.442 .151 Not Significant 
VO2max  RF -.283 .372 Not Significant 
VO2max  EF .097 .763 Not Significant 
VO2max  CF -.062 .849 Not Significant 
VO2max  SF -.050 .878 Not Significant 
VO2max  FA .589 .044 Positive 
VO2max  NV -.218 .497 Not Significant 
VO2max  PA .095 .768 Not Significant 
VO2max  DYSPNEA .287 .366 Not Significant 
VO2max  INSOMNIA -.408 .188 Not Significant 
VO2max  AP -.196 .541 Not Significant 
VO2max  CO -.225 .482 Not Significant 
VO2max  DI -.506 .093 Not Significant 
VO2max  FI -.392 .208 Not Significant 
VO2max  PGSGA .128 .691 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VEVCO2AT Age at start .002 .996 Not Significant 
VEVCO2AT Length of treatment  .006 .985 Not Significant 
VEVCO2AT Weight Kg  .218 .496 Not Significant 
VEVCO2AT BMI kg/m2 -.183 .570 Not Significant 
VEVCO2AT TSF -.211 .510 Not Significant 
VEVCO2AT MAC -.082 .801 Not Significant 
VEVCO2AT GS -.413 .182 Not Significant 
VEVCO2AT ECW .335 .288 Not Significant 
VEVCO2AT ICW .070 .828 Not Significant 
VEVCO2AT TBW .612 .035 Positive 
VEVCO2AT FFM .373 .233 Not Significant 
VEVCO2AT IL1β .038 .908 Not Significant 
VEVCO2AT IL1RA -.283 .372 Not Significant 
VEVCO2AT IL6 -.197 .540 Not Significant 
VEVCO2AT IL10 -.211 .511 Not Significant 
VEVCO2AT IP10 -.155 .631 Not Significant 
VEVCO2AT RANTES .218 .496 Not Significant 
VEVCO2AT IL18 .457 .135 Not Significant 
VEVCO2AT MIF .158 .623 Not Significant 
VEVCO2AT CRP -.067 .837 Not Significant 
VEVCO2AT ALBUMIN -.354 .259 Not Significant 
VEVCO2AT QL -.271 .395 Not Significant 
VEVCO2AT PF .681 .015 Positive 
VEVCO2AT RF .293 .355 Not Significant 
VEVCO2AT EF -.261 .412 Not Significant 
 269 
VEVCO2AT CF .085 .793 Not Significant 
VEVCO2AT SF .075 .817 Not Significant 
VEVCO2AT FA -.208 .516 Not Significant 
VEVCO2AT NV .577 .049 Positive 
VEVCO2AT PA .025 .939 Not Significant 
VEVCO2AT DYSPNEA .387 .214 Not Significant 
VEVCO2AT INSOMNIA -.194 .546 Not Significant 
VEVCO2AT AP -.211 .510 Not Significant 
VEVCO2AT CO -.199 .535 Not Significant 
VEVCO2AT DI .058 .857 Not Significant 
VEVCO2AT FI .283 .373 Not Significant 
VEVCO2AT PGSGA .002 .996 Not Significant 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
VO2HRmax Age at start -.286 .368 Not Significant 
VO2HRmax Length of treatment  -.106 .742 Not Significant 
VO2HRmax Weight Kg  .015 .964 Not Significant 
VO2HRmax BMI kg/m2 .144 .655 Not Significant 
VO2HRmax TSF .007 .982 Not Significant 
VO2HRmax MAC -.058 .858 Not Significant 
VO2HRmax GS .378 .225 Not Significant 
VO2HRmax ECW .100 .757 Not Significant 
VO2HRmax ICW .310 .326 Not Significant 
VO2HRmax TBW .044 .891 Not Significant 
VO2HRmax FFM .473 .120 Not Significant 
VO2HRmax IL1β .308 .329 Not Significant 
VO2HRmax IL1RA .346 .270 Not Significant 
VO2HRmax IL6 -.044 .891 Not Significant 
VO2HRmax IL10 .336 .285 Not Significant 
VO2HRmax IP10 -.443 .149 Not Significant 
VO2HRmax RANTES -.174 .589 Not Significant 
VO2HRmax IL18 -.340 .280 Not Significant 
VO2HRmax MIF -.203 .526 Not Significant 
VO2HRmax CRP -.628 .029 Negative 
VO2HRmax ALBUMIN .098 .762 Not Significant 
VO2HRmax QL -.464 .129 Not Significant 
VO2HRmax PF -.069 .831 Not Significant 
VO2HRmax RF .440 .152 Not Significant 
VO2HRmax EF -.205 .522 Not Significant 
VO2HRmax CF .406 .190 Not Significant 
VO2HRmax SF -.367 .240 Not Significant 
VO2HRmax FA .202 .529 Not Significant 
VO2HRmax NV -.134 .677 Not Significant 
VO2HRmax PA .532 .075 Not Significant 
VO2HRmax DYSPNEA .141 .662 Not Significant 
VO2HRmax INSOMNIA -.296 .351 Not Significant 
VO2HRmax AP -.522 .082 Not Significant 
VO2HRmax CO -.404 .193 Not Significant 
VO2HRmax DI -.339 .281 Not Significant 
VO2HRmax FI .079 .808 Not Significant 
VO2HRmax PGSGA -.286 .368 Not Significant 
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Secondary correlations (Hypothesis Two) 
 
 
Independent Variables 
 
Dependent  Correlation 
coefficients 
Significance 
p value 
Correlation trend 
QL Weight Kg  -.195 .544 Not Significant 
QL BMI kg/m2 -.621 .031 Negative 
QL TSF -.142 .660 Not Significant 
QL MAC -.449 .143 Not Significant 
QL GS .094 .771 Not Significant 
QL ECW -.013 .969 Not Significant 
QL ICW -.430 .163 Not Significant 
QL TBW1 .184 .567 Not Significant 
QL FFM -.603 .038 Negative 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
PF Weight Kg  .219 .495 Not Significant 
PF BMI kg/m2 -.102 .752 Not Significant 
PF TSF -.311 .325 Not Significant 
PF MAC -.030 .926 Not Significant 
PF GS -.388 .213 Not Significant 
PF ECW .445 .147 Not Significant 
PF ICW .145 .654 Not Significant 
PF TBW1 .275 .387 Not Significant 
PF FFM .642 .024 Positive 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
RF Weight Kg  .534 .074 Not Significant 
RF BMI kg/m2 .232 .468 Not Significant 
RF TSF -.309 .329 Not Significant 
RF MAC -.092 .775 Not Significant 
RF GS -.236 .460 Not Significant 
RF ECW .662 .019 Positive 
RF ICW -.232 .468 Not Significant 
RF TBW1 -.278 .382 Not Significant 
RF FFM .724 .008 Positive 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation trend 
EF Weight Kg  -.106 .743 Not Significant 
EF BMI kg/m2 -.346 .270 Not Significant 
EF TSF -.332 .292 Not Significant 
EF MAC -.130 .686 Not Significant 
EF GS .028 .930 Not Significant 
EF ECW .281 .376 Not Significant 
EF ICW .032 .922 Not Significant 
EF TBW1 -.290 .361 Not Significant 
EF FFM -.092 .776 Not Significant 
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Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
CF Weight Kg  -.381 .222 Not Significant 
CF BMI kg/m2 -.459 .134 Not Significant 
CF TSF -.288 .364 Not Significant 
CF MAC -.412 .184 Not Significant 
CF GS -.053 .870 Not Significant 
CF ECW .004 .991 Not Significant 
CF ICW .095 .768 Not Significant 
CF TBW1 .423 .170 Not Significant 
CF FFM .328 .298 Not Significant 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
SF Weight Kg  .355 .258 Not Significant 
SF BMI kg/m2 -.092 .776 Not Significant 
SF TSF .411 .184 Not Significant 
SF MAC -.158 .624 Not Significant 
SF GS -.078 .809 Not Significant 
SF ECW -.036 .913 Not Significant 
SF ICW -.213 .507 Not Significant 
SF TBW1 .376 .228 Not Significant 
SF FFM -.404 .192 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
FA Weight Kg  .077 .812 Not Significant 
FA BMI kg/m2 .242 .448 Not Significant 
FA TSF .556 .061 Not Significant 
FA MAC .268 .400 Not Significant 
FA GS .287 .366 Not Significant 
FA ECW -.293 .355 Not Significant 
FA ICW .211 .511 Not Significant 
FA TBW1 -.004 .991 Not Significant 
FA FFM -.354 .258 Not Significant 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
NV Weight Kg  .279 .380 Not Significant 
NV BMI kg/m2 -.134 .677 Not Significant 
NV TSF -.182 .572 Not Significant 
NV MAC -.264 .406 Not Significant 
NV GS -.316 .318 Not Significant 
NV ECW .076 .814 Not Significant 
NV ICW .201 .530 Not Significant 
NV TBW1 .654 .021 Positive 
NV FFM .187 .560 Not Significant 
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Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
PA Weight Kg  .577 .049 Positive 
PA BMI kg/m2 .331 .293 Not Significant 
PA TSF .476 .118 Not Significant 
PA MAC -.359 .251 Not Significant 
PA GS .028 .931 Not Significant 
PA ECW .127 .694 Not Significant 
PA ICW -.183 .569 Not Significant 
PA TBW1 .268 .400 Not Significant 
PA FFM .155 .631 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
DYSPNEA Weight Kg  .344 .273 Not Significant 
DYSPNEA BMI kg/m2 -.042 .896 Not Significant 
DYSPNEA TSF .090 .780 Not Significant 
DYSPNEA MAC -.281 .377 Not Significant 
DYSPNEA GS .069 .832 Not Significant 
DYSPNEA ECW .386 .216 Not Significant 
DYSPNEA ICW .074 .820 Not Significant 
DYSPNEA TBW1 .460 .132 Not Significant 
DYSPNEA FFM .228 .475 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
INSOMNIA Weight Kg  .216 .500 Not Significant 
INSOMNIA BMI kg/m2 -.106 .743 Not Significant 
INSOMNIA TSF -.305 .334 Not Significant 
INSOMNIA MAC -.136 .674 Not Significant 
INSOMNIA GS -.060 .852 Not Significant 
INSOMNIA ECW -.259 .417 Not Significant 
INSOMNIA ICW .032 .922 Not Significant 
INSOMNIA TBW1 .085 .793 Not Significant 
INSOMNIA FFM -.304 .336 Not Significant 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
AP Weight Kg  .222 .488 Not Significant 
AP BMI kg/m2 .187 .561 Not Significant 
AP TSF .548 .065 Not Significant 
AP MAC -.308 .329 Not Significant 
AP GS -.405 .191 Not Significant 
AP ECW -.442 .151 Not Significant 
AP ICW -.166 .607 Not Significant 
AP TBW1 .265 .406 Not Significant 
AP FFM -.593 .042 Negative 
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Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
CO Weight Kg  -.350 .264 Not Significant 
CO BMI kg/m2 .209 .515 Not Significant 
CO TSF .263 .410 Not Significant 
CO MAC .462 .131 Not Significant 
CO GS -.322 .308 Not Significant 
CO ECW -.502 .096 Not Significant 
CO ICW .138 .669 Not Significant 
CO TBW1 -.237 .458 Not Significant 
CO FFM -.170 .598 Not Significant 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
DI Weight Kg  .351 .263 Not Significant 
DI BMI kg/m2 -.095 .770 Not Significant 
DI TSF .050 .878 Not Significant 
DI MAC -.500 .098 Not Significant 
DI GS -.512 .089 Not Significant 
DI ECW .770 .003 Positive 
DI ICW -.674 .016 Negative 
DI TBW1 -.151 .640 Not Significant 
DI FFM .368 .239 Not Significant 
 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
PGSGA Weight Kg  .291 .359 Not Significant 
PGSGA BMI kg/m2 .356 .257 Not Significant 
PGSGA TSF -.063 .845 Not Significant 
PGSGA MAC .198 .538 Not Significant 
PGSGA GS .187 .560 Not Significant 
PGSGA ECW .295 .352 Not Significant 
PGSGA ICW .492 .104 Not Significant 
PGSGA TBW1 .050 .877 Not Significant 
PGSGA FFM .546 .066 Not Significant 
 
 
 
 
 
Independent Variables 
 
Dependent 
Variables 
Correlation 
coefficients 
Significance 
p value 
Correlation 
trend 
FI Weight Kg  .173 .590 Not Significant 
FI BMI kg/m2 -.050 .878 Not Significant 
FI TSF -.423 .170 Not Significant 
FI MAC .549 .064 Not Significant 
FI GS .242 .449 Not Significant 
FI ECW .436 .156 Not Significant 
FI ICW .060 .853 Not Significant 
FI TBW1 -.255 .424 Not Significant 
FI FFM .598 .040 Positive 
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